---
author-meta:
- Halie M. Rando
- Casey S. Greene
- Michael P. Robson
- Simina M. Boca
- Nils Wellhausen
- Ronan Lordan
- Christian Brueffer
- Sadipan Ray
- Lucy D\'Agostino McGowan
- Anthony Gitter
- Ronnie M. Russell
- Anna Ada Dattoli
- Ryan Velazquez
- John P. Barton
- Jeffrey M. Field
- Bharath Ramsundar
- Adam L. MacLean
- Alexandra J. Lee
- Immunology Institute of the Icahn School of Medicine
- Fengling Hu
- Nafisa M. Jadavji
bibliography:
- content/manual-references.bib
- content/manual-references.json
date-meta: '2020-04-10'
header-includes: '<!--

  Manubot generated metadata rendered from header-includes-template.html.

  Suggest improvements at https://github.com/manubot/manubot/blob/master/manubot/process/header-includes-template.html

  -->

  <meta name="dc.format" content="text/html" />

  <meta name="dc.title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />

  <meta name="citation_title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />

  <meta property="og:title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />

  <meta property="twitter:title" content="SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics" />

  <meta name="dc.date" content="2020-04-10" />

  <meta name="citation_publication_date" content="2020-04-10" />

  <meta name="dc.language" content="en-US" />

  <meta name="citation_language" content="en-US" />

  <meta name="dc.relation.ispartof" content="Manubot" />

  <meta name="dc.publisher" content="Manubot" />

  <meta name="citation_journal_title" content="Manubot" />

  <meta name="citation_technical_report_institution" content="Manubot" />

  <meta name="citation_author" content="Halie M. Rando" />

  <meta name="citation_author_institution" content="Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America" />

  <meta name="citation_author_orcid" content="0000-0001-7688-1770" />

  <meta name="twitter:creator" content="@tamefoxtime" />

  <meta name="citation_author" content="Casey S. Greene" />

  <meta name="citation_author_institution" content="Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America" />

  <meta name="citation_author_institution" content="Childhood Cancer Data Lab, Alex&#39;s Lemonade Stand Foundation, Philadelphia, Pennsylvania, United States of America" />

  <meta name="citation_author_orcid" content="0000-0001-8713-9213" />

  <meta name="twitter:creator" content="@GreeneScientist" />

  <meta name="citation_author" content="Michael P. Robson" />

  <meta name="citation_author_institution" content="Department of Computing Sciences, Villanova University, Villanova, Pennsylvania, United States of America" />

  <meta name="citation_author_orcid" content="0000-0002-4859-0033" />

  <meta name="citation_author" content="Simina M. Boca" />

  <meta name="citation_author_institution" content="Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, District of Columbia, United States of America" />

  <meta name="citation_author_orcid" content="0000-0002-1400-3398" />

  <meta name="citation_author" content="Nils Wellhausen" />

  <meta name="citation_author_institution" content="Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America" />

  <meta name="citation_author_orcid" content="0000-0001-8955-7582" />

  <meta name="citation_author" content="Ronan Lordan" />

  <meta name="citation_author_institution" content="Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5158, USA" />

  <meta name="citation_author_orcid" content="0000-0001-9668-3368" />

  <meta name="twitter:creator" content="@el_ronan" />

  <meta name="citation_author" content="Christian Brueffer" />

  <meta name="citation_author_institution" content="Department of Clinical Sciences, Lund University, Lund, Sweden" />

  <meta name="citation_author_orcid" content="0000-0002-3826-0989" />

  <meta name="twitter:creator" content="@cbrueffer" />

  <meta name="citation_author" content="Sadipan Ray" />

  <meta name="citation_author_institution" content="Department of Systems Pharmacology &amp; Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA" />

  <meta name="citation_author_institution" content="Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA" />

  <meta name="citation_author_orcid" content="0000-0002-9960-5768" />

  <meta name="citation_author" content="Lucy D\&#39;Agostino McGowan" />

  <meta name="citation_author_institution" content="Department of Mathematics and Statistics, Wake Forest University, Winston-Salem, North Carolina, United States of America" />

  <meta name="citation_author_orcid" content="0000-0001-7297-9359" />

  <meta name="twitter:creator" content="@LucyStats" />

  <meta name="citation_author" content="Anthony Gitter" />

  <meta name="citation_author_institution" content="Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America" />

  <meta name="citation_author_institution" content="Morgridge Institute for Research, Madison, Wisconsin, United States of America" />

  <meta name="citation_author_orcid" content="0000-0002-5324-9833" />

  <meta name="twitter:creator" content="@anthonygitter" />

  <meta name="citation_author" content="Ronnie M. Russell" />

  <meta name="citation_author_institution" content="Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA" />

  <meta name="citation_author_orcid" content="0000-0003-1484-4207" />

  <meta name="citation_author" content="Anna Ada Dattoli" />

  <meta name="citation_author_institution" content="Department of Systems Pharmacology &amp; Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA" />

  <meta name="citation_author_orcid" content="0000-0003-1462-831X" />

  <meta name="twitter:creator" content="@aadattoli" />

  <meta name="citation_author" content="Ryan Velazquez" />

  <meta name="citation_author_institution" content="Azimuth1, McLean, VA" />

  <meta name="citation_author_orcid" content="0000-0002-3655-3403" />

  <meta name="citation_author" content="John P. Barton" />

  <meta name="citation_author_institution" content="Department of Physics and Astronomy, University of California-Riverside, Riverside, California, United States of America" />

  <meta name="citation_author_orcid" content="0000-0003-1467-421X" />

  <meta name="twitter:creator" content="@_jpbarton" />

  <meta name="citation_author" content="Jeffrey M. Field" />

  <meta name="citation_author_institution" content="Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA" />

  <meta name="citation_author_orcid" content="000-0001-7161-7284" />

  <meta name="citation_author" content="Bharath Ramsundar" />

  <meta name="citation_author_institution" content="The DeepChem Project, https://deepchem.io/" />

  <meta name="citation_author_orcid" content="0000-0001-8450-4262" />

  <meta name="twitter:creator" content="@rbhar90" />

  <meta name="citation_author" content="Adam L. MacLean" />

  <meta name="citation_author_institution" content="Department of Biological Sciences, University of Southern California, Los Angeles, California, United States of America" />

  <meta name="citation_author_orcid" content="0000-0003-0689-7907" />

  <meta name="twitter:creator" content="@adamlmaclean" />

  <meta name="citation_author" content="Alexandra J. Lee" />

  <meta name="citation_author_institution" content="Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America" />

  <meta name="citation_author_orcid" content="0000-0002-0208-3730" />

  <meta name="citation_author" content="Immunology Institute of the Icahn School of Medicine" />

  <meta name="citation_author_institution" content="Immunology Institute of the Icahn School of Medicine" />

  <meta name="citation_author" content="Fengling Hu" />

  <meta name="citation_author_institution" content="Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America" />

  <meta name="citation_author_orcid" content="0000-0003-1081-5038" />

  <meta name="twitter:creator" content="@hufengling" />

  <meta name="citation_author" content="Nafisa M. Jadavji" />

  <meta name="citation_author_institution" content="Biomedical Science, Midwestern University, Glendale, AZ, United States of America" />

  <meta name="citation_author_institution" content="Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada" />

  <meta name="citation_author_orcid" content="0000-0002-3557-7307" />

  <meta name="twitter:creator" content="@nafisajadavji" />

  <link rel="canonical" href="https://greenelab.github.io/covid19-review/" />

  <meta property="og:url" content="https://greenelab.github.io/covid19-review/" />

  <meta property="twitter:url" content="https://greenelab.github.io/covid19-review/" />

  <meta name="citation_fulltext_html_url" content="https://greenelab.github.io/covid19-review/" />

  <meta name="citation_pdf_url" content="https://greenelab.github.io/covid19-review/manuscript.pdf" />

  <link rel="alternate" type="application/pdf" href="https://greenelab.github.io/covid19-review/manuscript.pdf" />

  <link rel="alternate" type="text/html" href="https://greenelab.github.io/covid19-review/v/8b70eab9cf249e9cac73ce42fe90a2eb8befb6bd/" />

  <meta name="manubot_html_url_versioned" content="https://greenelab.github.io/covid19-review/v/8b70eab9cf249e9cac73ce42fe90a2eb8befb6bd/" />

  <meta name="manubot_pdf_url_versioned" content="https://greenelab.github.io/covid19-review/v/8b70eab9cf249e9cac73ce42fe90a2eb8befb6bd/manuscript.pdf" />

  <meta property="og:type" content="article" />

  <meta property="twitter:card" content="summary_large_image" />

  <link rel="icon" type="image/png" sizes="192x192" href="https://manubot.org/favicon-192x192.png" />

  <link rel="mask-icon" href="https://manubot.org/safari-pinned-tab.svg" color="#ad1457" />

  <meta name="theme-color" content="#ad1457" />

  <!-- end Manubot generated metadata -->'
keywords:
- covid-19
- coronavirus
- pandemic
- viral infection
lang: en-US
manubot-clear-requests-cache: false
manubot-output-bibliography: output/references.json
manubot-output-citekeys: output/citations.tsv
manubot-requests-cache-path: ci/cache/requests-cache
title: 'SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics'
...






<small><em>
This manuscript
([permalink](https://greenelab.github.io/covid19-review/v/8b70eab9cf249e9cac73ce42fe90a2eb8befb6bd/))
was automatically generated
from [greenelab/covid19-review@8b70eab](https://github.com/greenelab/covid19-review/tree/8b70eab9cf249e9cac73ce42fe90a2eb8befb6bd)
on April 10, 2020.
</em></small>

<!-- include the Font Awesome library, per: https://fontawesome.com/start -->
<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.13.0/css/all.css">
[
[]{.fas .fa-info-circle .fa-lg} **This in progress manuscript is not intended for the general public.**<br>
This is a review paper that is authored by scientists for an audience of scientists to discuss research that is in progress.
If you are interested in guidelines on testing, therapies, or other issues related to your health, you should not use this document.
Instead, you should collect information from your local health department, the [CDC's guidance](https://www.cdc.gov/coronavirus/2019-ncov/index.html), or your own government.
]{.banner .lightred}

## Authors



+ **Halie M. Rando**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-7688-1770](https://orcid.org/0000-0001-7688-1770)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [rando2](https://github.com/rando2)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [tamefoxtime](https://twitter.com/tamefoxtime)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
     · Funded by the Gordon and Betty Moore Foundation (GBMF 4552)
  </small>

+ **Casey S. Greene**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-8713-9213](https://orcid.org/0000-0001-8713-9213)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [cgreene](https://github.com/cgreene)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [GreeneScientist](https://twitter.com/GreeneScientist)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Childhood Cancer Data Lab, Alex's Lemonade Stand Foundation, Philadelphia, Pennsylvania, United States of America
     · Funded by the Gordon and Betty Moore Foundation (GBMF 4552)
  </small>

+ **Michael P. Robson**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-4859-0033](https://orcid.org/0000-0002-4859-0033)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [mprobson](https://github.com/mprobson)<br>
  <small>
     Department of Computing Sciences, Villanova University, Villanova, Pennsylvania, United States of America
  </small>

+ **Simina M. Boca**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-1400-3398](https://orcid.org/0000-0002-1400-3398)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [SiminaB](https://github.com/SiminaB)<br>
  <small>
     Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, District of Columbia, United States of America
  </small>

+ **Nils Wellhausen**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-8955-7582](https://orcid.org/0000-0001-8955-7582)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [nilswellhausen](https://github.com/nilswellhausen)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
  </small>

+ **Ronan Lordan**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-9668-3368](https://orcid.org/0000-0001-9668-3368)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [RLordan](https://github.com/RLordan)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [el_ronan](https://twitter.com/el_ronan)<br>
  <small>
     Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5158, USA
  </small>

+ **Christian Brueffer**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-3826-0989](https://orcid.org/0000-0002-3826-0989)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [cbrueffer](https://github.com/cbrueffer)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [cbrueffer](https://twitter.com/cbrueffer)<br>
  <small>
     Department of Clinical Sciences, Lund University, Lund, Sweden
  </small>

+ **Sadipan Ray**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-9960-5768](https://orcid.org/0000-0002-9960-5768)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [rays1987](https://github.com/rays1987)<br>
  <small>
     Department of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  </small>

+ **Lucy D\'Agostino McGowan**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-7297-9359](https://orcid.org/0000-0001-7297-9359)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [LucyMcGowan](https://github.com/LucyMcGowan)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [LucyStats](https://twitter.com/LucyStats)<br>
  <small>
     Department of Mathematics and Statistics, Wake Forest University, Winston-Salem, North Carolina, United States of America
  </small>

+ **Anthony Gitter**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-5324-9833](https://orcid.org/0000-0002-5324-9833)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [agitter](https://github.com/agitter)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [anthonygitter](https://twitter.com/anthonygitter)<br>
  <small>
     Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Morgridge Institute for Research, Madison, Wisconsin, United States of America
  </small>

+ **Ronnie M. Russell**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-1484-4207](https://orcid.org/0000-0003-1484-4207)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [rmrussell](https://github.com/rmrussell)<br>
  <small>
     Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  </small>

+ **Anna Ada Dattoli**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-1462-831X](https://orcid.org/0000-0003-1462-831X)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [aadattoli](https://github.com/aadattoli)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [aadattoli](https://twitter.com/aadattoli)<br>
  <small>
     Department of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  </small>

+ **Ryan Velazquez**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-3655-3403](https://orcid.org/0000-0002-3655-3403)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [rdvelazquez](https://github.com/rdvelazquez)<br>
  <small>
     Azimuth1, McLean, VA
  </small>

+ **John P. Barton**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-1467-421X](https://orcid.org/0000-0003-1467-421X)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [johnbarton](https://github.com/johnbarton)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [_jpbarton](https://twitter.com/_jpbarton)<br>
  <small>
     Department of Physics and Astronomy, University of California-Riverside, Riverside, California, United States of America
  </small>

+ **Jeffrey M. Field**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [000-0001-7161-7284](https://orcid.org/000-0001-7161-7284)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [Jeff-Field](https://github.com/Jeff-Field)<br>
  <small>
     Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  </small>

+ **Bharath Ramsundar**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0001-8450-4262](https://orcid.org/0000-0001-8450-4262)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [rbharath](https://github.com/rbharath)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [rbhar90](https://twitter.com/rbhar90)<br>
  <small>
     The DeepChem Project, https://deepchem.io/
  </small>

+ **Adam L. MacLean**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-0689-7907](https://orcid.org/0000-0003-0689-7907)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [alavendelm](https://github.com/alavendelm)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [adamlmaclean](https://twitter.com/adamlmaclean)<br>
  <small>
     Department of Biological Sciences, University of Southern California, Los Angeles, California, United States of America
  </small>

+ **Alexandra J. Lee**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-0208-3730](https://orcid.org/0000-0002-0208-3730)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [ajlee21](https://github.com/ajlee21)<br>
  <small>
     Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
     · Funded by the Gordon and Betty Moore Foundation (GBMF 4552)
  </small>

+ **Immunology Institute of the Icahn School of Medicine**<br>
    · ![GitHub icon](images/github.svg){.inline_icon}
    [ismms-himc](https://github.com/ismms-himc)<br>
  <small>
     Immunology Institute of the Icahn School of Medicine
  </small>

+ **Fengling Hu**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0003-1081-5038](https://orcid.org/0000-0003-1081-5038)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [hufengling](https://github.com/hufengling)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [hufengling](https://twitter.com/hufengling)<br>
  <small>
     Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
  </small>

+ **Nafisa M. Jadavji**<br>
    ![ORCID icon](images/orcid.svg){.inline_icon}
    [0000-0002-3557-7307](https://orcid.org/0000-0002-3557-7307)
    · ![GitHub icon](images/github.svg){.inline_icon}
    [nafisajadavji](https://github.com/nafisajadavji)
    · ![Twitter icon](images/twitter.svg){.inline_icon}
    [nafisajadavji](https://twitter.com/nafisajadavji)<br>
  <small>
     Biomedical Science, Midwestern University, Glendale, AZ, United States of America; Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada
     · Funded by American Heart Association (20AIREA35050015)
  </small>



## Abstract {.page_break_before} 
Since late 2019, Coronavirus disease 2019 (COVID-19) has spread around the world, resulting in the declaration of a pandemic by the World Health Organization (WHO).
This infectious disease is caused by the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Research on the virus SARS-CoV-2 and the disease it causes is emerging rapidly through global scientific efforts.
The development of diagnostics, treatments, and vaccines will be critical to mitigating the impact of the virus.
Here we present a collaborative effort to organize and consolidate the rapidly emerging scientific literature related to SARS-CoV-2.
We present information about the virus in the context of what is known about related viruses and synthesize studies emerging about the diagnosis and treatment of COVID-19 alongside literature about related illnesses.
A broad scientific effort to understand this pandemic and related viruses and diseases will be foundational to efforts to predict possible interventions.
This text is an evolving and collaborative document that seeks to incorporate the ever-expanding body of information related to SARS-CoV-2 and COVID-19.

## Where to Contribute
Introduce Yourself (GitHub Issue) [https://github.com/greenelab/covid19-review/issues/17](https://github.com/greenelab/covid19-review/issues/17)

Community Chat (Gitter Room) [https://gitter.im/covid19-review/community](https://gitter.im/covid19-review/community)

More Info (GitHub Readme) [https://github.com/greenelab/covid19-review#sars-cov-2-and-covid-19-an-evolving-review-of-diagnostics-and-therapeutics](https://github.com/greenelab/covid19-review#sars-cov-2-and-covid-19-an-evolving-review-of-diagnostics-and-therapeutics)


## Introduction {.page_break_before} 

### General Background

On January 21, 2020, the World Health Organization (WHO) released its first report concerning what is now known as the Coronavirus disease 2019 (COVID-19) [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf].
This infectious disease came to international attention on December 31, 2019 following an announcement by national officials in China about 44 cases of a respiratory infection of unknown cause.
The first known cases were located in Wuhan City within the Hubei province of China, but the disease spread rapidly beyond Wuhan within China and subsequently around the world.
At the time of the first situation report [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf], 282 confirmed cases had been identified, primarily in China, but also 1-2 exported cases had been identified in several neighboring countries (Thailand, Japan, and the Republic of Korea).
One week later, 4593 confirmed cases had been identified, spanning not only Asia, but also Australia, North America, and Europe [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200128-sitrep-8-ncov-cleared.pdf].
On March 11, 2020, WHO formally classified the situation as a pandemic [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf].
By WHO Situation Report 61, released on March 20, 2020, 266,073 confirmed cases had been reported worldwide, with cases on every continent except Antarctica [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200321-sitrep-61-covid-19.pdf].
At this time, over 11,000 deaths had been reported worldwide.

[Note: Maybe add a graph here, update as new reports come out.]

COVID-19 is caused by the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
SARS-CoV-2 is a coronavirus, a family of RNA viruses known to cause respiratory and intestinal infections in humans and other species.
Infectious diseases of global concern have previously been associated with coronaviruses, including Severe Acute Respiratory Syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV) [@doi:10.1038/nrmicro.2016.81; @doi:10.1038/s41579-018-0118-9]; however, neither of these reached pandemic status, owing to proper containment procedures (SARS) or intrinsic limitations in virus transmission (MERS).
Additionally, there are four endemic human coronaviruses that rarely progress beyond the mild symptoms associated with the common cold [@doi:10.1038/s41579-018-0118-9].
The precise identity of SARS-CoV-2 virus was unknown until approximately January 12, 2020, when Chinese officials released its genetic sequence to aid in worldwide efforts to diagnose the disease [@url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf].
As researchers worldwide work to characterize SARS-CoV-2 and COVID-19, information about the transmission and life cycle of the virus as well as the diagnosis and treatment of the disease is emerging rapidly.
In this review, we seek to consolidate information about the virus in the context of related viruses and to synthesize what is known about the diagnosis and treatment of COVID-19 and related diseases.
This is a real-time, collaborative effort that welcomes submissions from scientists worldwide.

### About Coronaviruses

#### Classification:
Coronaviridae, commonly called Coronavirus, is a family of positive-sense RNA viruses [@isbn:0781760607]. 
Members of this family include the Middle East respiratory syndrome-related coronavirus (MERS-CoV) and Severe acute respiratory syndrome coronavirus (SARS-CoV), which are two species, as well as SARS-CoV-2 [@url:https://en.wikipedia.org/wiki/Coronaviridae#Taxonomy].

#### Virion, morphology, structure:
Coronavirus virions are spherical with diameters ranging between 100 to 160nm. 
The virion has a lipid envelope with spike (S) glycoproteins on the surface creating a distinctive "crown" shape, for which the family of viruses was named [@isbn:0781760607]. 

#### Genome structure and replication:
Coronavirus genomes are single-stranded non-segmented positive RNA (ssRNA+) that are 27 to 32kb in length. 
The SARS-CoV-2 genome lies in the middle of this range at 29,903 bp in length [@doi:10/ggjr43].
Coronavirus genomes are comprised of a replicase gene that is 2/3 of the genome and the remaining 1/3 that encodes structural proteins including: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. 
There are additional accessory genes that are present depending on the strain. 
The non-structural polypeptide is translated into 16 non-structural proteins (nsp1-16, except Gammacoronaviruses that do not contain nsp1), which form replication machinery to synthesize viral RNA [@doi:10.1002/jmv.25681]. 

Replication initiates with the binding of the virus to a host cell via the S protein. 
The viral membrane fuses with the endosomal membrane to release the viral genome into the host cytoplasm. 
The replicase gene is translated and assembled into the viral replicase complex, which can synthesize dsRNA genome from the genomic ssRNA(+).
The dsRNA genome is then transcribed and replicated to create viral mRNAs and new ssRNA(+) genomes [@doi:10.1007/978-1-4939-2438-7_1; @url:https://viralzone.expasy.org/30?outline=all_by_species].  

#### Transmission:
In general, respiratory viruses like coronavirus can have multiple routes of person-to-person transmission including droplet transmission (i.e. inhalation for cough, sneeze), aerosol transmission (i.e. virus suspended in air), and contact transmission (i.e. contact with oral, nasal, and eye mucous membranes). 
While there does not appear to be experimental evidence to conclude which mode of transmission different coronaviruses use [@doi:10.1038/s41368-020-0075-9], it is suggested that the coronavirus person-to-person transmission is droplet-based using simulations [@doi:10.1056/NEJMoa032867] and trace studies[@doi:10.3390/ijerph15122757].

### Origin of SARS-CoV-2 
[MERS and SARS? Where to put this?]
[Specifically about SARS-CoV-2/COVID19?]
The origin of the SARS-CoV-19 virus is not yet fully understood.
Genomic analyses and comparisons to other known coronaviruses suggest that SARS-CoV-19 is unlikely to have originated from a laboratory -- either purposely engineered and released, or escaped -- and instead evolved naturally in an animal host [@doi:10.1038/s41591-020-0820-9].
Among known coronaviruses, SARS-CoV-19 has the closest overall sequence similarity to RaTG13 (~96%) found in a *Rhinolophus affinis* bat [@doi:10.1038/s41586-020-2012-7], while the receptor binding domain (RBD) is highly similar to that of viruses found in pangolins [@doi:10.1101/2020.02.19.950253].
This suggests that SARS-CoV-19 may have originated in viral reservoirs of similar hosts, however current evidence cannot discriminate an origin of the virus before or after zoonotic transfer to humans [@doi:10.1038/s41591-020-0820-9].

### Disease (COVID19)

#### Mechanisms of Coronavirus-driven Disease in Humans

Coronaviruses are known to cause respiratory illnesses in humans through the following possible mechanisms...[Summarize relevant mechanisms for cell entry & address evidence for/against ACE2 being important]

#### Symptoms

*Presentation of COVID-19:* 
Information is rapidly becoming available about the wide range of symptoms that can be associated with COVID-19 as well as the range of symptom severity, onset from exposure, and possible risk or protective factors...

In a retrospective sample of COVID-19 patients in Wuhan observed during December 2019 and January 2020, [@doi:10/ggnxb3] found that a higher probability of mortality was associated with older age and higher Sequential Organ Failure Assessment score, as well as high levels of d-dimer. 
Mortality also appeared to be associated with other biomarkers measured in blood samples including lactate dehydrogenase and cardiac troponin I, although these analyses may not have been appropriately corrected for multiple testing.
They also found that survivors continued to shed the virus for a median of 20 days and a maximum of at least 37 days.


#### Vaccines for Viruses: Strategies for and challenges to development

What information is needed to develop a vaccine? How have vaccines for other viruses such as H1N1 been developed?

#### Diagnostics and Therapeutics for Viruses

Two major concerns within diagnosis include the detection of current infections in individuals with and without symptoms, and the detection of past exposure without an active infection.
In the latter category, identifying whether individuals can develop or have developed sustained immunity is also a major consideration.

Within therapeutics, some possible efforts include efforts to identify strategies for the management of symptoms as well as the development of antivirals...

In this review, we seek to consolidate information about efforts to develop strategies for diagnosis and therapeutics as new information is released by the scientific community.


## Pathogenesis

### Mechanism of Host Infection by SARS-CoV-2

This section would also be great for the introduction of zoonotic diseases which has been shown to be the origin of SARS-CoV2.

#### Primary Transmission and Viral Entry

[How does SARS-CoV-2 enter human cells?]
[What cells are primary infection sites for SARS-CoV-2?]
[What structural aspects allow for viral entry]?

#### Viral Replication and Spreading

[Renamed section with transmission dynamics below] 
[Basic introduction into replication cycle]
[What are the routes of transmission]

#### Reproduction Number and Dynamics of Transmission

Accurate estimates of the reproduction number of a virus are crucial to understanding the dynamics of infection and to predict the effects of different interventions.
The basic reproduction number, R~0~, is the expected number of new infections caused by one infected person, assuming no time dependence and a wholly susceptible population [@doi:10.1111/j.1467-9574.1996.tb01482.x].
The effective reproduction number, R~t~, describes how the reproduction number may change over time, and is used to quantify deviations in R from R~0~, for example as some fraction of the population becomes infected, or as interventions are put into place.
R~0~ and R~t~ can be estimated directly from epidemiological data or inferred using mathematical modeling.
Modeling approaches are typically based upon a classic epidemiological model structure: the susceptible-infected-recovered (SIR) model and its extensions [@doi:10.1126/science.272.5258.74]. 

R~0~ for COVID-19 is estimated to lie in the range R~0~=1.4-6.5 [@doi:10/ggjvr7; @doi:10.1093/jtm/taaa021; @doi:10.1126/science.abb3221]; estimates vary considerably depending on the data and the methods used.
Data-derived estimates (i.e. those that do not incorporate SIR-type models into their analysis) typically predict lower values of R~0~.
For data-derived estimates, in one study of international cases, the predicted value is R~0~=1.7 [@doi:10.1101/2020.03.21.20040329], in China (both Hubei province and nationwide), the value is predicted to lie in the range R~0~=2.0-3.6 [@doi:10.2139/ssrn.3524675; @doi:10.1101/2020.01.25.919787; @doi:10/ggjvr7], and on a cruise ship where an outbreak occurred, predicted R~0~=2.28 [@doi:10.1016/j.ijid.2020.02.033].
SIR model-derived estimates of R~0~ range from 2.0 - 6.5 in China [@doi:10.3390/jcm9020462; @url:https://doi.org/10.1101/2020.01.27.20018952; @doi:10.1101/2020.01.23.916726; @doi:10.1101/2020.01.23.20018549] to R~0~=4.8 in France [@doi:10.1101/2020.03.22.20040915]. 
Using the same model as for the French population, this study estimated R~0~=2.6 in South Korea [@doi:10.1101/2020.03.22.20040915], which is consistent with other studies [@tag:Park2020_distancing].
From a meta-analysis of studies estimating R~0~, [@doi:10.1093/jtm/taaa021] predict the median as R~0~=2.79. 

Inference of the effective reproduction number can provide insight into how populations respond to an infection, and the effectiveness of interventions.
In China, R~t~ was predicted to lie in the range 1.6-2.6 in Jan 2020, before travel restrictions [@doi:10/ggptcf].
R~t~ decreased from 2.35 one week before travel restrictions were imposed (Jan 23, 2020), to 1.05 one week after.
Using their model, the authors also estimate the probability of new outbreaks occurring: the probability of a single individual exporting virus causing a large outbreak is 17-25% assuming MERS-like or SARS-like transmission, and the probability of a large outbreak occurring after ≥4 infections exist at a new location is greater than 50%.
An independent study came to similar conclusions: in a two-week period before Jan 23 finding R~t~=2.38, and decreasing to R~t~ = 1.34 (using data from Jan 24 to Feb 3) or R~t~=0.98 (using data from Jan 24 to Feb 8) [@doi:10.1126/science.abb3221].
In South Korea, R~t~ was inferred for Feb-Mar 2020 in two cities: Daegu (the center of the outbreak), and Seoul [@tag:Park2020_distancing].
Metro data was also analyzed to estimate the effects of social distancing measures.
R~t~ decreased in Daegu from around 3 to <1 over the period that social distancing measures were introduced.
In Seoul, R~t~ decreased slightly, but remained close to 1 (and larger than R~t~ in Daegu).
This highlights that social distancing measures appeared to work to contain the infection in Daegu, but that in Seoul, R~t~ remains above 1, thus secondary outbreaks are possible.
It also shows the importance of region-specific analysis: the large decline in case load nationwide is mainly due to the Daegu region, and could hide persistence of the epidemic in other regions, such as Seoul and Gyeonggi-do.
In Iran, estimates of R~t~ declined from 4.86 in the first week to 2.1 by the fourth week after the first cases were reported [@doi:10.1101/2020.03.20.20038422].
In Europe, analysis of 11 countries inferred the dynamics of R~t~ over a time range from the beginning of the outbreak until March 28, 2020, by which point most countries had implemented major interventions (such as school closures, public gathering bans, and stay-at-home orders) [@doi:10.25561/77731].
Across all countries, the mean R~t~ before interventions began was estimated as 3.87; R~t~ varied considerably, from below 3 in Norway to above 4.5 in Spain.
After interventions, R~t~ decreased by an average of 64% across all countries, with mean R~t~=1.43.
The lowest predicted value was 0.97 for Norway and the highest was 2.64 for Sweden (note that this is in part because Sweden did not implement social distancing measures on the same scale as other countries).
The study concludes that while large changes in R~t~ are observed, it is too early to tell whether the interventions put into place are sufficient to decrease R~t~ below 1.

### Immune Response to SARS-CoV-2

[Cellular responses to SARS-CoV-2 infection]
[What is causing neutropenia and lymphopenia observed in COVID-19 patients]
[Antibody production against SARS-CoV-2 by patient who recovered vs patient who did not recover]
[Cytokines and other soluble factors contribution to immune response]

### Systems level approaches for understanding SARS-CoV-2 pathogenesis

Systems biology provides a cross-disciplinary analytical platform integrating the different omics (genomics, transcriptomics, proteomics, metabolomics, and other omics approaches), bioinformatics, and computational strategies.
These cutting-edge research approaches have enormous potential to study the complexity of biological systems and human diseases [@doi:10.1016/j.gpb.2012.08.004].
Over the last decade, systems biology approaches have been used widely to study the pathogenesis of diverse types of life-threatening acute and chronic infectious diseases [@doi:10.1038/s41576-020-0212-5].
Omics-based studies also provided meaningful information regarding host immune responses and surrogate protein markers in several viral, bacterial and protozoan infections [@doi:10.1002/prca.201300074].

The complex pathogenesis and clinical manifestations of SARS-CoV-2 infection are not understood adequately yet.
A significant breakthrough in SARS-CoV-2 research was achieved through the successful full-length genome sequencing of the pathogen [@doi:10.1038/s41586-020-2008-3; @doi:10/ggjr43; @doi:10.1038/s41586-020-2012-7].
Multiple research groups have drafted the genome sequence of SARS-CoV-2 based on sequencing of clinical samples collected from bronchoalveolar lavage fluid (BALF) [@doi:10.1038/s41586-020-2008-3; @doi:10.1038/s41586-020-2012-7] or from BALF, throat swabs, or isolates of the virus cultured from BALF [@doi:10/ggjr43].
Importantly, SARS-CoV-2 has significant sequence homology with SARS-CoV (about 79%) and also to some extent with MERS-CoV (about 50%) [@doi:10/ggjr43].
However, a higher level of similarity (about 90%) has been observed between SARS-CoV-2 and bat-derived SARS-like coronaviruses (bat-SL-CoVZC45 and bat-SL-CoVZXC21), indicating a possible origin in bats [@doi:10/ggjr43; @doi:10.1038/s41586-020-2012-7].

The genome sequence of the pathogen subsequently allowed its phylogenetic characterization and prediction of its protein expression profile, which is crucial for understanding the pathogenesis and virulence of this novel viral infection.
Availability of the genome sequence of SARS-CoV-2 enhances the potential for subsequent proteome-level studies to provide further mechanistic insights into the virus' complex pathogenesis.
Of note, the cryo-electron microscopy structure of the SARS-CoV-2 spike (S) glycoprotein, which plays an important role in the early steps of viral infection, was reported very recently [@doi:10.1126/science.abb2507].
Even though no comprehensive proteomic analysis of the pathogen or of patients suffering from its infection has yet been reported, one forthcoming study has demonstrated SARS-CoV-2 infected host cell proteomics using human Caco–2 cells as an infection model [@doi:10.21203/rs.3.rs-17218/v1].
The authors observed SARS-CoV-2 induced alterations in multiple vital physiological pathways, including translation, splicing, carbon metabolism and nucleic acid metabolism in the host cells.

There is a high level of sequence homology between SARS-CoV-2 and SARS-CoV, and sera from convalescent SARS-CoV patients might show some efficacy to cross-neutralize SARS-CoV-2-S-driven entry [@doi:10.1016/j.cell.2020.02.052].
However, despite the high level of sequence homology, certain protein structures might be immunologically distinct, prohibiting effective cross-neutralization across different SARS strains [@doi:10.1101/2020.03.21.990770].
Consequently, earlier proteome-level studies on SARS-CoV can also provide some essential information regarding the new pathogen [@doi:10.1073/pnas.0407992101; @doi:10.1016/j.bbrc.2004.02.074].
Considering the paucity of omics-level big data sets for SARS-CoV-2 up until now, existing data hubs that contain information for other coronaviruses such as UniProt, NCBI Genome Database, The Immune Epitope Database and Analysis Resource (IEDB), and The Virus Pathogen Resource (ViPR) will serve as useful resources for computational and bioinformatics research on SARS-CoV-2.


## Diagnostics

### Current Strategies for Diagnosing COVID-19 and Similar Viral Infections

Given the high transmissibility of SARS-CoV-2, the development of reliable assays to detect SARS-CoV-2 infection even in asymptomatic carriers is vitally important. 
For instance, the deployment of wide-scale diagnostic testing followed by the isolation of infected people has been a key factor in South Korea's successful strategy for controlling the spread of the virus. 
Following the first release of the genetic sequence of the virus by Chinese officials on January 10 2020, the first test was released about 13 days later [@doi:10.2807/1560-7917.ES.2020.25.3.2000045]. 
Identifying individuals who have contracted the infection is crucial to slowing down the global pandemic. 
The assays available to date use the following approaches to identify the active virus in patient samples.

#### RT-PCR 

The Drosten Lab, from Germany, was the first lab to establish and validate a diagnostic test to detect SARS-Cov-2. 
This test uses real-time PCR (RT-PCR) [@doi:10.2807/1560-7917.ES.2020.25.3.2000045] to detect several regions of the viral genome: the orf1b of the RNA dependent RNA polymerase (RdRP), the Envelope protein gene (E), and the Nucleocapsid protein gene (N). 
In collaboration with several other labs in Europe and in China, the researchers confirmed the specificity of this test with respect to other coronaviruses against specimens from 297 patients infected with a broad range of respiratory agents. 
Specifically this tests utilizes two probes against RdRP of which one is specific to SARS-CoV-2 [@doi:10.2807/1560-7917.ES.2020.25.3.2000045]. 
Importantly, this assay did not give any false positive results.

#### QRT-tPCR

Around the same time, researchers in China developed a Quantitative Real Time Reverse Transcription PCR (QRT-tPCR) test to identify two region of the viral genome, orf1b and N region [@doi:10.1093/clinchem/hvaa029]. 
Specifically, this assay was tested on samples coming from two COVID-19 patients, including a panel of positive and negative controls consisting of RNA extracted from several cultured viruses. 
The assay uses the N gene to screen patients, while the orf1b is used to confirm the infection [@doi:10.1093/clinchem/hvaa029].
In this case the test was designed to detect sabercoviruses, of which SARS-CoV-2 is one. 
Considering that no other sarbecoviruses are currently known to infect humans, a positive test indicates that the patient is infected with SARS-CoV-2. 
However, this test is not able to discriminate the genetics of viruses within the sabercovirus clade. 

#### Limitation of PCR tests

One advantage of PCR tests it their sensitivity; however, several limitations with these tests introduce challenges to high-throughput testing:


1. False-negative responses, which can present a significant problem to large-scale testing.
To reduce occurrence of false negatives, correct execution of the analysis is crucial [@doi:10.1038/d41587-020-00002-2]. 

2. Uncertainty surrounding the SARS-Cov-2 viral shedding kinetics, which could affect the result of a test depending on when it was taken [@doi:10.1038/d41587-020-00002-2].

3. Type of specimen, as it is not clear which clinical samples are best to detect the virus [@doi:10.1038/d41587-020-00002-2].

4. Expensive machinery, which might be present in major hospitals and/or diagnostic centers but is often not available to smaller facilities [@doi:10.1126/science.abb8400]. 

5. Timing of the test, which might take up to 4 days to give results [@doi:10.1126/science.abb8400].

#### CRSPR test

Recently, two American companies, Mammoth Biosciences and Sherlock Biosciences, proposed to use CRISPR technology [@doi:10.1016/j.cell.2014.05.010] to increase the speed of Coronavirus diagnostic testing [@doi:10.1101/2020.03.06.20032334]. 
Their methodology includes RNA extraction from patient specimens followed by loop-mediated amplification (fast amplification) of the RNA and addition of the CRISPR reagents CAS12, which cuts the DNA or RNA, and the RNA guidance. 
The RNA guidance helps CAS12 to direct the cut of a sequence corresponding to a piece of the coronavirus genome. 
With this test, if CAS12 and its guide find a match in the RNA, then the cut occurs and the patient is positive for SARS-CoV-2.
Specifically, when CAS12 is active, it also cuts a designed strand containing molecules that change color once they are free [@doi:10.1101/2020.03.06.20032334]. 
This test can be as fast as 30 minutes, and the results indicator can be as simple as a color change on a strip [@doi:10.1126/science.abb8400].

#### Limitation of CRISPR test

False positives are a concern with this technique, as the guide RNA can recognize other interspersed sequences on the patient’s genome, resulting in a loss of specificity.

#### Sierological Tests

Despite diagnostic tests based on the detection of the genetic material can be quite sensitive, they cannot provide information about the real extent of the disease. In fact, they would not work on a recovered patient who defeated the virus. 
In this context, immunity tests are significantly more informative. 
In fact, they can help scientists figuring out why the disease has different course among patients, as well as what strategy might work to manage the spread of the infection. 
Furthermore, sierological tests hold significant interest at present because they can be leveraged to advance economic recovery.
For instance, people that have developed antibodies can return to work prior to the others, helping to develop the herd immunity which will prevent further diffusion of the virus.
Several countries are now focused on implementing antibody tests, and in the United States, the FDA recently approved a sierological test by Cellex for use under emergency conditions [@url:https://www.fda.gov/media/136625/download].
Specifically, the Cellex qSARS-CoV-2 IgG/IgM Rapid Test is a chromatographic immunoassay designed to qualitatively detect IgM and IgG antibodies against SARS-Cov-2 in the plasma of patients suspected to have developed the infection [@url:https://www.fda.gov/media/136625/download]. 
Such tests allow for the progress of the viral disease to be understood, as IgM are the first antibodies produced by the body and indicate that the infection is active. 
Once the body has responded to the infection, IgG are produced and gradually replace IgM, indicating that the body has developed immunogenic memory [@doi:10.1002/jmv.25820]. 
The test cassette contains a pad of SARS-Cov-2 antigens and a nitrocellulose strip with lines for each of IgG and IgM, as well as a control (goat IgG) [@url:https://www.fda.gov/media/136625/download].
In a specimen that contains antibodies against the SARS-CoV-2 antigen, the antibodies will bind to the strip and be captured by the IgM and/or IgG line(s), resulting in a change of color [@url:https://www.fda.gov/media/136625/download]. 
With this particular assay results can be read within 15-20 minutes [@url:https://www.fda.gov/media/136625/download]. 
Importantly, false positives can occur due to cross-reactivity with other antibodies depending on the clinical condition of the patient [@url:https://www.fda.gov/media/136625/download]. 
Therefore, this test should be used in combination with RNA detection tests [@url:https://www.fda.gov/media/136625/download]. 

### Possible Alternatives to Current Practices for Identifying Active Cases

[Are there other approaches that have worked for diagnosing other viruses at a rapid pace in large numbers of people?]
[What are some approaches people are currently testing for detecting live viruses, especially SARS-CoV-2?]

### Detection of Past Exposure and/or Sustained Immunity

[What are approaches that allow us to detect past exposure for other viruses?]
[What efforts are underway to develop similar approaches for SARS-CoV-2?]
[What is sustained immunity and what are the indicators?]

### Limitations to Implementation of Large-Scale Testing

[Right now, reagent supply is an issue. Are there others concerns that are likely to emerge?]

### Strategies and Considerations for Determining Whom to Test

[If it's not possible to test everyone, what strategies exist for selecting who to test?]
[Are these strategies likely to change over time? Presumably there are different stages of managing spread vs mitigating severity once it's already at high prevalence?]


## Therapeutics

Given the rapid predicted spread of the disease, the development of therapeutics will be critical to mitigating its effect on health and the mortality rate.
Typically, therapeutics can take a few forms.
First, the treatment and reduction of symptoms can result in the reduction of the severity and risk associated with an active infection.
Second, the development of antiviral drugs can drive a reduced recovery time for patients by inhibiting the development of the virus once an individual is infected.
Finally, vaccines present a strategy for bolstering the immune response of the populus broadly to the virus, resulting in a lower rate of infection.
All three of these strategies have been valuable elements of responses to other viruses, including coronaviruses, and are being investigated by researchers at present.
Additionally, there have been suggestions within the scientific community that nutraceutical or dietary supplement interventions may prime an individual’s immune system to prevent or lessen the impact of RNA virus infections [@doi:10.1016/j.pcad.2020.02.007; @doi:10/ggkd3b].
In the following sections, we critically appraise the literature surrounding the repurposing of existing treatments and development of novel therapeutics for the prevention, mitigation, and treatment of coronavirus infections.  

### Treatment of Symptoms

The clinical picture of SARS-CoV-2 infection differs dramatically between individuals.
Some are asymptomatic.
Others experience mild COVID-19 symptoms, such as cough, sore throat and fever, while the most severe cases of COVID-19 include severe complications including pneumonia and Acute Respiratory Distress Syndrome (ARDS), which can lead to respiratory failure and death [@url:https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html].
Vaccines are one avenue to mitigate harm from viral pathogens, but in the case of a rapidly growing pandemic the longer timeframe of vaccine development and distribution means that there can be a key for treatments that palliate symptoms to avoid the most severe outcomes from infection.

#### Tocilizumab

A recent study carried out on a sample of 191 adult COVID-19 in-patients at two Wuhan hospitals found that blood samples taken at admission contained significantly higher concentrations of interleukin-6 (IL-6) in patients who ultimately deceased compared to those who survived; average concentrations of IL-6 remained higher in the deceased group than the surviving group throughout hospitalization [@doi:10/ggnxb3].
This suggests that these individuals may be experiencing a "cytokine storm", which refers to an excessive inflammatory response.
IL-6 plays a key role in this response [@doi:10.1128/mmbr.05015-11].
IL-6 is a pro-inflammatory cytokine belonging to the family of interleukins, which are immune system regulators that are primarily responsible for immune cell differentiation.
Specifically, IL-6 promotes the differentiation of activated B cells into immunoglobulin-producing plasma cells [@pmid:9052836] and acts as a growth factor for hybridoma and myeloma cells [@pmid:8431556; @pmid:2104241].
In addition, IL-6 also induces the differentiation of naïve CD4+ T cells into effector T-cell subsets [@doi:10.1158/2326-6066.CIR-14-0022].
In this way interleukins regulate both the pro- and anti-inflammatory responses.
In this context, the observation of elevated IL-6 in patients who died may reflect an over-production of proinflammatory interleukins.

In a healthy situation the lung respiratory epithelium together with alveolar macrophages limits the activation of the immune system, ensuring homeostasis.
The introduction of the S-protein from SARS-CoV to mouse macrophages was found to increase production of IL-6 and TNF-α [@doi:10.1016/j.virusres.2007.02.007], and deceased SARS-CoV patients were found to have intermediate levels of IL-6, IL-1𝛽, and TNF-α expressed in a number of ACE2-expressing cell types sampled from the lung and bronchial tissues during autopsy [@doi:10.1002/path.2067].
However, other reports found the severe respiratory condition ARDS to be associated with elevated concentrations of IL-6 in BALF, but that concentrations of Tumor Necrosis Factor α (TNF-α) and IL-1𝛽 decreased with the onset of ARDS [@doi:10.1164/ajrccm.164.10.2104013].
These cytokines enhance the pro-inflammatory reaction by increase acute-phase signaling, trafficking of immune cells to the site of primary infection, epithelial cell activation, and secondary cytokine production.
The acute phase response to infection results in the heavily damage of the endotelium of blood vessels, which disrupts the balance between pro and anti-inflammatory response [@doi:10.1164/ajrccm.164.10.2104013].
Thus, the holes generated allow not just for the passage of neutrophils, macrophages and lymphocytes to the site of the infection but also the accumulation of liquids into the lungs, which is the ultimate cause of the death as per Acute Distress Respiratory Syndrome (ADRS) or Severe Acute Respiratory Syndrome (SARS) [@doi:10.1007/s00281-017-0629-x], also caused by the new coronavirus.
Recently Chinese and Italian doctors have found that the the Tocilizumab (actemra, by Roche), a drug commonly used in the rheumatoid arthritis, may palliate the most severe symptoms associated with COVID-19.

##### Anticipated Mechanism

Human IL-6 is a glycoprotein of 26 kDa and it consists of 184 amino acids containing 2 potential N-glycosylation sites and four cysteine residues. IL-6 binds to its receptor either in the insoluble (IL-6R) and soluble (sIL-6R) form.
The receptor specificity determines the type of signaling. Specifically, the binding of IL-6 to the cell membrane receptor IL-6R gives rise to the "classical transduction of the signaling", while to binding to sIL-6R generate the so called "trans-signaling" [@doi:10.1016/j.cytogfr.2012.04.001; @doi:10.1042/bj3000281].
IL-6 signaling occurs through 3 independent pathways: the Janus-activated kinase (JAK)-STAT3 pathway, the Ras/Mitogen-Activated Protein Kinases (MAPK) pathway and the Phosphoinositol-3 Kinase (PI3K)/Akt pathway [@doi:10.3389/fimmu.2016.00604].
The ultimate result of the IL-6 cascade is to direct transcriptional activity of various promoters of pro-inflammatory cytokines, such as IL-1 and TFN, including IL-6 own regulation through the activity of NF-κB [@doi:10.3389/fimmu.2016.00604].
Particularly, IL-6 synthesis is tightly regulated both transcriptionally and post-transcriptionally . In this context, it has been shown that viral proteins can enhance transcription of the IL-6 gene, via strengthening the DNA-binding activity between several transciptional factors and IL-6 gene-cis-regulatory elements [@doi:10.2492/inflammregen.33.054].
Tocilizumab is a humanised monoclonal antibody that binds both to the insoluble and soluble receptor of IL-6, de facto inhibiting the IL-6 immune cascade.

##### Current Evidence

Chinese doctors have started a trial enrolling 188 patients of which 14 with severe lung disease have shown clear sings of improvements, according to their results [@url:https://www.genengnews.com/virology/coronavirus/genentech-launches-phase-iii-trial-of-actemra-as-coronavirus-treatment/].
Also, The AIFA (the Italian Drug Agency) approved the start of a new trial on March 19 recruiting patients at the initial stage of the infection [@url:https://www.univadis.co.uk/viewarticle/covid-19-italy-launches-an-independent-trial-on-tocilizumab-715741].
Together with these independent trials, Roche, also in collaboration with the FDA, will start a randomised, double-blind, placebo-controlled phase III trial early April.
The trial will enroll 330 patients globally, which will be followed for 60 days upon use of the drug via injection to analyse its efficiency/safety (Biopharma-reporter.com).
However, previous studies on RA showed that in patients treated with TCZ the rate of incident infections in clinical practice patients was higher than the one observed during clinical trial [@doi:10.1093/rheumatology/ker223].
Also, RA patients with chronic hepatitis B (HB) infection showed high risk of HB virus reactivation upon TCZ administration in combination with other RA drugs [@doi:10.1111/1756-185X.13010].
These last findings highlight the need to search for a balance between impairing a harmful immune response, such as the one generated by the cytokine storm, and preventing the worsening of the clinical picture of the patients by potential new viral infections.
This aspect is probably crucial to be investigated further in the trials that are about to start.
Perhaps, the TCZ treatment would best suit patients with severely compromised lungs due to the Covid-19 infection and are therefore at greater risk of death, in order to stop the uncontrolled immune response before it’s too late.

##### Summary

Summarize the state of the symptom management approach.

### Small Molecule Drugs for Targeting SARS-CoV-2

The replication cycle of a virus within an epithelial host cell includes 6 basic steps which can be shortly summarised as follow: i) attachment of the virus to the host cell; ii) penetration by endocytosis; iii) uncoating, classically defined as the release of viral contents into the host cell; iv) biosynthesis, during which the viral genetic material enters the nucleus where it gets replicated; v) assembly, where viral proteins are translated and new viral particles are assembled; vi) release, when the new viruses are released into the extracellular environment [@isbn:978-1405136457].
Antiviral drugs do not kill the virus, rather they inhibit its amplification by impairing one of these steps.
Nowadays, many of these drugs act during the biosynthesis step in order to inhibit the virus’ genetic material replication.
Importantly, SARS-CoV-2 is an RNA virus.
Differently from a DNA virus, which can use the host enzymes to propagate itself, RNA viruses depends on their own polymerase, the RNA-dependent RNA polymerase (RdRP), in order to be replicated [@doi:10.1007/978-1-4939-2438-7; @doi:10.1002/jmv.25761].

#### Nucleotide Analogs

Why one might use nucleotide analogs.

##### Avigan

Avigan (Flavipiravir, from Toyama chemical Fujifilm) is a drug which has been found effective to block viral amplification in the Influenza virus infection.

###### Anticipated Mechanism

Specifically, Avigan is a nucleoside precursor efficiently recognised as guanosine and adenosine analogue by the virus polymerase (RNA-dependent RNA polymerase).
While a single incorporation does not influence RNA transcription, multiple events of incorporation lead to the arrest of RNA synthesis [@doi:10.1371/journal.pone.0068347].
Importantly It was already shown that Avigan is able to give 100% coverage against the Ebola virus in mice [@doi:10.1016/j.antiviral.2014.02.014].
Furthermore, there are evidences that drug might also work against Corona virus infection.
For instance, a recent study showed its effectiveness compared to other antivirals such as lopinavir and ritonavir [@doi:10.1016/j.eng.2020.03.007].
The drug was tested on a sample of 80 patients (35 experimental sample, 45 control group) and increased the speed of recovery (measured as viral clearance from the patient by RT-PCR) of about 4 days, compared to the control sample treated with the other anti-virals, such as Lopinavir and Ritonavir.
Also lung body scan seem to look better in about 91% of the patients analysed [@doi:10.1016/j.eng.2020.03.007].
However, the size of the sample is too small to give a powerful statistics, as well as the choice of the patients did not take into consideration important factors such as previous clinical conditions, sex, while there was no age categorisation.

###### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

###### Summary

Summarize the state of the antiviral approach.

##### Remdesivir

Remdesivir (GS-5734) was developed by Gilead Sciences to treat Ebola.
It does not have any FDA-approved use.
Although a clinical trial in the Democratic Republic of Congo found some evidence of effectiveness against ebola, two antibody preparations were found to be more effective, and Remdesivir was not pursued [@doi:10.1056/NEJMoa1910993].

###### Anticipated Mechanism

Remdesivir is metabolized to GS-441524, an adenosine analog that inhibits a broad range of polymerases and then evades exonuclease repair causing chain termination [@doi:10.1074/jbc.AC120.013056; @doi:10.1128/mBio.00221-18; @doi:10.1038/s41422-020-0282-0].
Although it was developed against Ebola, it also inhibits the MERS-CoV and SARS-CoV polymerase and inhibits coronavirus replication in cell culture assays with submicromolar IC50s [@doi:10.1126/scitranslmed.aal3653].
It also inhibits SARS-CoV-2, showing synergy with chloroquine [@doi:10.1038/s41422-020-0282-0].

###### Current Evidence

In addition to the previous work showing Remdesivir to be an effective treatment for viral pathogens such as SARS-CoV and MERS-CoV in cultured cells and animal models, a recent study found that administration of Remdesivir to non-human primate models resulted in 100% protection against infection by the Ebola virus.
Remdesivir has also been reported to inhibit SARS-CoV-2 infection in a human cell line sensitive to the virus [@doi:10.1038/s41422-020-0282-0].

The effectiveness of Remdesivir for treating patients with COVID-19 is currently under investigation.
Remdesivir has been used on some COVID-19 patients under compassionate use guidelines [@doi:10.1126/science.abb7243, @doi:10.1056/NEJMoa2001191; @doi:10.1101/2020.03.09.20032896].
All were in late stages of COVID-19 infection, and these reports are inconclusive about the drug's efficacy.
Remdesivir recently entered controlled clinical trials, and as of March 2020, there are six clinical trials underway to treat COVID-19 patients at both early and late stages of infection and in combinations with other drugs [@doi:10.1038/s41422-020-0282-0; @url:https://clinicaltrials.gov/ct2/show/NCT04292730; @url:https://clinicaltrials.gov/ct2/show/NCT04292899; @url:https://clinicaltrials.gov/ct2/show/NCT04280705; @url:https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR; @url:https://clinicaltrials.gov/ct2/show/NCT04252664; @url:https://clinicaltrials.gov/ct2/show/NCT04257656].

###### Summary

Remdesivir is a major drug candidate since it attacks the virus with high potency and known mechanism.
Moreover, one of the most successful therapies for viral diseases is to target the viral replication machinery, which are typically virally encoded polymerases.
Small molecule drugs targeting viral polymerases are the backbones of treatments for other viral diseases including HIV and Herpes.
Note that the HIV and Herpes polymerases are a reverse transcriptase and a DNA polymerase respectively, whereas SARS-CoV-2 encodes an RNA dependent RNA polymerase, so most of the commonly used polymerase inhibitors are not likely to be active against SARS-CoV-2.
In clinical use, polymerase inhibitors show short term benefits for HIV patients but for long term benefits they must be part of combination regimens.
They are typically combined with protease inhibitors, integrase inhibitors and even other polymerase inhibitors.   

###### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

###### Summary

Summarize the state of the antiviral approach.

#### Protease Inhibitors

Why it may be useful

##### Protease Inhibitor 1

###### Anticipated Mechanism

###### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

###### Summary

Summarize the state of the antiviral approach.

#### Molecules Targeting the Viral Envelope

Why it may be useful

##### Viral Envelope Targeter 1

###### Anticipated Mechanism

###### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

###### Summary

Summarize the state of the antiviral approach.

### Drugs Targeting Host Proteins

Brief background on the therapeutic.

#### Drug (or drug class) 1

##### Viral Entry Receptors

Why it may be useful

###### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

###### Summary

Summarize the state of the antiviral approach.

### Broad-Spectrum Pharmaceuticals

##### Hydroxychloroquine and Chloroquine

Hydroxychloroquine (HCQ) and chloroquine (CQ) are quinolones that have been widely used as anti-malarial and disease-modifying anti-rheumatic drugs in humans.
HCQ and CQ act through the same mechanism of action, but HCQ is regarded to be safer [@doi:10.1136/ard.2008.101766].
HCQ/CQ have been reported to have anti-viral effects, including in HIV-1, SARS-CoV, MERS-CoV, and SARS-CoV-2 [@doi:10/dh8phb; @doi:10.1128/AAC.03011-14; @doi:10.1093/cid/ciaa237; @doi:10.1038/s41422-020-0282-0].
_In vitro_ studies of CQ use for SARs-CoV infection suggest anti-viral activity is due to inhibition of viral entry through elevation of endosomal pH and terminal glycosylation of angiotensin-converting enzyme 2, the cellular entry receptor [@doi:10.1186/1743-422X-2-69].
In vitro studies of SARS-CoV-2 infection show both HCQ and CQ to be effective in inhibiting viral replication, with HCQ being more potent [@doi:10.1093/cid/ciaa237].
Thus, there is excitement about HCQ as a potential therapeutic for SARS-CoV-2 and COVID-19.
This section will discuss current efforts on assessing the potential impact of HCQ in treating COVID-19.

###### Current Evidence

Gautret et al conducted a non-randomized, non-blinded, non-placebo clinical trial on 42 hospitalized patients comparing HCQ to standard care [@doi:10.1016/j.ijantimicag.2020.105949].
This trial found patients who received HCQ showed higher rates of virological clearance by nasopharyngeal swab on Days 3-6 when compared to standard care.
This study also treated six patients with both HCQ + azithromycin and found this combination therapy to be more effective than HCQ alone.
This study showed design and analysis weaknesses that severely limit interpretability of results.
These weaknesses include: lack of randomization, lack of blinding, lack of placebo, lack of Intention-To-Treat analysis, lack of correction for sequential multiple comparisons, trial arms entirely confounded by hospital, false negatives in outcome measurements, lack of trial pre-registration, and small sample size.
Two of these weaknesses are due to inappropriate data analysis and can therefore be corrected post-hoc by recalculating p-values (lack of Intention-To-Treat analysis and multiple comparisons.)
However, all other weaknesses are fundamental design flaws and can not be corrected for.
Thus, conclusions cannot be generalized outside of the study.
Additionally, the International Society of Antimicrobial Chemotherapy, the scientific organization that publishes _International Journal of Antimicrobial Agents_ where the article appeared, has announced that the article does not meet its expected standard for publications [@url:https://www.isac.world/news-and-publications/official-isac-statement], although it has not been officially retracted.
Because of the preliminary data presented in this study, the use of HCQ in COVID-19 treatment has subsequently been explored by other researchers.

A randomized, non-placebo trial of 62 COVID-19 patients at the Renmin Hospital of Wuhan University studied whether HCQ decreased time to fever break or time to cough relief when compared to standard care [@doi:10.1101/2020.03.22.20040758].
This trial found HCQ decreased both average time to fever break and average time to cough relief, defined as mild or no cough.
However, this study also had flaws in trial design and analysis that prevent generalization of the results.
These weaknesses include: lack of placebo, lack of correction for multiple primary outcomes, inappropriate choice of outcomes, lack of sufficient detail to understand analysis, drastic disparities between pre-registration and published protocol, and small sample size.
The choice of outcomes may be inappropriate as both fevers and cough may break periodically without resolution of illness.
Additionally, for these outcomes, the authors report 23/62 patients did not have fever and 25/62 patients did not have cough at the start of the study - the authors fail to describe how these patients were included in a study assessing time to fever break and time to cough relief.
It is important to note here that the authors claim "neither the research performers nor the patients were aware of the treatment assignments."
This seems impossible in a non-placebo trial - at the very least, providers would know whether they were administering a medication or not, and this knowledge could lead to systematic differences in how care is given.
Correction for multiple primary outcomes can be adjusted post-hoc by recalculating p-values, but all other issues are design and statistical weaknesses that cannot be corrected for.
Additionally, the observation of drastic disparities between pre-registration and published protocol may be suggestive of p-hacking.
Conclusions cannot de generalized outside of the study, but the results support further investigation.

A randomized trial from the Shanghai Public Health Clinical Center of 30 COVID-19 patients studied whether HCQ increased rates of virological clearance by respiratory pharyngeal swab on Day 7 post-treatment compared to standard care [@doi:10/drbx].
This trial was published in Chinese with an abstract also in English.
Only the English abstract was read and interpreted.
The trial found HCQ showed comparable outcomes to standard care with regard to virological clearance rate, time to virological clearance, and time to body temperature normalization.
A known weakness is small sample size.
This problem suggests the study is underpowered to detect potentially useful differences and precludes interpretation of results.
Additionally, because only the abstract could be read, other design and analysis issues could be present.
Conclusions should be interpreted very cautiously.
However, these preliminary negative results do reiterate the need for further study.

A case study treated 11 consecutive patients with HCQ + azithromycin using the same dosing regime reported by Gautret et al [@doi:10.1016/j.medmal.2020.03.006].
One patient died, two were transferred to the ICU, and one developed a prolonged QT interval leading to discontinuation of HCQ + azithromycin.
As in the Gautret et al study, the outcome measurement was virological clearance at Day 6 post-treatment by nasopharyngeal swabs.
Of the ten living patients on Day 6, eight of the patients remained positive for SARS-CoV-2 RNA.
Interpretation of conclusions are severely limited by lack of comparison group and small sample size.
However, these results stand in contrast to claims by Gautret et al that all six patients treated with HCQ + azithromycin tested negative for SARS-CoV-2 RNA by Day 6 post-treatment.
This case study illustrates the need for better and further investigation.

A Letter to the Editor was published in BioScience Trends claiming numerous clinical trials showed HCQ is superior to control treatment in inhibiting the exacerbation of COVID-19 pneumonia [@doi:10.5582/bst.2020.01047].
This Letter has been cited by numerous primary literature, review articles, and media alike [@doi:10.7150/ijbs.45498; @doi:10.7150/ijbs.45053].
Yet, this Letter's claims of clinical trials supporting HCQ use refer only to 15 pre-registration identifiers from the Chinese Clinical Trial Registry.
When these identifiers are followed back to the registry, most trials claim they are not yet recruiting patients or are currently recruiting patients.
For all of these 15 identifiers, no data uploads or links to publications could be located on the pre-registrations.
At the very least, an inability to locate primary data means such claims cannot be verified.
Additionally, citation of unavailable sources cast doubt on policies and research based on the assumption that HCQ is effective in treating COVID-19.

###### Summary

In vitro evidence shows HCQ may be an effective therapeutic against SARS-CoV-2 and COVID-19. 
Multiple clinical studies have already been carried out to assess this possibility.
All current studies are low-quality and have small sample sizes.
Thus, interpretation is severely limited and must be done cautiously.
Additionally, disagreements between studies demonstrate there is controversy on the effectiveness of HCQ, as well as HCQ + azithromycin combination therapy.
<!-- 
rishirajgoel to add text on Azithromycin
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262884/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918160/
https://www.ncbi.nlm.nih.gov/pubmed/28099856
https://www.ncbi.nlm.nih.gov/pubmed/27911847
-->
This uncertainty is important to recognize clinically because HCQ-based treatments can lead to dangerous side effects like prolonged QT interval [@doi:10.1155/2016/4626279].
HCQ use for COVID-19 also leads to shortages for anti-malarial or anti-rheumatic use, where it has been definitively proven to be effective.
Further investigation of HCQ in large, rigorous, multi-center clinical trials is necessary.

#### Nutraceuticals

Considering the current pandemic, scientists and the medical community are scrambling to repurpose or discover novel host-directed therapies for which nutraceuticals hold some promise.
Nutraceuticals are classified as supplements with health benefits beyond their basic nutritional value designed for the prophylaxis and treatment of disease [@doi:10.1080/10408390902841529; @doi:10.1038/nrcardio.2016.103].
Nutraceuticals purported to boost the immune response, reduce  immunopathology, exhibit antiviral activities or prevent acute respiratory distress syndrome (ARDS) are being considered for their potential therapeutic value [@doi:10/ggkd3b].
A host of potential candidates have been highlighted in the literature that target various aspects of the COVID-19 viral pathology, while others are thought to prime the host immune system.
These candidates include vitamins and minerals along with extracts and omega-3 polyunsaturated fatty acids (n-3 PUFA) [@doi:10.1002/jmv.25707].
Considerable evidence in vitro and in vivo suggests that nutraceuticals containing phycocyanobilin, N-acetylcysteine, glucosamine, selenium or phase 2 inductive nutraceuticals (e.g. ferulic acid, lipoic acid, or sulforaphane) can prevent or modulate RNA virus infections via amplification of the signaling activity of mitochondrial antiviral-signaling protein (MAVS) and activation of toll-like receptor 7 (TLR7) [@doi:10.1016/j.pcad.2020.02.007]. 
While promising, further animal and human studies are required to assess the therapeutic potential of these various nutraceuticals against COVID-19. 

##### n-3 PUFA

Another potential nutraceutical that has exhibited beneficial effects against various viral infections is n-3 PUFA [@doi:10.1002/jmv.25707], such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
EPA and DHA intake can come from a diet high in fish intake or through dietary supplementation with fish oils or purified oils [@doi:10.3390/molecules22111964].


###### Potential Mechanisms

N-3 PUFA nutraceuticals can mediate inflammation and they have the capacity to modulate the adaptive immune response [@doi:10.1111/j.1365-2125.2012.04374.x; @doi:10.3390/molecules22111964; @doi:10.1038/nrcardio.2016.103].
Another potential mechanism by which n-3 PUFA could exert beneficial effects against viral infections is by acting as precursor molecules for the biosynthesis of endogenous specialised proresolving mediators (SPM) like protectins and resolvins that actively resolve inflammation and infection [@doi:10.1016/j.immuni.2014.02.009]. 

###### Current Evidence

SPM have exhibited beneficial effects against a variety of lung infections including RNA viruses [@doi:10.1038/nri.2015.4].
Indeed, protectin D1 has been shown to increase survival from H1N1 viral infection in mice by affecting the viral replication machinery [@doi:10.1016/j.cell.2013.02.027].
Moreover, not all studies are in agreement that n-3 PUFA are effective against infections [@doi:10.3945/jn.109.108027]. 
Indeed, the effectiveness of n-3 PUFA against infections is dependent on the dosage, timing, and the specific pathogens responsible [@doi:10.1016/j.jinf.2016.10.001].  

###### Summary

However, the overall lack of human studies in this area means there is limited evidence as to whether these nutraceuticals could affect COVID-19 infection.  

##### Zinc Supplements

There is evidence that nutrient supplements may exhibit some benefit against RNA viral infections.
Zinc is a trace metal obtained from dietary sources or supplementation that is important for the maintenance of immune cells involved in adaptive and innate immunity [@doi:10.1016/j.abb.2016.03.022].
Zinc supplements can be administered orally as a tablet or as a lozenge and they are available in many forms such zinc picolinate, zinc acetate, and zinc citrate.
Zinc is also available from dietary sources including meat, seafood, nuts, seeds, legumes, and dairy.

###### Potential Mechanisms

The role of zinc in immune function has been extensively reviewed [@doi:10.1016/j.abb.2016.03.022].
Zinc is an important signaling molecule and zinc levels can alter host defense systems. 
In inflammatory situations such as an infection, zinc can regulate leukocyte immune responses and it can activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), thus altering cytokine production [@doi:10.4049/jimmunol.179.6.4180; @doi:10.1067/mlc.2001.118108]. 
In particular, zinc supplementation can increase natural killer cell levels, which are important cells for host defense against viral infections [@doi:10.1126/science.1198687; @doi:10.1016/j.abb.2016.03.022].

###### Current Evidence

Adequate zinc intake has been associated with reduced incidence of infection [@doi:10.1093/ajcn/85.3.837] and antiviral immunity [@doi:10.1093/advances/nmz013].
Similarly, a randomized, double-blind, placebo-controlled trial that administered zinc supplementation to elderly subjects over the course of a year found zinc deficiency to be associated with increased susceptibility to infection and that zinc deficiency could be prevented through supplementation [@doi:10.1093/ajcn/85.3.837].
Clinical trial data supports the utility of zinc to diminish the duration and severity of symptoms associated with common colds when it is provided within 24 hours of the onset of symptoms [@doi:10.1331/1544-3191.44.5.594.Hulisz; @doi:10.2174/1874306401105010051].
In coronaviruses specifically, in vitro evidence demonstrates that the combination of zinc (Zn2+) and zinc ionophores (pyrithione) can interrupt the replication mechanisms of SARS-CoV-GFP (a flourescently tagged SARS-CoV) and a variety of other RNA viruses [@doi:10.1371/journal.ppat.1001176; @doi:10.1016/j.antiviral.2014.12.015].

###### Summary

While overall there is encouraging data for zinc supplementation against the common cold and viral infections, there is currently limited evidence to suggest zinc supplementation has any beneficial effects against the current novel COVID-19, thus further research is imperative.
However, it would be advisable to maintain a healthy diet to ensure an adequate zinc status to prevent the likelihood of an infection. 

##### Vitamin C

Vitamins B, C, D, and E have also been suggested as potential nutrient supplement interventions for COVID-19 [@doi:10.1002/jmv.25707; @doi:10.20944/preprints202003.0347.v1].
In particular vitamin C has been proposed as a potential prophylactic and therapeutic agent against COVID-19. 
Vitamin C can be obtained via dietary sources such as fruit and vegetable or via supplementation.  

###### Potential Mechanisms
Vitamin C plays a signifiant role in promoting immune function due to its effects on various immune cells. 
Vitamin C affects inflammation by modulating cytokine production, decreasing histamine levels, enhancing the differentiation and proliferation of T- and B-lymphocytes, increasing antibody levels, and protecting against the negative effects of reactive oxygen species amongst other effects [@doi:10.1155/2014/426740; @doi:10.1007/s00210-013-0880-1; @doi:10.3390/nu9111211]. 
During viral infections vitamin C is utilised as evinced by lower concentrations in leukocytes and lower concentrations of urinary vitamin C. 
Post-infection, these levels return to baseline ranges [@doi:10.1177/003693307301800102; @doi:10.1111/j.1749-6632.1975.tb29312.x; @doi:10/fd22sv; @doi:10.3390/nu9040339; @doi:10.1079/bjn19920004]. 

###### Current Evidence

A recent meta-analysis found consistent support for regular vitamin C supplementation reducing the duration of the common cold, but that supplementation with vitamin C (> 200 mg) failed to reduce the incidence of colds [@doi:10.1002/14651858.CD000980.pub4].
Individual studies have found Vitamin C to reduce the susceptibility of patients to lower respiratory tract infections such as pneumonia [@doi:10.1097/00006454-199709000-00003].
A recent meta-analysis has demonstrated in twelve trials that vitamin C supplementation reduced the length of stay of patients in intensive care units (ICUs) by 7.8% (95% CI: 4.2% to 11.2%; p = 0.00003).
Furthermore, high doses (1-3 g/day) significantly reduced the length of an ICU stay by 8.6% in six trials (p = 0.003).
Vitamin C also shortened the duration of mechanical ventilation by 18.2% in three trials in which patients required intervention for over 24 hours (95% CI 7.7% to 27%; p = 0.001)  [@doi:10.3390/nu11040708]. 
Despite these findings, the CITRUS ALI study failed to show a benefit of a 96-hour infusion of vitamin C to treat ARDS, which is a severe complication of COVID-19 infection [@doi:10.1001/jama.2019.11825].

###### Summary

The evidence suggests that vitamin C supplementation can shorten the duration of a cold, reduce an individual's susceptibility to infections, and shorten a patient's stay in ICU when administered at high doses.
While there is anecdotal evidence from China and the United States that vitamin C is currently being used for the treatment of COVID-19,  further controlled research is required.

##### Vitamin D

In terms of other dietary supplements, vitamin D can modulate the adaptive and innate immune system and has been associated with various aspects of health. 
Vitamin D can be sourced through diet or supplementation, but it is mainly biosyntheised by the body on exposure to sunlight.

###### Potential Mechanisms

Vitamin D deficiency is associated with an increased susceptibility to infection [@doi:10.2310/JIM.0b013e31821b8755].
In particular, vitamin D deficient patients are at risk of developing acute respiratory infections [@doi:10.1016/j.jsbmb.2012.11.017] and ARDS [@doi:10.1016/j.jsbmb.2012.11.017]. 
1,25-dihydroxyvitamin D3 is the active form of vitamin D that is involved in adaptive and innate resopnses, whereby the vitamin D receptor is expressed in various immunne cells and vitamin D is an immunomodulator of antigen presenting cells, dendritic cells, macrophages, monocytes, and T- and B-lymphocytes [@doi:10.2310/JIM.0b013e31821b8755; @doi:10.1016/j.coph.2010.04.001].
Due to its potential immunomodulating properties, vitamin D supplementation may be advantageous to maintain a healthy immune system. 

###### Current Evidence

A recent preprint postulated that an individual’s vitamin D status may significantly affect one’s risk of developing COVID-19. 
This hypothesis was derived from the fact that the current pandemic occurred in winter in Wuhan China when 25-hydroxyvitamin D concentrations are at their lowest due to lack of sunlight, whereas in the Southern Hemisphere, where it was nearing the end of the summer, the number of cases was low at that time coinciding with higher 25-hydroxyvitamin D concentrations [@doi:10.20944/preprints202003.0235.v2].
The authors suggest that people at risk of developing COVID-19 should increase their vitamin D3 intake to reach 25-hydroxyvitamin D plasma concentrations above 40–60 ng/ml.
The authors also suggest supplementation of vitamin D to treat infected patients and to prevent infection in hospital staff.
While vitamin D is relatively inexpensive and safe to consume, caution is warranted when interpreting this review as it has yet to be determined whether vitamin D levels effect COVID-19 specifically. 
Likewise, it is assumed that COVID-19 may be seasonal, but there are multiple other factors at play that can affect vitamin D levels that need to be considered.
These factors include an individual’s nutritional status, their age, their occupation, skin pigmentation, potential comorbidities, and the variation of exposure to sunlight due to latitude amongst others [@doi:10.3390/nu7075111].   

###### Summary
  
Supplementation of vitamin D and maintaining a healthy diet for optimum vitamin D status warrants further investigation. 
This is particularly important considering ‘stay in place’ guidance has been implemented in many densely populated cities around the world.
This measure is likely to limit people’s exposure to sunlight and thus reduce endogenous synthesis of vitamin D, potentially weakening the immune system and increasing the risk of COVID-19 infection. 

##### Nutraceutical Conclusions

Despite all the potential benefits of nutraceutical and dietary supplement interventions presented, currently there is a paucity of clinical evidence to support their use for the prevention or mitigation of COVID-19 infections. 
Nevertheless, optimal nutritional status will undoubtedly prime an individual’s immune system to protect against the effects of acute respiratory viral infections by supporting normal maintenance of the immune system [@url:https://www.preprints.org/manuscript/202003.0199/v1].
Overall, supplementation of vitamin C, vitamin D, and zinc may be an effective method of ensuring their adequate intake to maintain optimal immune function, which may also convey beneficial effects against viral infections due to their immunomodulatory effects.
However, many supplements and nutraceuticals designed for various ailments are available in the United States and beyond that are not strictly regulated [@doi:10.1080/10408398.2019.1592107]. 
Indeed, there can be safety and efficacy concerns associated with many of these products.
Often, the vulnerable memeber of society can be exploited in this regard and unfortunately the COVID-19 pandemic is no different. 
The Food and Drug Administration (FDA) has issued warnings to several companies for advertising falsified claims in relation to the preventative and therapeutic capabilities of their products against COVID-19 [@url:https://www.fda.gov/news-events/press-announcements/coronavirus-update-fda-and-ftc-warn-seven-companies-selling-fraudulent-products-claim-treat-or].  
In light of these serious occurrences, it is pertinent to clarify that the nutraceuticals discussed in this review have been selected because of their possible relevance to the biological mechanisms that can beneficially affect viral and respiratory infections.
Therefore, further intensive investigation is required to establish the effects of these nutraceticals, if any, against COVID-19.  

### Biological Drugs for COVID-19

#### Neutralizing Antibodies

Monoclonal antibodies (mAbs) have revolutionized the way we treat human diseases. 
As a result, they have become some of the best-selling drugs in the pharmaceutical market in recent years [@doi:10.1186/s12929-019-0592-z].
There are currently 79 FDA approved mAbs on the market including antibodies for viral infections (e.g. Ibalizumab for HIV and Palivizumab for RSV) [@doi:10.1186/s12929-019-0592-z; @doi:10.1146/annurev-immunol-032712-095916].
Although vaccines remain the most important way to prevent viral infections, their development process is long and they fail to provide immediate prophylactic protection or treat ongoing infections [@doi:10.3390/v10120680].
For that reason, neutralizing antibodies have emerged to address these shortcomings.
Virus-specific neutralizing antibodies commonly target viral surface glycoproteins or host structures, thereby inhibiting viral entry through receptor binding intereference [@doi:10.3389/fmicb.2017.02323; @doi:10.1080/21645515.2017.1337614].
This section discusses current efforts in developing neutralizing antibodies against SARS-CoV-2 and how expertise gained from previous approaches for MERS-CoV and SARS-CoV may benefit antibody development.

##### Spike (S) Neutralizing Antibody

During the first SARS epidemic in 2002, nAbs were found in SARS-CoV infected patients [@doi:10.1111/j.1469-0691.2004.01009.x;@doi:10.1086/423286].
Several studies following up on these findings identified various S glycoprotein epitopes as the major targets of neutralizing antibodies against SARS-CoV [@doi:10.1517/14712590902763755].
The passive transfer of immune serum containing nAbs from SARS-CoV-infected mice resulted in protection of naïve mice from viral lower respiratory tract infection upon intranasal challenge [@doi:10.1128/jvi.78.7.3572-3577.2004].
Similarly, a meta-analysis suggested that administration of plasma from recovered SARS-CoV patients reduced mortality upon SARS-CoV infection [@doi:10.1093/infdis/jiu396]. 

Similar results have been observed for MERS-CoV infections, which emerged as the second coronavirus-related epidemic.
Neutralizing antibodies have been identified against various epitopes of the RBD of the S glycoprotein [@doi:10.1073/pnas.1402074111; doi:10.1128/JVI.00912-14].

###### Spike (S) Neutralizing Antibody Anticipated Mechanisms

Coronaviruses use trimeric spike (S) glycoproteins on their surface to bind to host cell receptors, such as ACE2, allowing for cell entry [@doi:10.1016/j.cell.2020.02.052; @doi:10.1016/j.cell.2020.02.058].
Each S glycoprotein protomer is comprised of an S1 domain, also called the receptor binding domain (RBD), and an S2 domain.
The S1 domain binds to host cell receptors while the S2 domain facilitates the fusion between the viral envelope and host cell membranes [@doi:10.1517/14712590902763755].
Although targeting of the host cell receptor ACE2 shows efficacy in inhibiting SARS-CoV-2 infection [@doi:10.1038/nature02145], given the physiological relevance of ACE2 [@doi:10/bsbp49], it would be favorable to target virus-specific structures rather than host receptors.
This forms the rationale of developing neutralizing antibodies against the S glycoprotein, disrupting its interaction with ACE2 and other receptors and thereby inhibiting viral entry.


###### Spike (S) Neutralizing Antibody Current Evidence

The first human neutralizing antibody against SARS-CoV-2 targeting the trimeric spike (S) glycoproteins has been developed using hybridoma technology, [@doi:10.1101/2020.03.11.987958], where antibody-producing B-cells developed by mice can be inserted into myeloma cells to produce a hybrid cell line (the hybridoma) that is grown in culture.
The 47D11 clone was able to cross-neutralize SARS-CoV and SARS-CoV2 by a mechanism that is different from receptor binding interference.
The exact mechanism of how this clone neutralizes SARS-CoV-2 and inhibits infection in vitro remains unknown, but a potential mechanism might be antibody induced destabilization of the membrane prefusion structure [@doi:10.1101/2020.03.11.987958; @doi:10.1016/j.cell.2018.12.028].
The ability of this antibody to prevent infection at a feasible dose needs to be validated in vivo, especially since in vitro neutralization effects have been shown to not be reflective of in vivo efficacy [@doi:10.1128/JVI.01603-17].
Only a week later, a different group successfully isolated multiple nAbs targeting the RBD of the S glycoprotein from blood samples taken from COVID-19 patients in China [@doi:10.1101/2020.03.21.990770].
Interestingly, the patient isolated antibodies did not cross-react with RBD’s from SARS-CoV and MERS-CoV, although cross-reactivity to the trimeric spike proteins of SARS-CoV and MERS-CoV was observed.
This suggests that the RBDs between the three coronavirus species are immunologically distinct and that the isolated nAbs targeting the RBD of SARS-CoV-2 are species specific.
While this specificity is desirable, it also raises the question of whether these antibodies are more susceptible to viral escape mechanisms.
Viral escape is a common resistance mechanism to nAbs therapy due to selective pressure from neutralizing antibodies [@doi:10.2217/imt.15.33; @doi:10.1126/science.1213256].
For HIV, broadly neutralizing antibodies (bnAbs) targeting the CD4 binding site (CD4bs) show greater neutralization breadth than monoclonal antibodies, which target only specific HIV strains [@doi:10.1016/j.molmed.2019.01.007].
For MERS-CoV, a combination of multiple neutralizing antibodies targeting different antigenic sites prevented neutralization escape [@doi:10.1128/JVI.02002-17].
It was found that the different antibody isolates did not target the same epitopes, suggesting that using them in combination might produce a synergistic effect that prevents viral escape [@doi:10.1101/2020.03.21.990770].
It was also demonstrated that binding affinity of the antibodies does not reflect their capability to compete with ACE2 binding.
Furthermore, no conclusions about correlations between the severity of disease and the ability to produce neutralizing antibodies can be drawn at this point.
Rather, higher neutralizing antibody titers were more frequently found in patients with severe disease.
Correspondingly, higher levels of anti-spike IgG were observed in patients that deceased from infection compared to patient that recovered [@doi:10.1172/jci.insight.123158].

###### Spike (S) Neutralizing Antibody Summary 

Results from the SARS-CoV and MERS-CoV epidemics can provide valuable lessons for the design of neutralizing antibodies for the current outbreak.
The findings for SARS-CoV and MERS can aid in identifying which structures constitute suitable targets for nAbs, despite the fact that the RBD appears to be distinct between the three coronavirus species.
These studies also suggest that a combination of nAbs targeting distinct antigens might be necessary to provide protection [@doi:10.1128/JVI.02002-17].
The biggest challenge remains identifying antibodies that not only bind to their target, but also prove to be beneficial for disease management.
On that note, a recently published study indicates that anti-spike antibodies could make the disease worse rather than eliminating the virus [@doi:10.1172/jci.insight.123158].
These findings underscores our current lack of understanding the full immune response to SARS-CoV-2.

##### Anticipated Mechanism

Why it may be useful

##### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

##### Summary

Summarize the state of the neutralizing antibody approach.

#### Interferons

Interferons (IFNs) are a family of cytokines crucial to activate the first (innate) immune system response against viral infections.
Interferons are classified into three categories based on their receptor specificity: type I, II and III [@doi:10.1128/mmbr.05015-11].
Specifically, IFNs I (IFN-𝛼 and 𝛽) and II (IFN-𝛾 ) induce the expression of antiviral proteins which bring the viral RNA to degradation [@doi:10.1016/j.jcv.2003.11.013].
Among these IFNs, IFN- 𝛽 was already found to strongly inhibit the replication of other corona viruses, such as SARS-Cov, in cell culture, while IFN-𝛼 and 𝛾 were shown to be less effective in this context [@doi:10.1016/j.jcv.2003.11.013].
There are evidences that patients with higher susceptibility to develop Acute respiratory distress syndrome (ARDS) show indeed deficiency of IFN- 𝛽.
For instance, upon other Corona viruses infection IFN- 𝛽 expression and synthesis is impaired, so that the virus can in fact escape the innate immune response [@doi:10.1016/j.virusres.2014.07.024].

On March 18 2020 Synairgen plc has received approval to start a phase II trial for SNG001, an IFN- 𝛽-1a formulation to be delivered to lungs via inhalation.
SNG001 was already shown to be effective reducing viral load in swine flu in vivo model, as well as it has been shown to be effective in the protection from other Corona virus infection in vitro (Synairgen plc, press release).

##### Anticipated Mechanism

Why it may be useful

##### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

##### Summary

Summarize the state of interferons.


### Vaccines

Vaccines, widely recognized as one of the most significant advances in human health during the 20th century, can be used to bolser both individual and herd immunity to a virus by promoting the development of antibodies without infection.
[Are vaccines available for other coronaviruses or related viral illnesses?]
[What are some of the challenges to developing a vaccine? What needs to be taken into account about how the virus works?]
[Are there any challenges or opportunities unique to coronaviruses and/or SARS-CoV-2?]
[What are some approaches being tested or considered?]

#### DNA Vaccines

Brief background on the therapeutic.

##### Anticipated Mechanism

Why it may be useful

##### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

##### Summary

Summarize the state of the vaccine approach.

#### RNA Vaccines

Brief background on the therapeutic.

##### Anticipated Mechanism

Why it may be useful

##### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

##### Summary

Summarize the state of the vaccine approach.

#### Viral Particle Vaccines

Brief background on the therapeutic.	

##### Anticipated Mechanism

Why it may be useful	

##### Current Evidence	

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.	

##### Summary

Summarize the state of the vaccine approach.

#### Oligonucleotide Therapies

Background

##### Anticipated Mechanism

Why it may be useful

##### Current Evidence

A list of current studies and their results, using carefully the information requested in the therapeutic paper tickets.

##### Summary

Summarize the state of the neutralizing antibody approach.

### Underexplored Therapeutics

A summary of therapeutic avenues that future research may explore. Possible alternatives to current options and an overview of drug development processes.


## Methods

### Article Selection and Evaluation

The authors solicited relevant articles to be submitted via [GitHub](https://github.com/greenelab/covid19-review) for review.
Articles were classified as _diagnostic_, _therapeutic_, or _other_.
Following a framework often used for assessing medical literature, the review consisted of examining the methods used in the article, the assignment (whether the study was observational or randomized), the assessment, the results, the interpretation, and how well the study extrapolates [@doi:10.5014/ajot.60.4.367].

#### Diagnostic Papers

##### Methods

Reviewers began by describing the study question(s) being investigated by the article.
They then described the study population, the sample size, the prevalence of the disease in the study population, if in human subjects, the countries / regions considered, the demographics of participants, the setting, and any remaining inclusion / exclusion criteria considered.
They then described the reference test or "gold standard," if one was utilized.

##### Assignment

Reviewers described how the new and reference tests were assigned and any further details about the study design, for example whether the diagnostic test was biased towards sicker or healthier individuals or very clear-cut positive/negative cases.

##### Assessment

Reviewers described how the test was performed.
For example, if provided, reviewers described the technical details of the assays used, when measurements were taken and by whom for both the standard and reference diagnostic tests.
They then described how individuals were classified as positive or negative and whether there was evidence that the test results were precise or reproducible when repeated more than once.
Reviewers described whether there was any missing data, whether some participants underwent only one test, or whether there were individuals with inconclusive results.

##### Results

Reviewers reported the estimated sensitivity, specificity, positive predictive value (PPV), and negative predicted value (NPV), as well as the confidence bounds around these measures, if provided.

##### Interpretation

Reviewers reported how well the test ruled in or rules out disease based on the population, if there were identified side effects, and patient adherence.

##### Extrapolation

Reviewers described how well this test will extrapolate outside the measured population.

#### Therapeutic Papers

##### Methods

Reviewers began by describing the study question(s) being investigated by the article.
They then described the study population, the sample size, the prevalence of the disease in the study population, if in human subjects, the countries / regions considered, the demographics of participants, the setting, and any remaining inclusion / exclusion criteria considered.

##### Assignment

Reviewers described how the treatment is assigned, whether it was an interventional or observational study, whether randomization took place, etc.

##### Assessment

###### Outcome Assessment

Reviewers described the outcome that was assessed and evaluated whether it was appropriate given the underlying study question.
They described whether there was any missing data, for example whether there were individuals lost to follow up.
They then describe whether there were any potential sources of bias, for example lack of blinding in a randomized controlled trial.

###### Statistical Methods Assessment

Reviewers describe which statistical methods were used for inference and whether the methods were appropriate for the study.
They then described whether adjustments were made for possible confounders.

##### Results

Reviewers described the estimated association between the treatment and outcome.
They described measures of confidence or statistical significance, if provided.

##### Interpretation

Reviewers described whether a causal claim could be made.
They described whether any side effects or interactions with other drugs were identified, as well as any subgroup findings.

##### Extrapolation

Reviewers describe how the study may extrapolate to a different species or population.

### Collaborative Writing

Crowd-sourced writing with Manubot [@doi:10.1371/journal.pcbi.1007128].


## Additional Items {.page_break_before} 

### Competing Interests

|Author|Competing Interests|Last Reviewed|
|---|---|---|
|Halie M. Rando|None|2020-03-22|
|Casey S. Greene|None|2020-03-22|
|Michael P. Robson|None|2020-03-23|
|Simina M. Boca|None|2020-03-23|
|Nils Wellhausen|None|2020-03-22|
|Ronan Lordan|None|2020-03-25|
|Christian Brueffer|None|2020-03-25|
|Sadipan Ray|None|2020-03-25|
|Lucy D\'Agostino McGowan|None|2020-03-26|
|Anthony Gitter|None|2020-03-26|
|Ronnie M. Russell|None|2020-04-07|
|Anna Ada Dattoli|None|2020-03-26|
|Ryan Velazquez|None|2020-04-04|
|John P. Barton|None|2020-04-06|
|Jeffrey M. Field|None|2020-03-30|
|Bharath Ramsundar|None|2020-04-06|
|Adam L. MacLean|None|2020-04-06|
|Alexandra J. Lee|None|2020-04-07|
|Immunology Institute of the Icahn School of Medicine|None|2020-04-07|
|Fengling Hu|None|2020-04-08|
|Nafisa M. Jadavji|None|2020-04-09|

### Author Contributions

|Author|Contributions|
|---|---|
|Halie M. Rando|Project Administration, Writing - Original Draft, Writing - Review & Editing, Methodology|
|Casey S. Greene|Conceptualization, Software|
|Michael P. Robson|Software|
|Simina M. Boca|Methodology|
|Nils Wellhausen|Writing - Original Draft, Writing - Review & Editing|
|Ronan Lordan|Writing - Original Draft, Writing - Review & Editing|
|Christian Brueffer|Writing - Original Draft|
|Sadipan Ray|Writing - Original Draft|
|Lucy D\'Agostino McGowan|Methodology, Writing - Original Draft|
|Anthony Gitter|Methodology|
|Ronnie M. Russell|Writing - Original Draft, Writing - Review & Editing|
|Anna Ada Dattoli|Writing - Original Draft|
|Ryan Velazquez|Methodology|
|John P. Barton|Writing - Original Draft, Writing - Review & Editing|
|Jeffrey M. Field|Writing - Original Draft|
|Bharath Ramsundar|Investigation, Writing - Review & Editing|
|Adam L. MacLean|Writing - Original Draft|
|Alexandra J. Lee|Writing - Original Draft|
|Immunology Institute of the Icahn School of Medicine|Data Curation|
|Fengling Hu|Writing - Original Draft, Writing - Review & Editing|
|Nafisa M. Jadavji|Writing - Original Draft, Writing - Review & Editing|


## References {.page_break_before}

<!-- Explicitly insert bibliography here -->
<div id="refs"></div>

<!-- Define citation tags below -->
[@tag:Park2020_distancing]: url:https://github.com/parksw3/Korea-analysis/blob/master/v1/korea.pdf


## Appendix 1 {.page_break_before}

This appendix contains reviews produced by the Immunology Institute of the Icahn School of Medicine


### Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Tian et al. *Emerg Microbes Infect 2020* [@doi:10.1101/2020.01.28.923011]

#### Keywords

- Monoclonal antibody
- Cross-reactivity
- receptor binding domain

#### Summary

Considering the relatively high identity of the receptor binding domain
(RBD) of the spike proteins from 2019-nCoV and SARS-CoV (73%), this
study aims to assess the cross-reactivity of several anti-SARS-CoV
monoclonal antibodies with 2019-nCoV. The results showed that the
SARS-CoV-specific antibody CR3022 can potently bind 2019-nCoV RBD.

#### Main Findings

The structure of the 2019-nCoV spike RBD and its conformation in complex
with the receptor angiotensin-converting enzyme (ACE2) was modeled *in
silico* and compared with the SARS-CoV RBD structure. The models
predicted very similar RBD-ACE2 interactions for both viruses. The
binding capacity of representative SARS-CoV-RBD specific monoclonal
antibodies (m396, CR3014, and CR3022) to recombinant 2019-nCoV RBD was
then investigated by ELISA and their binding kinetics studied using
biolayer interferometry. The analysis showed that only CR3022 was able
to bind 2019-nCoV RBD with high affinity (KD of 6.3 nM), however it did
not interfere with ACE2 binding. Antibodies m396 and CR3014, which
target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike
protein.

#### Limitations

The 2019-nCoV RBD largely differ from the SARS-CoV at the C-terminus
residues, which drastically impact the cross-reactivity of antibodies
described for other B beta-coronaviruses, including SARS-CoV. This study
claims that CR3022 antibody could be a potential candidate for therapy.
However, none of the antibodies assayed in this work showed
cross-reactivity with the ACE2 binding site of 2019-nCoV, essential for
the replication of this virus. Furthermore, neutralization assays with
2019-nCoV virus or pseudovirus were not performed. Although the use of
neutralizing antibodies is an interesting approach, these results
suggest that it is critical the development of novel monoclonal
antibodies able to specifically bind 2019-nCoV spike protein.

#### Credit

*Review by D.L.O as part of a project by students, postdocs and faculty
at the Immunology Institute of the Icahn School of Medicine, Mount
Sinai.*


### Integrative Bioinformatics Analysis Provides Insight into the Molecular Mechanisms of 2019-nCoV

He et al. *medRxiv* [@doi:10.1101/2020.02.03.20020206]

#### Keywords

- ACE2
- lungs
- smoking
- COPD
- asthma
- SARS-Cov
- IL-1
- IL-10
- IL-6
- IL-8

#### Main Findings

The authors used bioinformatics tools to identify features
of ACE2 expression in the lungs of different patent groups: healthy,
smokers, patients with chronic airway disease (i.e., COPD) or asthma.
They used gene expression data publicly available from GEO that included
lung tissues, bronchoalveolar lavage, bronchial epithelial cells, small
airway epithelial cells, or SARS-Cov infected cells.

The authors describe no significant differences in ACE2 expression in
lung tissues of Healthy, COPD, and Asthma groups (p=0.85); or in BAL of
Healthy and COPD (p=0.48); or in epithelial brushings of Healthy and
Mild/Moderate/Severe Asthma (p=0.99). ACE2 was higher in the small
airway epithelium of long-term smokers vs non-smokers (p&lt;0.001).
Consistently, there was a trend of higher ACE2 expression in the
bronchial airway epithelial cells 24h post-acute smoking exposure
(p=0.073). Increasing ACE2 expression at 24h and 48h compared to 12h
post SARS-Cov infection (p=0.026; n=3 at each time point) was also
detected.

15 lung samples’ data from healthy participants were separated into high
and low ACE2 expression groups. “High” ACE2 expression was associated
with the following GO pathways: innate and adaptive immune responses, B
cell mediated immunity, cytokine secretion, and IL-1, IL-10, IL-6, IL-8
cytokines. The authors speculate that a high basal ACE2 expression will
increase susceptibility to SARS-CoV infection.

In 3 samples SARS-Cov infection was associated with IL-1, IL-10 and IL-6
cytokine production (GO pathways) at 24h. And later, at 48h, with T-cell
activation and T-cell cytokine production. It is unclear whether those
changes were statistically significant.

The authors describe a time course quantification of immune infiltrates
in epithelial cells infected with SARS-Cov infection. They state that in
healthy donors ACE2 expression did not correlate with the immune cell
infiltration. However, in SARS-Cov samples, at 48h they found that ACE2
correlated with neutrophils, NK-, Th17-, Th2-, Th1- cells, and DCs.
Again, while authors claim significance, the corresponding correlation
coefficients and p-values are not presented in the text or figures. In
addition, the source of the data for this analysis is not clear.

Using network analysis, proteins SRC, FN1, MAPK3, LYN, MBP, NLRC4, NLRP1
and PRKCD were found to be central (Hub proteins) in the regulating
network of cytokine secretion after coronavirus infection. Authors
conclude this indicates that these molecules were critically important
in ACE2-induced inflammatory response. Additionally, authors speculate
that the increased expression of ACE2 affected RPS3 and SRC, which were
the two hub genes involved in viral replication and inflammatory
response.

#### Limitations

The methods section is very limited and does not
describe any of the statistical analyses; and description of the
construction of the regulatory protein networks is also limited. For the
findings in Figures 2 authors claim significance, which is not supported
by p-values or coefficients. For the sample selection, would be useful
if sample sizes and some of the patients’ demographics (e.g. age) were
described.

For the analysis of high vs low ACE2 expression in healthy subjects, it
is not clear what was the cut off for ‘high’ expression and how it was
determined. Additionally, further laboratory studies are warranted to
confirm that high ACE2 gene expression would have high correlation with
the amount of ACE2 protein on cell surface. For the GO pathway analysis
significance was set at p&lt;0.05, but not adjusted for multiple
comparisons.

There were no samples with SARS-CoV-2 infection. While SARS-Cov and
SARS-CoV-2 both use ACE2 to enter the host cells, the analysis only
included data on SARS-Cov and any conclusions about SARS-CoV2 are
limited.

Upon checking GSE accession numbers of the datasets references, two
might not be cited correctly: GSE37758 ("A spergillus niger: Control
(fructose) vs. steam-exploded sugarcane induction (SEB)"" was used in
this paper as “lung tissue” data) and GSE14700 ("Steroid Pretreatment
of Organ Donors to Prevent Postischemic Renal Allograft Failure: A
Randomized, Controlled Trial" – was used as SARS-Cov infection data).

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Diarrhea may be underestimated: a missing link in 2019 novel coronavirus

Liang et al. *medRxiv* [@doi:10.1101/2020.02.03.20020289]

#### Keywords

- SARS-CoV-2
- diarrhea
- ACE2
- scRNA-seq

#### Main Findings

This study examined the incidence of diarrhea in
patients infected with SARS-CoV-2 across three recently published
cohorts and found that there are statistically significant differences
by Fisher’s exact test. They report that this could be due to subjective
diagnosis criterion for diarrhea or from patients first seeking medical
care from gastroenterologist. In order to minimize nosocomial infections
arising from unsuspected patients with diarrhea and gain comprehensive
understanding of transmission routes for this viral pathogen, they
compared the transcriptional levels of ACE2 of various human tissues
from NCBI public database as well as in small intestine tissue from
CD57BL/6 mice using single cell sequencing. They show that ACE2
expression is not only increased in the human small intestine, but
demonstrate a particular increase in mice enterocytes positioned on the
surface of the intestinal lining exposed to viral pathogens. Given that
ACE2 is the viral receptor for SARS-CoV-2 and also reported to regulate
diarrhea, their data suggests the small intestine as a potential
transmission route and diarrhea as a potentially underestimated symptom
in COVID19 patients that must be carefully monitored. Interestingly,
however, they show that ACE2 expression level is not elevated in human
lung tissue.

#### Limitations

Although this study demonstrates a
statistical difference in the incidence of diarrhea across three
separate COVID19 patient cohorts, their conclusions are limited by a
small sample size. Specifically, the p-value computed by Fisher’s exact
test is based on a single patient cohort of only six cases of which 33%
are reported to have diarrhea, while the remaining two larger cohorts
with 41 and 99 cases report 3% and 2% diarrhea incidence, respectively.
Despite showing significance, they would need to acquire larger sample
sizes and cohorts to minimize random variability and draw meaningful
conclusions. Furthermore, they do not address why ACE2 expression level
is not elevated in human lung tissue despite it being a major
established route of transmission for SARS-CoV-2. It could be helpful to
validate this result by looking at ACE2 expression in mouse lung tissue.
Finally, although this study is descriptive and shows elevated ACE2
expression in small intestinal epithelial cells, it does not establish a
mechanistic link to SARS-CoV-2 infection of the host. Overall, their
claim that infected patients exhibiting diarrhea pose an increased risk
to hospital staff needs to be further substantiated.

#### Significance

This study provides a possible transmission route and a
potentially underappreciated clinical symptom for SARS-CoV-2 for better
clinical management and control of COVID19.

#### Credit

*Summary generated as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection

Chai et al. *bioRxiv* [@doi:10.1101/2020.02.03.931766]

#### Keywords

- ACE2
- Cholangiocytes
- COVID-associated Liver Damage

#### Summary

Using both publicly available scRNA-seq dataset of liver
samples from colorectal patients and scRNA-sequencing of four liver
samples from healthy volunteers, the authors show that ACE2 is
significantly enriched in the majority of cholangiocytes (59.7 %) but
not in hepatocytes (2.6%).

#### Main Findings

Using bioinformatics approaches of
RNASeq analysis, this study reveals that ACE2 dominates in
cholangiocytes and is present at very low levels in hepatocytes.

#### Limitations

The
study does not provide mechanistic insights into how SARS-CoV-2 can
infect and replicate in cholangiocytes and the types of intrinsic
anti-viral responses induced by cholangiocytes when infected. In
addition, because the study relies on the assumption that SARS-CoV-2
infects cells only through ACE2, it cannot discount the possibility that
the virus can infect hepatocytes through mechanisms other than
ACE2-mediated entry. Furthermore, because the scRNA-seq analysis were
performed on healthy liver samples, one cannot draw any definitive
conclusions about gene expression states (including ACE2 expression in
liver cell types) in system-wide inflammatory contexts.

#### Significance

This article with other studies on liver
damage in COVID patients suggests that liver damage observed in COVID
patients is more due to inflammatory cytokines than direct infection of
the liver. Even if cholangiocytes are infectable by SARS-CoV-2 (which
was demonstrated by human liver ductal organoid study
([@doi:10.1101/2020.03.16.990317]),
published clinical data show no significant increase in bile duct injury
related indexes (i.e. alkaline phosphatase, gamma-glutamyl
transpeptidase and total bilirubin). In sum, it underscores the
importance of future studies characterizing cellular responses of
extra-pulmonary organs in the context of COVID or at least in viral lung
infections..

#### Credit

*Summary generated by Chang Moon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism

Wang et al. *medRxiv*. [@doi:10.1101/2020.02.05.20020545]

#### Keywords

- single cell RNA seq
- ACE2 expression
- human colonic biopsy

#### Main Findings

Colonic enterocytes primarily express ACE2. Cellular pathways associated with ACE2 expression include innate immune signaling, HLA up regulation, energy metabolism and apoptotic signaling.  

#### Limitations

This is a study of colonic biopsies taken from 17 children with and without IBD and analyzed using scRNAseq to look at ACE2 expression and identify gene families correlated with ACE2 expression. The authors find ACE2 expression to be primarily in colonocytes.  It is not clear why both healthy and IBD patients were combined for the analysis. Biopsies were all of children so extrapolation to adults is limited. The majority of genes found to be negatively correlated with ACE2 expression include immunoglobulin genes (IGs). IG expression will almost certainly be low in colonocytes irrespective of ACE2 expression.  

#### Significance

This study performs a retrospective analysis of ACE2 expression using an RNAseq dataset from intestinal biopsies of children with and without IBD. The implications for the CoV-19 epidemic are modest, but do provide support that ACE2 expression is specific to colonocytes in the intestines.  The ontological pathway analysis provides some limited insights into gene expression associated with ACE2.

#### Credit

*Summary generated as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice

Bao et al. *bioRxiv* [@doi:10.1101/2020.02.07.939389]

#### Keywords

- Covid-19 mouse model
- hACE2 mice
- 2019-nCoV model
- ACE2
- 2019-nCoV 

#### Main Findings

Using a transgenic human Angiotensin-converting enzyme 2
(hACE2) mouse that has previously been shown susceptible to infection by
SARS-CoV, Bao et al. create a model of pandemic 2019-nCoV strain
coronavirus. The model includes interstitial hyperplasia in lung tissue,
moderate inflammation in bronchioles and blood vessels, and histology
consistent with viral pneumonia at 3 days post infection. Wildtype did
not experience these symptoms. In addition, viral antigen and hACE2
receptor were found to co-localize the lung by immunofluorescence 3-10
days post infection only in the hACE2 infected mice.

#### Limitations

The characterization of the infection remains incomplete,
as well as lacking characterization of the immune response other than
the presence of a single antiviral antibody. Though they claim to
fulfill Koch’s postulates, they only isolate the virus and re-infect
Vero cells, rather than naive mice.

#### Significance

This paper establishes a murine model for 2019-nCoV
infection with symptoms consistent with viral pneumonia. Though not
fully characterized, this model allows in vivo analysis of viral entry
and pathology that is important for the development of vaccines and
antiviral therapeutics.

#### Credit

*Review by Dan Fu Ruan, Evan Cody and Venu Pothula as part of a project by students, postdocs and faculty
at the Immunology Institute of the Icahn School of Medicine, Mount
Sinai.*


### Caution on Kidney Dysfunctions of 2019-nCoV Patients

Li et al. *medRxiv*. [@doi:10.1101/2020.02.08.20021212]

#### Keywords

CoVID-19, 2019-nCoV, SARS-CoV-2, kidney, clinical, creatinine,
proteinuria, albuminuria, CT

#### Main Findings

-   Retrospective study of 59 patients assayed key function indicators
    of the kidney–including urine protein, blood urea nitrogen (BUN),
    plasma creatinine (Cre), and renal CT scan data.

-   Found that 34% of patients developed massive albuminuria on the
    first day of admission, and 63% developed proteinuria during their
    stay in hospital; and 19% of patients had high plasma creatinine,
    especially the terminal cases.

-   CT analyses of 27 patients showed all patients to have abnormal
    kidney damage; indicate that inflammation and edema of the renal
    parenchyma very common.

#### Limitations

-   No analysis of immunity-dependent damage and cytokines in
    blood/plasma/urine. Will be worth correlating disease progression
    with cytokine production, immune activity and kidney function.

-   Extrapolating to earlier SARS-CoV studies provides the only
    rationale for viral-damage in kidney and resultant pathologic immune
    response *(understandable for this clinical study)*.

#### Significance

-   Multiple lines of evidence along this study’s finding point to the
    idea that renal impairment/injury is a key risk factor in 2019-nCoV
    patients similar to what has been reported for SARS-CoV[@doi:10.1111/j.1523-1755.2005.67130.x]; this
    may be one of the major causes of virally-induced damage and
    contribute to multiorgan failure.

-   ACE2 expression in kidney proximal tubule epithelia and bladder
    epithelia [@doi:10.1101/2020.02.08.939892] support
    these clinical findings.

-   Study argues for closely monitoring kidney function, and applying
    potential interventions including continuous renal replacement
    therapies (CRRT) for protecting kidney functions as early as
    possible, particularly for those with rising plasma creatinine.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Profiling the immune vulnerability landscape of the 2019 Novel Coronavirus

Zhu et al. *bioRxiv* [@doi:10.1101/2020.02.08.939553]

#### Keywords

- epitope prediction
- vaccine development.

#### Main Findings

This study harnesses bioinformatic profiling to predict the potential of
COV2 viral proteins to be presented on MHC I and II and to form linear
B-cell epitopes. These estimates suggest a T-cell antigenic profile
distinct from SARS-CoV or MERS-CoV, identify focused regions of the
virus with a high density of predicted epitopes, and provide preliminary
evidence for adaptive immune pressure in the genetic evolution of the
virus.

#### Limitations

While the study performs a comprehensive analysis of potential epitopes
within the virus genome, the analysis relies solely on bioinformatic
prediction to examine MHC binding affinity and B-cell epitope potential
and does not capture the immunogenicity or recognition of
these epitopes. Future experimental validation in data from patients
infected with SARS-CoV-2 will be important to validate and refine these
findings. Thus some of the potential conclusions stated, including viral
evolution toward lower immunogenicity or a dominant role for CD4+
T-cells rather than CD8+ T-cells in viral clearance, require further
valiadtion.

#### Significance

These findings may help direct peptide vaccine design toward relevant
epitopes and provide intriguing evidence of viral evolution in response
to immune pressure.

#### Credit

*Summary generated as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Single-cell Analysis of ACE2 Expression in Human Kidneys and Bladders Reveals a Potential Route of 2019-nCoV Infection

Lin et al. *bioRxiv* [@doi:10.1101/2020.02.08.939892]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- ACE2
- scRNAseq
- kidney
- bladder
- public dataset

#### Main Findings

-   To investigate the possible cause of kidney damage in 2019-nCoV
    patients, authors used published kidney and bladder cell atlas data
    (GSE131685, GSE108097; 3 healthy donors each) as well as an
    unpublished kidney single-cell RNA-Seq data (in-house from 2
    transplant donors) to evaluate ACE2 gene expressions in all cell
    types of healthy kidneys and bladders.

-   They find enriched expression of ACE2 transcript in all subtypes of
    proximal tubule cells of kidney, with 5%-15% of both straight and
    convoluted proximal tubule cells expressing ACE2.

-   They also find detectable levels of ACE2 in bladder epithelial
    cells, noting expression from around 1.5% of cells in the outer
    layer umbrella cells of the bladder epithelium and decreasing in the
    basal cells.

-   Importantly endothelial or immune cells in kidney/bladder do not
    express ACE2.

#### Limitations

-   This study primarily characterizes ACE2 expression (amongst other
    genes) from a small healthy-donor dataset, and will benefit from
    supporting data in (expired) patient samples to show functional
    viral damage. ACE2 transcript does not necessarily translate to
    viral permissiveness in kidney/bladder epithelia or cytokine
    release.

-   This study focuses on only healthy tissue; it will be useful to
    analyze kidney/bladder epithelial ACE2 expression under inflammatory
    conditions or in patients with underlying kidney conditions.

-   Given what is known about protease TMPRSS2 expression during
    SARS-CoV-2 infection, ACE2+TMPRSS2+ double-positive cell
    identification would be useful in these datasets.

#### Significance

-   ACE2 protein is spatially restricted to brush border of proximal
    tubules and in bladder umbrella cells [@doi:10.1002/path.1570], such cells in direct
    contact with viral particles are likely to be highly sensitive to
    viral-induced damage.

-   SARS-CoV and MERS-CoV have been shown to be detected in urine of
    patients and associate with higher mortality [@doi:10.1111/j.1523-1755.2005.67130.x; @doi:10.7326/m13-2486], thus worth
    understanding kidney damage and resultant immune response in
    SARS-CoV-2 as well.

-   This study argues for a potential mode of viral infectivity and
    resultant inflammatory responses in these tissue in addition to
    reported infectivity in the lung and digestive system, which is
    supported by clinical data showing acute and early kidney
    complications in 2019-nCoV patients [@doi:10.1101/2020.02.08.20021212].

-   Clinically, thus very important to track urinary CoVID-19 shedding
    as well as study acute kidney injury-related co-morbidities.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage

Liu et al. *medRxiv* [@doi:10.1101/2020.02.10.20021584]

#### Keywords

- severe disease
- pneumonia
- lymphocytes
- neutrophils

#### Main Findings

This study aimed to find prognostic biomarkers of COVID-19
pneumonia severity. Sixty-one (61) patients with COVID-19 treated in
January at a hospital in Beijing, China were included. On average,
patients were seen within 5 days from illness onset. Samples were
collected on admission; and then patients were monitored for the
development of severe illness with a median follow-up of 10 days\].

Patients were grouped as “mild” (N=44) or “moderate/severe” (N=17)
according to symptoms on admission and compared for different
clinical/laboratory features. “Moderate/severe” patients were
significantly older (median of 56 years old, compared to 41 years old).
Whereas comorbidies rates were largely similar between the groups,
except for hypertension, which was more frequent in the severe group (p=
0.056). ‘Severe’ patients had higher counts of neutrophils, and serum
glucose levels; but lower lymphocyte counts, sodium and serum chlorine
levels. The ratio of neutrophils to lymphocytes (NLR) was also higher
for the ‘severe’ group. ‘Severe’ patients had a higher rate of bacterial
infections (and antibiotic treatment) and received more intensive
respiratory support and treatment.

26 clinical/laboratory variables were used to select NLR and age as the
best predictors of the severe disease. Predictive cutoffs for a severe
illness as NLR ≥ 3.13 or age ≥ 50 years.

#### Limitations

Identification of early biomarkers is important for
making clinical decisions, but large sample size and validation cohorts
are necessary to confirm findings. It is worth noting that patients
classified as “mild” showed pneumonia by imaging and fever, and in
accordance with current classifications this would be consistent with
“moderate” cases. Hence it would be more appropriate to refer to the
groups as “moderate” vs “severe/critical”. Furthermore, there are
several limitations that could impact the interpretation of the results:
e.g. classification of patients was based on symptoms presented on
admission and not based on disease progression, small sample size,
especially the number of ‘severe’ cases (with no deaths among these
patients). Given the small sample size, the proposed NLR and age cut
offs might not hold for a slightly different set of patients. For
example, in a study of &gt;400 patients, ‘non-severe’ and ‘severe’ NLR
were 3.2 and 5.5, respectively [@doi:10.1093/cid/ciaa248].

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Wan et. al. *medRxiv* [@doi:10.1101/2020.02.10.20021832]

#### Keywords

- Cytokines
- lymphocyte subsets
- CD8 + T
- B cells
- NK cells,
- PBMCs
- IL-6
- IL-10

#### Main Findings

The authors analyzed lymphocyte subsets and cytokines of 102 patients
with mild disease and 21 with severe disease. CD8+T cells and CD4+T
cells were significantly reduced in both cohort. particularly in severe
patients. The cytokines IL6 and IL10 were significantly elevated in
severe patients as compared to mild. No significant differences were
observed in frequency of B cells and NK cells.

The authors argue that the measurement of T cell frequencies and
cytokine levels of IL6 and IL10 can be used to predict progression of
disease from Mild to severe Cov-2 infection.

#### Limitations

The study demonstrates in a limited cohort
similar associations to several other reported studies. The authors
didn’t compare the changes in lymphocyte and cytokine with healthy
individual (Covid-19 Negative) rather used an internal standard value.
The recently preprint in LANCET shows The degree of lymphopenia and a
pro-inflammatory cytokine storm is higher in severe COVID-19 patients
than in mild cases, and is associated with the disease severity [@doi:10.2139/ssrn.3539682].

#### Significance

This translational data identifies key cytokines and lymphopenia
associated with disease severity although mechanism and key cellular
players are still unknown. Higher level IL-6 production in severe
patient suggests potential role of Tocilizumab (anti-IL6R) biologic
although clinical trial will be necessary.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China

Li et al. *medRxiv* [@doi:10.1101/2020.02.11.20022053]

#### Keywords

- epidemiology
- clinical characteristics

#### Major Findings

These authors looked at 17 hospitalized patients with COVID-19
confirmed by RT-PCR in Dazhou, Sichuan. Patients were admitted between
January 22 and February 10 and the final data were collected on February
11. Of the 17 patients, 12 remained hospitalized while 5 were discharged
after meeting national standards. The authors observed no differences
based on the sex of the patients but found that the discharged patients
were younger in age (p = 0.026) and had higher lymphocyte counts (p =
0.005) and monocyte counts (p = 0.019) upon admission.

#### Limitations

This study is limited in the sample size of the study and the last
data collection point was only one day after some of the patients were
admitted.

#### Significance

These findings have been somewhat supported by subsequent studies
that show that older age and an immunocompromised state are more likely
to result in a more severe clinical course with COVID-19. However, other
studies have been published that report on larger numbers of cases.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection

[@doi:10.1101/2020.02.12.20022418]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- kidney
- testis
- ACE2
- scRNAseq

#### Main Findings

-   Study used online datasets (scRNAseq GSE131685, scRNAseq GSE107585,
    Human Protein Atlas, GTEx portal, CCLE) to analyze ACE2 expression
    in different human organs.

-   Study re-analyzed three clinical datasets (n=6, n=99, and n=41) to
    show 3\~10% of 2019-nCoV patients present with abnormal renal
    function.

-   results indicate ACE2 highly expressed in renal tubular cells,
    Leydig cells and seminiferous ductal cells of testis.

#### Limitations

-   Very preliminary transcript/protein dataset analysis in healthy
    cohorts; does not necessarily translate to actual viral tropism and
    permissiveness.

-   Clinically, would be important to determine with larger longitudinal
    dataset if SARS-CoV-2 infection changes sperm quality or testicular
    inflammation.

-   Similarly, would be important to determine if simultaneous HBV or
    syphilis infection and orchitis impacts SARS-CoV-2 severity.

-   Examination and follow-up of renal function and viral orchitis/sperm
    quality of CoVID-19 patients not done in this preliminary study.

#### Significance

-   Kidney ACE2 result supports other concurrent sequencing studies
    [@doi:10.1101/2020.02.08.939892] and clinical reports
    of abnormal renal function or even kidney damage in patients
    infected with 2019-nCoV
    [@doi:10.1101/2020.02.08.20021212].

-   High ACE2 expression in testis suggests potential tropism of the
    virus to testicular tissues and indicates potential risks for male
    fertility. Viral orchitis reported for SARS-CoV previously \[1\],
    but no clear evidence so far of infertility in SARS, MERS or
    CoVID-19 patients.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus

[@doi:10.1101/2020.02.12.945576]

#### Keywords
- immunopathology
- Th1
- inflammatory monocytes
- GM-CSF
- IFN-γ
- IL-6

#### Main Findings

The authors of this study sought to characterize the immune
mechanism causing severe pulmonary disease and mortality in 2019-nCoV
(COVID-19) patients. Peripheral blood was collected from hospitalized
ICU (n=12) and non-ICU (n=21) patients with confirmed 2019-nCoV and from
healthy controls (n=10) in The First Affiliated Hospital of University
of Science and Technology China (Hefei, Anhui). Immune analysis was
conducted by flow cytometry. 2019-nCoV patients had decreased
lymphocyte, monocyte, and CD4 T cell counts compared to healthy
controls. ICU patients had fewer lymphocytes than non-ICU patients. CD4
T cells of 2019-nCoV patients expressed higher levels of activation
markers (OX40, CD69, CD38, CD44) and exhaustion markers (PD-1 and Tim3)
than those of healthy controls. CD4 cells of ICU patients expressed
significantly higher levels of OX40, PD-1, and Tim3 than those of
non-ICU patients. 2019-nCoV patients had higher percentages of CD4 T
cells co-expressing GM-CSF and IL-6 compared to healthy controls, while
ICU patients had a markedly higher percentage of GM-CSF+ IFN-γ+ CD4 T
cells than non-ICU patients. The CD4 T cells of nCoV patients and
healthy controls showed no differences in TNF-α secretion.

The CD8 T cells of 2019-nCoV patients also showed higher expression of
activation markers CD69, CD38, and CD44, as well as exhaustion markers
PD-1 and Tim3, compared to healthy controls. CD8 T cells of ICU patients
expressed higher levels of GM-CSF than those of non-ICU patients and
healthy controls. No IL-6 or TNF-α was found in the CD8 T cells of any
group. There were no differences in numbers of NK cells or B cells in
2019-nCoV patients and healthy controls, nor was there any GM-CSF or
IL-6 secretion from these cells in either group.

Percentages of CD14+ CD16+ GM-CSF+ and CD14+ CD16+ IL-6+ inflammatory
monocytes were significantly increased in nCoV patients compared to
healthy controls; in particular, patients in the ICU had greater
percentages of CD14+ CD16+ IL-6+ monocytes than non-ICU patients. The
authors suggest that in 2019-nCoV patients, pathogenic Th1 cells produce
GM-CSF, recruiting CD14+ CD16+ inflammatory monocytes that secrete high
levels of IL-6. These may enter pulmonary circulation and damage lung
tissue while initiating the cytokine storm that causes mortality in
severe cases. This is consistent with the cytokine storm seen in similar
coronaviruses, as IL-6, IFN-γ, and GM-CSF are key inflammatory mediators
seen in patients with SARS-CoV-1 and MERS-CoV.

#### Limitations

Though the results of this study open
questions for further investigation, this is an early study on a small
cohort of patients, and as such there are a number of limitations. The
study included only 12 ICU patients and 21 non-ICU patients, and ideally
would be repeated with a much larger patient cohort. Though the authors
make claims about differences in lymphocyte and monocyte counts between
patients and healthy controls, they did not report baseline laboratory
findings for the control group. Additionally, severity of disease was
classified based on whether or not patients were in the ICU. It would be
interesting to contextualize the authors’ immunological findings with
more specific metrics of disease severity or time course. Noting
mortality, time from disease onset, pre-existing conditions, or severity
of lung pathology in post-mortem tissue samples would paint a fuller
picture of how to assess risk level and the relationship between
severity of disease and immunopathology. Another limitation is the
selection of cytokines and immune markers for analysis, as the selection
criteria were based on the cell subsets and cytokine storm typically
seen in SARS-CoV-1 and MERS-CoV patients. Unbiased cytokine screens and
immune profiling may reveal novel therapeutic targets that were not
included in this study.

#### Significance

This study identifies potential therapeutic targets
that could prevent acute respiratory disease syndrome (ARDS) and
mortality in patients most severely affected by COVID-19. The authors
propose testing monoclonal antibodies against IL6-R or GM-CSF to block
recruitment of inflammatory monocytes and the subsequent cytokine storm
in these patients.

#### Credit

*Review by Gabrielle Lubitz as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical Characteristics of 2019 Novel Infected Coronavirus Pneumonia：A Systemic Review and Meta-analysis

Qian et al. *medRxiv*.
[@doi:10.1101/2020.02.14.20021535]

#### Keywords
- White Blood Cells
- Lymphocytes
- Neutrophils

#### Main Findings

The authors performed a meta analysis of literature on clinical,
laboratory and radiologic characteristics of patients presenting with
pneumonia related to SARSCoV2 infection, published up to Feb 6 2020.
They found that symptoms that were mostly consistent among studies were
sore throat, headache, diarrhea and rhinorrhea. Fever, cough, malaise
and muscle pain were highly variable across studies. Leukopenia (mostly
lymphocytopenia) and increased white blood cells were highly variable
across studies. They identified three most common patterns seen on CT
scan, but there was high variability across studies. Consistently across
the studies examined, the authors found that about 75% of patients need
supplemental oxygen therapy, about 23% mechanical ventilation and about
5% extracorporeal membrane oxygenation (ECMO). The authors calculated a
staggering pooled mortality incidence of 78% for these patients.

#### Limitations

The authors mention that the total number of studies included in this
meta analysis is nine, however they also mentioned that only three
studies reported individual patient data. It is overall unclear how many
patients in total were included in their analysis. This is mostly
relevant as they reported an incredibly high mortality (78%) and mention
an absolute number of deaths of 26 cases overall. It is not clear from
their report how the mortality rate was calculated.

The data is based on reports from China and mostly from the Wuhan area,
which somewhat limits the overall generalizability and applicability of
these results.

#### Significance

This meta analysis offers some important data for clinicians to refer to
when dealing with patients with COVID-19 and specifically with
pneumonia. It is very helpful to set expectations about the course of
the disease.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Liu et al. *medRxiv* [@doi:10.1101/2020.02.16.20023671]

#### Keywords

- Lymphopenia
- Neutrophil to CD8 T cell ratio (N8R)
- inflammatory cytokines

#### Main Findings

Liu et al. enrolled a cohort of 40 patients from Wuhan
including 27 mild cases and 13 severe cases of COVID-19. They performed
a 16-day kinetic analysis of peripheral blood from time of disease
onset. Patients in the severe group were older (medium age of 59.7,
compared to 48.7 in mild group) and more likely to have hypertension as
a co-morbidity. Lymphopenia was observed in 44.4% of the mild patients
and 84.6% of the severe patients. Lymphopenia was due to low T cell
count, specially CD8 T cells. Severe patients showed higher neutrophil
counts and an increase of cytokines in the serum (IL2, IL6, IL10 and
IFNγ). The authors measured several other clinical laboratory parameters
were also higher in severe cases compared to mild, but concluded that
neutrophil to CD8 T cell ratio (N8R) as the best prognostic factor to
identify the severe cases compared to other receiver operating
characteristic (ROC).

#### Limitations

This was a small cohort (N=40), and two of the patients
initially included in the severe group (N=13) passed away and were
excluded from the analysis due to lack of longitudinal data. However, it
would be most important to be able to identify patients with severe
disease with higher odds of dying. It seems that the different time
points analyzed relate to hospital admission, which the authors describe
as disease onset. The time between first symptoms and first data points
is not described. It would have been important to analyze how the
different measured parameters change according to health condition, and
not just time (but that would require a larger cohort). The predictive
value of N8R compared to the more commonly used NLR needs to be assessed
in other independent and larger cohorts. Lastly, it is important to note
that pneumonia was detected in patients included in the “mild” group,
but according to the Chinese Clinical Guidance for COVID-19 Pneumonia
Diagnosis and Treatment (7th edition) this group should be considered
“moderate”.

#### Significance

Lymphopenia and cytokine storm have been described to be
detrimental in many other infections including SARS-CoV1 and MERS-CoV.
However, it was necessary to confirm that this dramatic immune response
was also observed in the SARS-CoV2 infected patients. These results and
further validation of the N8R ratio as a predictor of disease severity
will contribute for the management of COVID19 patients and potential
development of therapies.

#### Credit

*Review by Pauline Hamon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019

Chen et al. *medRxiv* [@doi:10.1101/2020.02.16.20023903]

#### Keywords

- severe disease
- lymphocytes
- cytokines
- IFNy
- CD4 Tcells
- HLA-DR CD8
- Tcells

#### Main Findings

This study retrospectively evaluated clinical, laboratory,
hematological, biochemical and immunologic data from 21 subjects
admitted to the hospital in Wuhan, China (late December/January) with
confirmed SARS-CoV-2 infection. The aim of the study was to compare
‘severe’ (n=11, \~64 years old) and ‘moderate’ (n=10, \~51 years old)
COVID-19 cases. Disease severity was defined by patients’ blood oxygen
level and respiratory output. They were classified as ‘severe’ if SpO2
93% or respiratory rates 30 per min.

In terms of the clinical laboratory measures, ‘severe’ patients had
higher CRP and ferritin, alanine and aspartate aminotransferases, and
lactate dehydrogenase but lower albumin concentrations.

The authors then compared plasma cytokine levels (ELISA) and immune cell
populations (PBMCs, Flow Cytometry). ‘Severe’ cases had higher levels of
IL-2R, IL-10, TNFa, and IL-6 (marginally significant). For the immune
cell counts, ‘severe’ group had higher neutrophils, HLA-DR+ CD8 T cells
and total B cells; and lower total lymphocytes, CD4 and CD8 T cells
(except for HLA-DR+), CD45RA Tregs, and IFNy-expressing CD4 T cells. No
significant differences were observed for IL-8, counts of NK cells,
CD45+RO Tregs, IFNy-expressing CD8 T and NK cells.

#### Limitations

Several potential limitations should be noted: 1) Blood samples were
collected 2 days post hospital admission and no data on viral loads were
available; 2) Most patients were administered medications (e.g.
corticosteroids), which could have affected lymphocyte counts.
Medications are briefly mentioned in the text of the manuscript; authors
should include medications as part of Table 1. 3) ‘Severe’ cases were
significantly older and 4/11 ‘severe’ patients died within 20 days.
Authors should consider a sensitivity analysis of biomarkers with the
adjustment for patients’ age.

#### Significance

Although the sample size was small, this paper presented a broad range
of clinical, biochemical, and immunologic data on patients with
COVID-19. One of the main findings is that SARS-CoV-2 may affect T
lymphocytes, primarily CD4+ T cells, resulting in decreased IFNy
production. Potentially, diminished T lymphocytes and elevated cytokines
can serve as biomarkers of severity of COVID-19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development

Sun et al. *bioRxiv* [@doi:10.1101/2020.02.16.951723]

#### Keywords

- SARS-CoV
- SARS-CoV-2
- ACE2
- Spike (S) protein
- receptor binding domain (RBD)
- receptor binding motif (RBM)
- neutralizing antibody

#### Main Findings

This study compared the structure of SARS-CoV and SARS-CoV-2 Spike (S)
protein receptor binding domain (RBD) and interactions with ACE2 using
computational modeling, and interrogated cross-reactivity and
cross-neutralization of SARS-CoV-2 by antibodies against SARS-CoV. While
SARS-CoV and SARS-CoV-2 have over 70 % sequence homology and share the
same human receptor ACE2, the receptor binding motif (RBM) is only 50%
homologous.

Computational prediction of the SARS-CoV-2 and ACE2 interactions based
on the previous crystal structure data of SARS-CoV, and measurement of
binding affinities against human ACE2 using recombinant SARS-CoV and
SARS-CoV-2 S1 peptides, demonstrated similar binding of the two S1
peptides to ACE2, explaining the similar transmissibility of SARS-CoV
and SARS-CoV-2 and consistent with previous data (Wall et al Cell
2020).

The neutralization activity of SARS-CoV-specific rabbit polyclonal
antibodies were about two-order of magnitude less efficient to
neutralize SARS-CoV-2 than SARS-CoV, and four potently neutralizing
monoclonal antibodies against SARS-CoV had poor binding and neutralizing
activity against SARS-CoV-2. In contrast, 3 poor SARS-CoV-binding
monoclonal antibodies show some efficiency to bind and neutralize
SARS-CoV-2. The results suggest that that antibodies to more conserved
regions outside the RBM motif might possess better cross-protective
neutralizing activities between two strains.

#### Limitations

It would have been helpful to show the epitopes recognized by the
monoclonal antibodies tested on both SARS-CoV, SARS-CoV-2 to be able to
make predictions for induction of broadly neutralizing antibodies. The
data on monoclonal antibody competition with ACE2 for binding to
SARS-CoV RBD should have also included binding on SARS-CoV2, especially
for the three monoclonal antibodies that showed neutralization activity
for SARS-CoV2. Because of the less homology in RBM sequences between
viruses, it still may be possible that these antibodies would recognize
the ACE2 RBD in SARS-CoV-2.

#### Significance

It is noteworthy that immunization to mice and rabbit with SARS-CoV S1
or RBD protein could induce monoclonal antibodies to cross-bind and
cross-neutralize SARS-CoV-2 even if they are not ACE2-blocking. If these
types of antibodies could be found in human survivors or in the
asymptomatic populations as well, it might suggest that exposure to
previous Coronavirus strains could have induced cross-neutralizing
antibodies and resulted in the protection from severe symptoms in some
cases of SARS-CoV2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Protection of Rhesus Macaque from SARS-Coronavirus challenge by recombinant adenovirus vaccine

Chen et al. *bioRxiv* [@doi:10.1101/2020.02.17.951939]

#### Keywords

- SARS-CoV-1
- rhesus macaque
- recombinant adenovirus vaccine

#### Main Findings

Rhesus macaques were immunized intramuscularly twice (week 0 and
week 4) with SV8000 carrying the information to express a S1-orf8
fusion protein and the N protein from the BJ01 strain of SARS-CoV-1.
By week 8, immunized animals had signs of immunological protection
(IgG and neutralization titers) against SARS-CoV-1 and were
protected against challenge with the PUMC-1 strain, with fewer
detectable symptoms of respiratory distress, lower viral load,
shorter periods of viral persistence, and less pathology in the
lungs compared to non-immunized animals.

#### Limitations

The authors should write clearer descriptions of the methods used in
this article. They do not describe how the IgG titers or
neutralization titers were determined. There are some issues with
the presentation of data, for example, in Figure 1a, y-axis should
not be Vmax; forming cells and 1d would benefit from showing error
bars. Furthermore, although I inferred that the animals were
challenged at week 8, the authors did not explicitly detail when the
animals were challenged. The authors should explain the design of
their vaccine, including the choice of antigens and vector. The
authors also do not include a description of the ethical use of
animals in their study.

#### Significance

The authors describe a vaccine for SARS-CoV-1 with no discussion of
possible implications for the current SARS-CoV-2 pandemic. Could a
similar vaccine be designed to protect against SARS-CoV-2 and would
the concerns regarding emerging viral mutations that the authors
describe as a limitation for SARS-CoV-1 also be true in the context
of SARS-CoV-2?

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Reduction and Functional Exhaustion of T cells in Patients with Coronavirus Disease 2019 (COVID-19)

[@doi:10.1101/2020.02.18.20024364]

#### Keywords

- T cell exhaustion
- T cell lymphopenia
- IL-6
- IL-10
- TNF-α

#### Main Findings

Based on a retrospective study of 522 COVID patients and 40
healthy controls from two hospitals in Wuhan, China, authors show both
age-dependent and clinical severity-dependent decrease in T cell numbers
with elderly patients and patients who are in ICU-care showing the most
dramatic decrease in T cell counts. Cytokine profiling of COVID patients
reveal that TNF-α, IL-6 and IL-10 are increased in infected patients
with patients in the ICU showing the highest levels. Interestingly,
these three cytokine levels were inversely correlated with T cell counts
and such inverse relationship was preserved throughout the disease
progression. Surface staining of exhaustion markers (PD-1 and Tim-3) and
flow cytometry of stained peripheral blood of 14 patients and 3 healthy
volunteers demonstrate that T cells of COVID patients have increased
expression of PD-1 with patients in ICU having the highest number of
CD8^+^PD-1^+^ cells than their counterparts in non-ICU groups.

#### Limitations

Compared to the number of patients, number of control (n=
40) is small and is not controlled for age. Additional data linking
inflammatory cytokines and the quality of the adaptive response
including humoral and antigen specific T cell response is much needed. T
cell exhaustion study relies on marker-dependent labeling of T cell
functionality of a very limited sample size (n=17)—a
functional/mechanistic study of these T cells from PBMCs would have
bolstered their claims.

#### Significance

Limited but contains interesting
implications. It is already known in literature that in the context of
acute respiratory viral infections CD8 T cells exhibit exhaustion-like
phenotypes which further underscores the importance of mechanistic
studies that can elucidate how COVID infection leads to lymphopenia and
T cell exhaustion-like phenotype.

However, as authors have noted, the data does point to an interesting
question: How these inflammatory cytokines (TNF-α, IL-6 and IL-10)
correlate with or affect effective viral immunity and what types of
cells produce these cytokines? Answering that question will help us
refine our targets for immune-modulatory therapies especially in
patients suffering from cytokine storms.

#### Credit

*This review by Chang Moon was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical Characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China

[@doi:10.1101/2020.02.19.20025239]

#### Keywords

- COVID-19
- pneumonia
- hypertension
- diabetes
- biomarker
- neutrophilia
- lymphopenia

#### Main Findings

Most common chronic conditions among 25 patients that died from
COVID-19 related respiratory failure were hypertension (64%) and
diabetes (40%). Disease progression was marked by progressive organ
failure, starting first with lung dysfunction, then heart (e.g.
increased cTnI and pro-BNP), followed by kidney (e.g. increased BUN,
Cr), and liver (e.g. ALT, AST). 72% of patients had neutrophilia and 88%
also had lymphopenia. General markers of inflammation were also
increased (e.g. PCT, D-Dimer, CRP, LDH, and SAA).

#### Limitations

The limitations of this study include small sample size and
lack of measurements for some tests for several patients. This study
would also have been stronger with comparison of the same measurements
to patients suffering from less severe disease to further validate and
correlate proposed biomarkers with disease severity.

#### Significance

This study identifies chronic conditions (i.e. hypertension
and diabetes) that strongly correlates with disease severity. In
addition to general markers of inflammation, the authors also identify
concomitant neutrophilia and lymphopenia among their cohort of patients.
This is a potentially interesting immunological finding because we would
typically expect increased lymphocytes during a viral infection.
Neutrophilia may also be contributing to cytokine storm. In addition,
PCT was elevated in 90.5% of patients, suggesting a role for sepsis or
secondary bacterial infection in COVID-19 related respiratory failure.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 infection does not significantly cause acute renal injury: an analysis of 116 hospitalized patients with COVID-19 in a single hospital, Wuhan, China

[@doi:10.1101/2020.02.19.20025288]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- kidney
- clinical
- longitudinal

#### Main Findings

-   Clinical data from 116 hospitalized CoVID-19 patients analyzed over
    4 weeks for correlation with renal injury. Comorbidities included
    chronic renal failure (CRF) in 5 patients (4.3%).

-   10.8% of patients with no prior kidney disease showed elevations in
    blood urea or creatinine, and 7.2% of patients with no prior kidney
    disease showed albuminuria.

-   Patients with pre-existing CRF underwent continuous renal
    replacement therapy (CRRT) alongside CoVID-19 treatment. Renal
    functions remained stable in these patients.

-   All 5 patients with CRF survived CoVID-19 therapy without
    progression to ARDS or worsening of CRF.

#### Limitations

-   Renal injury biomarkers in patients with incipient kidney
    abnormalities not tabulated separately, making overall data hard to
    interpret. It will be critical to separately examine kidney function
    (BUN, urine creatinine and eGFR) in patients that developed any
    kidney abnormalities (7.2\~10.8% of cohort).

-   No information on type of CoVID-19 therapy used across cohort; will
    be useful to correlate how treatment modality influences kidney
    function (and other parameters).

-   Invokes previous clinical-correlation studies that indicate low
    instances of kidney damage[@doi:10.1001/jama.2020.1585; @doi:10.1101/2020.02.06.20020974], but those studies did not track
    longitudinal urine samples for acute renal injury markers and viral
    shedding.

-   CRRT in patients with CRF is standard therapy irrespective of
    CoVID-19 status; it will be important to compare clinical parameters
    of these patients (n=5) with virus-naïve CRF patients (none in this
    study) to make any meaningful conclusions.

#### Significance

-   This study argues that renal impairment is uncommon in CoVID-19 and
    not associated with high mortaility, in stark contrast with a
    concurrent study [@doi:10.1101/2020.02.08.20021212].
    If supported by further studies, this argues kidney impairment is
    secondary to cytokine storm/inflammation-induced organ failure, and
    not due to direct viral replication.

-   Will be important to comprehensively characterize large-datasets of
    CoVID-19 patients to conclude if kidney function actively disrupted
    due to viral infection.


#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Potential T-cell and B-Cell Epitopes of 2019-nCoV

[@doi:10.1101/2020.02.19.955484]

#### Keywords

- COVID-19
- vaccine
- epitopes
- spike protein
- MHC-I
- MHC-II
- neutralizing antibodies
- ACE2

#### Main Findings

The authors use 2 neural network algorithms, NetMHCpan4 and
MARIA, to identify regions within the COVID-19 genome that are
presentable by HLA. They identify 405 viral epitopes that are
presentable on MHC-I and MHC-II and validate using known epitopes from
SARS-CoV. To determine whether immune surveillance drives viral
mutations to evade MHC presentation, the authors analyzed 68 viral
genomes from 4 continents. They identified 93 point mutations that
occurred preferentially in regions predicted to be presented by MHC-I
(p=0.02) suggesting viral evolution to evade CD8 T-cell mediated
killing. 2 nonsense mutations were also identified that resulted in loss
of presentation of an associated antigen (FGDSVEEVL) predicted to be
good antigen for presentation across multiple HLA alleles.

To identify potential sites of neutralizing antibody binding, the
authors used homology modeling to the SARS-CoV’s spike protein (S
protein) to determine the putative structure of the CoV2 spike protein.
They used Discotope2 to identify antibody binding sites on the protein
surface in both the down and up conformations of the S protein. The
authors validate this approach by first identifying antibody binding
site in SARS-CoV S protein. In both the down and up conformation of the
CoV2 S protein, the authors identified a potential antibody binding site
on the S protein receptor binding domain (RBD) of the ACE2 receptor
(residues 440-460, 494-506). While RBDs in both SARS-CoV and CoV2 spike
proteins may be important for antibody binding, the authors note that
SARS-CoV has larger attack surfaces than CoV2. These results were later
validated on published crystal structures of the CoV2 S protein RBD and
human ACE2. Furthermore, analysis of 68 viral genomes did not identify
any mutations in this potential antibody binding site in CoV2.

Finally, the authors compile a list of potential peptide vaccine
candidates across the viral genome that can be presented by multiple HLA
alleles. Several of the peptides showed homology to SARS-CoV T-cell and
B-cell epitopes.

#### Limitations

While the authors used computational methods of validation,
primarily through multiple comparisons to published SARS-CoV structures
and epitopes, future work should include experimental validation of
putative T-cell and B-cell epitopes.

#### Significance

The authors identified potential T-cell and B-cell epitopes
that may be good candidates for peptide based vaccines against CoV2.
They also made interesting observations in comparing SARS-CoV and CoV2
potential antibody binding sites, noting that SARS-CoV had larger attack
surfaces for potential neutralizing antibody binding. One of the
highlights of this paper was the authors’ mutation analysis of 68 viral
genomes from 4 continents. This analysis not only validated their
computational method for identifying T-cell epitopes, but showed that
immune surveillance likely drives viral mutation in MHC-I binding
peptides. The smaller attack surface may point to potential mechanisms
of immune evasion by CoV2. However, absence of mutations in the RBD of
CoV2 and the small number of mutations in peptides presentable to T
cells suggests that vaccines against multiple epitopes could still
elicit robust immunity against CoV2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein

Walls et al. *bioRxiv*. [@doi:10.1101/2020.02.19.956581] now [@doi:10.1016/j.cell.2020.02.058]

#### Keywords
- binding affinity
- antigenicity
- neutralizing antibody

#### Main Findings

The authors highlight a human angiotensin-converting enzyme 2
(hACE2), as a potential receptor used by the current Severe Acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) as a host factor that
allows the virus target human cells. This virus-host interaction
facilitates the infection of human cells with a high affinity comparable
with SARS-CoV. The authors propose this mechanism as a probable
explanation of the efficient transmission of SARS-CoV-2 between humans.
Besides, Walls and colleagues described SARS-CoV-2 S glycoprotein S by
Cryo-EM along with neutralizing polyclonal response against SAR-CoV-2 S
from mice immunized with SAR-CoV and blocking SAR-CoV-2 S-mediated entry
into VeroE6 infected cells.**

#### Limitations

The SARS-CoV-2 depends on the cell factors ACE2 and TMPRSS2, this
last, according to a recent manuscript by Markus Hoffman et al., *Cell*,
2020. The authors used green monkey (VeroE6) and hamster (BHK) cell
lines in the experiments to drive its conclusions to humans; however, it
is well known the caucasian colon adenocarcinoma human cell line
(CaCo-2), highly express the hACE2 receptor as the TMPRSS2 protease as
well. In humans, ACE2 protein is highly expressed in the
gastrointestinal tract, which again, makes the CaCo-2 cell line suitable
for the following SARS-CoV-2 studies.


#### Significance

The results propose a functional receptor used by SARS-CoV-2 to
infect humans worldwide and defining two distinct conformations of spike
(S) glycoprotein by cryogenic electron microscopy (Cryo-EM). This study
might help establish a precedent for initial drug design and treatment
of the current global human coronavirus epidemic.

#### Credit
*Review by postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Breadth of concomitant immune responses underpinning viral clearance and patient recovery in a non-severe case of COVID-19

Thevarajan et al. *medRxiv* [@doi:10.1101/2020.02.20.20025841]

#### Keywords

- IgG
- IgM
- TfH cells
- NK cells
- SNP

#### Main Findings

The authors characterized the immune response in peripheral blood of a
47-year old COVID-19 patient.

SARS-CoV2 was detected in nasopharyngeal swab, sputum and faeces
samples, but not in urine, rectal swab, whole blood or throat swab. 7
days after symptom onset, the nasopharyngeal swab test turned negative,
at day 10 the radiography infiltrates were cleared and at day 13 the
patient became asymptomatic.

Immunofluorescence staining shows from day 7 the presence of
**COVID-19-binding IgG and IgM** antibodies in plasma, that increase
until day 20.

Flow cytometry on whole blood reveals a plasmablast peak at day 8, a
gradual increase in T follicular helper cells, stable HLA-DR^+^ NK
frequencies and decreased monocyte frequencies compared to healthy
counterparts. The expression of CD38 and HLA-DR peaked on T cells at D9
and was associated with higher production of cytotoxic mediators by
CD8^+^ T cells.

IL-6 and IL-8 were undetectable in plasma.

The authors further highlight the presence of the **IFITM3
SNP-rs12252-C/C variant** in this patient, which is associated with
higher susceptibility to influenza virus.

#### Limitations

These results need to be confirmed in additional patients.

COVID-19 patients have increased infiltration of macrophages in their
lungs [@doi:10.1101/2020.02.23.20026690]. Monitoring monocyte proportions in blood earlier in the
disease might help to evaluate their eventual migration to the lungs.

The stable concentration of HLA-DR^+^ NK cells in blood from day 7 is
not sufficient to rule out NK cell activation upon SARS-CoV2 infection.
In response to influenza A virus, NK cells express higher levels of
activation markers CD69 and CD38, proliferate better and display higher
cytotoxicity [@doi:10.3389/fimmu.2019.01116]. Assessing these parameters in COVID-19 patients is
required to better understand NK cell role in clearing this infection.

Neutralization potential of the COVID-19-binding IgG and IgM antibodies
should be assessed in future studies.

This patient was able to clear the virus, while presenting a SNP
associated with severe outcome following influenza infection. The
association between this SNP and outcome upon SARS-CoV2 infection should
be further investigated.

#### Significance

This study is among the first to describe the appearance of
COVID-19-binding IgG and IgM antibodies upon infection. The emergence of
new serological assays might contribute to monitor more precisely the
seroconversion kinetics of COVID-19 patients [@doi:10.1101/2020.03.17.20037713]. Further association
studies between IFITM3 SNP-rs12252-C/C variant and clinical data might
help to refine the COVID-19 outcome prediction tools.

#### Credit

*Review by Bérengère Salomé as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

Liao et al. *medRxiv* [@doi:10.1101/2020.02.23.20026690]

#### Keywords

- COVID-19
- SARS-CoV-2
- Broncho-alveolar lavage
- macrophages
- NK cells
- T cells
- cytokine storm
- scRNAseq

#### Main Findings

The authors performed single-cell RNA sequencing (scRNAseq) on
bronchoalveolar lavage fluid (BAL) from 6 COVID-19 patients (n=3 mild
cases, n=3 severe cases). Data was compared to previously generated
scRNAseq data from healthy donor lung tissue (n=8).

Clustering analysis of the 6 patients revealed distinct immune cell
organization between mild and severe disease. Specifically, they found
that transcriptional clusters annotated as tissue resident alveolar
macrophages were strongly reduced while monocytes-derived FCN1^+^SPP1^+^
inflammatory macrophages dominated the BAL of patients with severe
COVID19 diseases. They show that inflammatory macrophages upregulated
interferon-signaling genes, monocytes recruiting chemokines including
CCL2, CCL3, CCL4 as well as IL-6, TNF, IL-8 and profibrotic cytokine
TGF-β, while alveolar macrophages expressed lipid metabolism genes, such
as PPARG.

The lymphoid compartment was overall enriched in lungs from patients.
Clonally expanded CD8 T cells were enriched in mild cases suggesting
that CD8 T cells contribute to viral clearance as in Flu infection,
whereas proliferating T cells were enriched in severe cases.

SARS-CoV-2 viral transcripts were detected in severe patients, but
considered here as ambient contaminations.

#### Limitations

These results are based on samples from 6 patients and should therefore
be confirmed in the future in additional patients. Longitudinal
monitoring of BAL during disease progression or resolution would have
been most useful.

The mechanisms underlying the skewing of the macrophage compartment in
patients towards inflammatory macrophages should be investigated in
future studies.

Deeper characterization of the lymphoid subsets is required. The
composition of the “proliferating” cluster and how these cells differ
from conventional T cell clusters should be assessed. NK and CD8 T cell
transcriptomic profile, in particular the expression of cytotoxic
mediator and immune checkpoint transcripts, should be compared between
healthy and diseased lesions.

#### Significance

COVID-19 induces a robust inflammatory cytokine storm in patients that
contributes to severe lung tissue damage and ARDS [@doi:10/ggjfnn]. Accumulation of
monocyte-derived inflammatory macrophages at the expense of Alveolar
macrophages known to play an anti-inflammatory role following
respiratory viral infection, in part through the PPARγ pathway [@doi:10.3389/fimmu.2018.01777; @doi:10.1128/JVI.00030-19] are
likely contributing to lung tissue injuries. These data suggest that
reduction of monocyte accumulation in the lung tissues could help
modulate COVID-19-induced inflammation. Further analysis of lymphoid
subsets is required to understand the contribution of adaptive immunity
to disease outcome.

#### Credit

*Review by Bérengère Salomé and Assaf Magen as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Can routine laboratory tests discriminate 2019 novel coronavirus infected pneumonia from other community-acquired pneumonia?

Pan et al. *medRxiv* [@doi:10.1101/2020.02.25.20024711]

#### Keywords

- Routine laboratory testing

#### Main Findings

In an attempt to use standard laboratory testing for the discrimination
between “Novel Coronavirus Infected Pneumonia” (NCIP) and a usual
community acquired pneumonia (CAP), the authors compared laboratory
testing results of 84 NCIP patients with those of a historical group of
316 CAP patients from 2018 naturally COVID-19 negative. The authors
describe significantly lower white blood- as well as red blood- and
platelet counts in NCIP patients. When analyzing differential blood
counts, lower absolute counts were measured in all subsets of NCIP
patients. With regard to clinical chemistry parameters, they found
increased AST and bilirubin in NCIP patients as compared to CAP
patients.

#### Limitations

The authors claim to describe a simple method to rapidly assess a
pre-test probability for NCIP. However, the study has substantial
weakpoints. The deviation in clinical laboratory values in NCIP patients
described here can usually be observed in severely ill patients. The
authors do not comment on how severely ill the patients tested here were
in comparison to the historical control. Thus, the conclusion that the
tests discriminate between CAP and NCIP lacks justification.

#### Significance

The article strives to compare initial laboratory testing results in
patients with COVID-19 pneumonia as compared to patients with a usual
community acquired pneumonia. The implications of this study for the
current clinical situation seem restricted due to a lack in clinical
information and the use of a control group that might not be
appropriate.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia

[@doi:10.1101/2020.02.25.20025643]

#### Keywords
- cytokine
- COVID-19 pneumonia
- severity
- disease progression

#### Main Findings

This study is a cross-sectional analysis of 100 patients with
COVID-19 pneumonia, divided into mild (n = 34), severe (n = 34), and
critical (n = 32) disease status based on clinical definitions.

The criteria used to define disease severity are as follows:

1.  *Severe* – any of the following: respiratory distress or respiratory
    rate ≥ 30 respirations/minute; oxygen saturation ≤ 93% at rest;
    oxygen partial pressure (PaO2)/oxygen concentration (FiO2) in
    arterial blood ≤ 300mmHg, progression of disease on imaging
    to &gt;50% lung involvement in the short term.

2.  *Critical* – any of the following: respiratory failure that requires
    mechanical ventilation; shock; other organ failure that requires
    treatment in the ICU.

3.  Patients with pneumonia who test positive for COVID-19 who do not
    have the symptoms delineated above are considered *mild*.

Peripheral blood inflammatory markers were correlated to disease status.
Disease severity was significantly associated with levels of IL-2R,
IL-6, IL-8, IL-10, TNF-α, CRP, ferroprotein, and procalcitonin. Total
WBC count, lymphocyte count, neutrophil count, and eosinophil count were
also significantly correlated with disease status. Since this is a
retrospective, cross-sectional study of clinical laboratory values,
these data may be extrapolated for clinical decision making, but without
studies of underlying cellular causes of these changes this study does
not contribute to a deeper understanding of SARS-CoV-2 interactions with
the immune system.

It is also notable that the mean age of patients in the mild group was
significantly different from the mean ages of patients designated as
severe or critical (p &lt; 0.001). The mean patient age was not
significantly different between the severe and critical groups. However,
IL-6, IL-8, procalcitonin (Table 2), CRP, ferroprotein (Figure 3A, 3B),
WBC count, and neutrophil count (Figure 4A, 4B) were all significantly
elevated in the critical group compared to severe. These data suggest
underlying differences in COVID-19 progression that is unrelated to age.

#### Significance

Given the inflammatory profile outlined in this study,
patients who have mild or severe COVID-19 pneumonia, who *also* have any
elevations in the inflammatory biomarkers listed above, should be
closely monitored for potential progression to critical status.

#### Credit

*This review by JJF was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors' CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

Herst et al. *bioRxiv* [@doi:10.1101/2020.02.25.963546]

#### Keywords

- Peptide vaccine
- Ebolavirus
- nucleocapsid
- epitope
- vaccine design
- microsphere

#### Main Findings

Vaccination of mice with a single dose of a 9-amino-acid peptide NP44-52
located in a conserved region of ebolavirus (EBOV) nucleocapsid protein
(NP) confers CD8+ T-cell-mediated immunity against mouse adapted EBOV
(maEBOV). Bioinformatic analyses predict multiple conserved CD8+ T cell
epitopes in the SARS-CoV-2 NP, suggesting that a similar approach may be
feasible for vaccine design against SARS-CoV-2.

The authors focus on a site within a 20-peptide region of EBOV NP which
was commonly targeted by CD8+ T cells in a group of EBOV survivors
carrying the HLA-A\*30:01:01 allele. To justify the testing of specific
vaccine epitopes in a mouse challenge setting, the authors cite known
examples of human pathogen-derived peptide antigens that are also
recognized by C57BL/6 mice, as well as existing data surrounding known
mouse immunogenicity of peptides related to this EBOV NP region. Testing
3 distinct 9mer peptides over an 11 amino-acid window and comparing to
vaccination with the 11mer with a T-cell reactivity readout demonstrated
that optimizing peptide length and position for immunogenicity may be
crucial, likely due to suboptimal peptide processing and MHC-class-I
loading.

Vaccines for maEBOV challenge studies were constructed by packaging
NP44-52 in d,l poly(lactic-co-glycolic) acid microspheres. CpG was also
packaged within the microspheres, while Monophosphoryl Lipid A (a TLR4
ligand) was added to the injectate solution. A second peptide consisting
of a predicted MHC-II epitope from the EBOV VG19 protein was added using
a separate population of microspheres, and the formulation was injected
by intraperitoneal administration. The vaccine was protective against a
range of maEBOV doses up to at least 10,000 PFU. Survival was
anticorrelated with levels of IL6, MCP-1 (CCL2), IL9, and GM-CSF, which
recapitulated trends seen in human EBOV infection.

While HLA-A\*30:01:01 is only present in a minority of humans, the
authors state that MHC binding algorithms predict NP44-52 to be a strong
binder of a set of more common HLA-A\*02 alleles. The authors predict
that a peptide vaccine based on the proposed formulation could elicit
responses in up to 50% of people in Sudan or 30% of people in North
America.

SARS-CoV-2 NP, meanwhile, has conserved regions which may provide
peptide-vaccine candidates. Scanning the SARS-CoV-2 NP sequence for
HLA-binding 9mers identified 53 peptides with predicted binding affinity
&lt; 500nM, including peptides that are predicted to bind to HLA-class-I
alleles of 97% of humans, 7 of which have previously been tested
*in-vitro*.

The results support previously appreciated correlations between certain
cytokines and disease severity, specifically IL6 which relates to
multiple trial therapies. Prediction of HLA-class-I binding of
SARS-CoV-2 NP peptides suggests the plausibility of a peptide vaccine
targeting conserved regions of SARS-CoV-2 NP although further validation
in previously infected patient samples will be essential.

#### Credit

*Review by Andrew M. Leader as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2

Li et al. *bioRxiv*. [@doi:10.1101/2020.02.25.965434]

#### Keywords
- SARS-CoV-2
- immune-informatics
- vaccine design
- T cell epitope
- B cell epitope

#### Main Findings

This study employs a series of bioinformatic
pipelines to identify T and B cell epitopes on spike (S) protein of
SARS-CoV-2 and assess their properties for vaccine potential. To
identify B cell epitopes, they assessed structural accessibility,
hydrophilicity, and beta-turn and flexibility which are all factors that
promote their targeting by antibodies. To identify T cell epitopes, they
filtered for peptides with high antigenicity score and capacity to bind
3 or more MHC alleles. Using the protein digest server, they also
demonstrated that their identified T and B cell epitopes are stable,
having multiple non-digesting enzymes per epitope. Epitopes were also
determined to be non-allergenic and non-toxin as assessed by Allergen FP
1.0 and ToxinPred, respectively. For T cell epitopes, they assessed the
strength of epitope-HLA interaction via PepSite. Overall, they predict
four B cell and eleven T cell epitopes (two MHC I and nine MHC II
binding) to pass stringent computational thresholds as candidates for
vaccine development. Furthermore, they performed sequence alignment
between all identified SARS-CoV-2 S protein mutations and predicted
epitopes, and showed that the epitopes are conserved across 134 isolates
from 38 locations worldwide. However, they report that these conserved
epitopes may soon become obsolete given the known mutation rate of
related SARS-CoV is estimated to be 4x10-4/site/year, underscoring the
urgency of anti-viral vaccine development.

#### Limitations

While spike (S) protein may have a
critical role in viral entry into host cells and their epitope
prediction criterion were comprehensive, this study did not examine
other candidate SARS-CoV-2 proteins. This point is particularly
important given that a single epitope may not be sufficient to induce
robust immune memory, and recent approaches involve multi-epitope
vaccine design. Furthermore, their study only included a direct
implementation of various published methods, but did not validate
individual bioinformatic tools with controls to demonstrate robustness.
Finally, it is critical that these predicted epitopes are experimentally
validated before any conclusions can be drawn about their potential as
vaccine candidates or their clinical efficacy.

#### Significance

This study provides a computational framework to
rapidly identify epitopes that may serve as potential vaccine candidates
for treating SARS-CoV-2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis

Wang Jr. et al. *medRxiv*.
[@doi:10.1101/2020.02.26.20026989]

#### Keywords
- Cytokine release syndrome (CRS)
- biomarkers
- ARDS
- IL-6
- lymphopenia

#### Main Findings

This study describes the occurrence of a cytokine release syndrome-like
(CRSL) toxicity in ICU patients with COVID-19 pneumonia. The median time
from first symptom to acute respiratory distress syndrome (ARDS) was 10
days. All patients had decreased CD3, CD4 and CD8 cells, and a
significant increase of serum IL-6. Furthermore, 91% had decreased NK
cells. The changes in IL-6 levels preceded those in CD4 and CD8 cell
counts. All of these parameters correlated with the area of pulmonary
inflammation in CT scan images. Mechanical ventilation increased the
numbers of CD4 and CD8 cells, while decreasing the levels of IL-6, and
improving the immunological parameters.

#### Limitations

The number of patients included in this retrospective single center
study is small (n=11), and the follow-up period very short (25 days).
Eight of the eleven patients were described as having CRSL, and were
treated by intubation (7) or ECMO (2). Nine patients were still in the
intensive care unit at the time of publication of this article, so their
disease outcome is unknown.

#### Significance

The authors define a cytokine release syndrome-like toxicity in patients
with COVID-19 with clinical radiological and immunological criteria: 1)
decrease of circulating CD4, CD8 and NK cells; 2) substantial increase
of IL-6 in peripheral blood; 3) continuous fever; 4) organ and tissue
damage. This event seems to occur very often in critically ill patients
with COVID-19 pneumonia. Interestingly, the increase of IL-6 in the
peripheral blood preceded other laboratory alterations, thus, IL-6 might
be an early biomarker for the severity of COVID-19 pneumonia. The
manuscript will require considerable editing for organization and
clarity.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China

Huang et al. *medRxiv*. [@doi:10.1101/2020.02.27.20029009]

#### Keywords

- Clinical Characteristics
- Non Survivors
- retrospective study

#### Main Findings

This is a simple study reporting clinical
characteristics of patients who did not survive COVID-19. All patients
(mean age=69.22 years) had acute respiratory distress syndrome (ARDS)
and their median time from onset to ARDS was 11 days. The median time
from onset to death was 17 days. Most patients were older male (70%
male) with co-morbidities and only 11 % were smokers. 75% patients
showed bilateral pneumonia. Many patients had chronic diseases,
including hypertension (58.33%). cardiovascular disease (22.22%) and
diabetes (19.44%). Typical clinical feature measured in these patients
includes lymphopenia and elevated markers of inflammation.

#### Limitations

As noted by the authors, the conclusions of this study are
very limited because this is single-centered study focusing on a small
cohort of patients who did not survive. Many clinical parameters
observed by the authors (such* as increase levels of serum CRP, PCT,
IL-6) have also been described in other COVID19 patients who survived
the infection

#### Significance

This study is essentially descriptive and may be useful for
clinical teams monitoring COVID19 patients.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Risk Factors Related to Hepatic Injury in Patients with Corona Virus Disease 2019

[@doi:10.1101/2020.02.28.20028514]

#### Keywords

- COVID-related Hepatic Injury

#### Main Findings

Based on a retrospective study of 85 hospitalized COVID
patients in a Beijing hospital, authors showed that patients with
elevated ALT levels (n = 33) were characterized by significantly higher
levels of lactic acid and CRP as well as lymphopenia and hypoalbuminemia
compared to their counterparts with normal ALT levels. Proportion of
severe and critical patients in the ALT elevation group was
significantly higher than that of normal ALT group. Multivariate
logistic regression performed on clinical factors related to ALT
elevation showed that CRP $\geq$ 20mg/L and low lymphocyte count
(&lt;1.1\*10\^9 cells/L) were independently related to ALT elevation—a
finding that led the authors to suggest cytokine storm as a major
mechanism of liver damage.

#### Limitations

The article’s most attractive claim that liver damage seen in COVID
patients is caused by cytokine storm (rather than direct infection of
the liver) hinges solely on their multivariate regression analysis.
Without further mechanistic studies a) demonstrating how high levels of
inflammatory cytokines can induce liver damage and b) contrasting types
of liver damage incurred by direct infection of the liver vs.
system-wide elevation of inflammatory cytokines, their claim remains
thin. It is also worth noting that six of their elevated ALT group
(n=33) had a history of liver disease (i.e. HBV infection, alcoholic
liver disease, fatty liver) which can confound their effort to pin down
the cause of hepatic injury to COVID.

#### Significance

Limited. This article confirms a rich body
of literature describing liver damage and lymphopenia in COVID patients.

#### Credit

*Review by Chang Moon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

[@doi:10.1101/2020.02.29.20029520]

#### Keywords

- ARDS
- interleukin-6 (IL-6)
- procalcitonin (PCT)
- pro-inflammatory cytokines
- SARS-CoV-2 RNAaemia

#### Main Findings

48 adult patients diagnosed with Covid19 according to Chinese guidelines
for Covid19 diagnosis and treatment version 6 were included in this
study. Patients were further sub-divided into three groups based on
clinical symptoms and disease severity: (1) mild, positive Covid19 qPCR
with no or mild clinical symptoms (fever; respiratory; radiological
abnormalities); (2) severe, at least one of the following: shortness of
breath/respiratory rate &gt;30/min, oxygen saturation SaO~2~&lt;93%,
Horowitz index paO2/FiO~2~ &lt; 300 mmHg (indicating moderate pulmonary
damage); and (3) critically ill, at least one additional complicating
factor: respiratory failure with need for mechanical ventilation;
systemic shock; multi-organ failure and transfer to ICU. Serum samples
and throat-swaps were collected from all 48 patients enrolled.
SARS-CoV-2 RNA was assessed by qPCR with positive results being defined
as Ct values &lt; 40, and serum interleukin-6 (IL-6) was quantified
using a commercially available detection kit. Briefly, patient
characteristics in this study confirm previous reports suggesting that
higher age and comorbidities are significant risk factors of clinical
severity. Of note, 5 out of 48 of patients (10.41%), all in the
critically ill category, were found to have detectable serum SARS-CoV-2
RNA levels, so-called RNAaemia. Moreover, serum IL-6 levels in these
patients were found to be substantially higher and this correlated with
the presence of detectable SARS-CoV-2 RNA levels. The authors
hypothesize that viral RNA might be released from acutely damages
tissues in moribund patients during the course of Covid19 and that
RNaemia along with IL-6 could potentially be used as a prognostic
marker.

#### Limitations

While this group’s report generally confirms some of the major findings
of a more extensive study, published in early February 2020, [@doi:10/ggjfnn],
there are limitations that should be taken into account. First, the
number of patients enrolled is relatively small; second, interpretation
of these data would benefit from inclusion of information about study
specifics as well as providing relevant data on the clinical course of
these patients other than the fact that some were admitted to ICU (i.e.
demographics on how many patients needed respiratory support, dialysis,
APACHE Ii/III or other standard ICU scores as robust prognostic markers
for mortality etc). It also remains unclear at which time point the
serum samples were taken, i.e. whether at admission, when the diagnosis
was made or during the course of the hospital stay (and potentially
after onset of therapy, which could have affected both IL-6 and RNA
levels). The methods section lacks important information on the qPCR
protocol employed, including primers and cycling conditions used. From a
technical point of view, Ct values &gt;35 seem somewhat non-specific
(although Ct &lt;40 was defined as the CDC cutoff as well) indicating
that serum RNA levels are probably very low, therefore stressing the
need for highly specific primers and high qPCR efficiency. In addition,
the statistical tests used (t-tests, according to the methods section)
do not seem appropriate as the organ-specific data such as BUN and
troponin T values seem to be not normally distributed across groups (n=
5 RNAaemia+ vs. n= 43 RNAaemia-). Given the range of standard deviations
and the differences in patient sample size, it is difficult to believe
that these data are statistically significantly different.

#### Significance

This study is very rudimentary and lacks a lot of relevant clinical
details. However, it corroborates some previously published observations
regarding RNAemia and IL-6 by another group. Generally, regarding future
studies, it would be important to address the question of IL-6 and other
inflammatory cytokine dynamics in relation to Covid19 disease kinetics
(high levels of IL-6, IL-8 and plasma leukotriene were shown to have
prognostic value at the onset of ARDS ; serum IL-2 and IL-15 have been
associated with mortality; reviewed by Chen W & Ware L, Clin Transl Med.
2015 [@doi:10.1186/s40169-015-0065-2]).

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

[@doi:10.1101/2020.03.01.20029074]

#### Keywords

- Lymphopenia

#### Main Findings
Based on a retrospective study of 162 COVID patients from a
local hospital in Wuhan, China, the authors show an inverse correlation
between lymphocyte % (LYM%) of patients and their disease severity. The
authors have also tracked LYM% of 70 cases (15 deaths; 15 severe; 40
moderate) throughout the disease progression with fatal cases showing no
recovery of lymphocytes ( &lt;5%) even after 17-19 days post-onset. The
temporal data of LYM % in COVID patients was used to construct a
Time-Lymphocyte% model which is used to categorize and predict patients’
disease severity and progression. The model was validated using 92
hospitalized cases and kappa statistic test was used to assess agreement
between predicted disease severity and the assigned clinical severity (k
= 0.49).

#### Limitations

Time-Lymphocyte % Model (TLM) that authors have proposed as
a predictive model for clinical severity is very simple in its
construction and derives from correlative data of 162 patients. In order
for the model to be of use, it needs validation using a far more robust
data set and possibly a mechanistic study on how COVID leads to
lymphopenia in the first place. In addition, it should be noted that no
statistical test assessing significance of LYM % values between disease
severities was performed.

#### Significance

This article is of limited significance as
it simply reports similar descriptions of COVID patients made in
previous literature that severe cases are characterized by lymphopenia.

#### Credit

*Review by Chang Moon as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The potential role of IL-6 in monitoring severe case of coronavirus disease 2019

Liu et al. *medRxiv*. [@doi:10.1101/2020.03.01.20029769]

#### Keywords
- Cytokine Release Syndrome
- lymphocytopenia
- IL-6
- CRP
- COVID19
- pneumonia

#### Main Findings

Study on blood biomarkers on 80 COVID19 patients (69 severe
and 11 non-severe). Patients with severe symptoms at admission
(baseline) showed obvious lymphocytopenia and significantly increased
interleukin-6 (IL-6) and CRP, which was positively correlated with
symptoms severity. IL-6 at baseline positively correlates with CRP, LDH,
ferritin and D-Dimer abundance in blood.

Longitudinal analysis of 30 patients (before and after treatment) showed
significant reduction of IL-6 in remission cases.

#### Limitations

Limited sample size at baseline, especially for the
non-severe leads to question on representativeness. The longitudinal
study method is not described in detail and suffers from
non-standardized treatment. Limited panel of pro-inflammatory cytokine
was analyzed. Patients with severe disease show a wide range of altered
blood composition and biomarkers of inflammation, as well as differences
in disease course (53.6% were cured, about 10% developed acute
respiratory distress syndrome). The authors comment on associations
between IL-6 levels and outcomes, but these were not statistically
significant (maybe due to the number of patients, non-standardized
treatments, etc.) and data is not shown. Prognostic biomarkers could
have been better explored. Study lacks multivariate analysis.

#### Significance

IL-6 could be used as a pharmacodynamic
marker of disease severity. Cytokine Release Syndrome (CRS) is a
well-known side effect for CAR-T cancer therapy and there are several
effective drugs to manage CRS. Drugs used to manage CRS could be tested
to treat the most severe cases of COVID19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease 2019 in Hefei, China

Zhao et al. *medRxiv*. [@doi:10.1101/2020.03.01.20029785]

#### Keywords

- Routine laboratory testing

#### Main Findings

The authors of this study provide a comprehensive analysis of clinical
laboratory assessments in 75 patients (median age 47 year old)
hospitalized for Corona virus infection in China measuring differential
blood counts including T-cell subsets (CD4, CD8), coagulation function,
basic blood chemistry, of infection-related biomarkers including CRP,
Procalcitonin (PCT) (Precursor of calcitonin that increases during
bacterial infection or tissue injury), IL-6 and erythrocyte
sedimentation rate as well as clinical parameters. Among the most common
hematological changes they found increased neutrophils, reduced CD4 and
CD8 lymphocytes, increased LDH, CRP and PCT

When looking at patients with elevated IL-6, the authors describe
significantly reduced CD4 and CD8 lymphocyte counts and elevated CRP and
PCT levels were significantly increased in infected patients suggesting
that increased IL-6 may correlate well with disease severity in COVID-19
infections

#### Limitations

The authors performed an early assessment of clinical standard
parameters in patients infected with COVID-19. Overall, the number of
cases (75) is rather low and the snapshot approach does not inform about
dynamics and thus potential relevance in the assessment of treatment
options in this group of patients.

#### Significance

The article summarizes provides a good summary of some of the common
changes in immune cells inflammatory cytokines in patients with a
COVID-19 infection and. Understanding how these changes can help predict
severity of disease and guide therapy including IL-6 cytokine receptor
blockade using Tocilizumab or Sarilumab will be important to explore.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome

Yang et al. *medRxiv* [@doi:10.1101/2020.03.02.20029975]

#### Keywords

- cytokine
- IP-10
- MCP-3
- IL-1Ra
- lymphocyte
- neutrophil
- stratification
- disease severity
- viral load
- lung function
- complications
- clinical data

#### Summary

Plasma cytokine analysis (48 cytokines) was
performed on COVID-19 patient plasma samples, who were sub-stratified as
severe (N=34), moderate (N=19), and compared to healthy controls (N=8).
Patients were monitored for up to 24 days after illness onset: viral
load (qRT-PCR), cytokine (multiplex on subset of patients), lab tests,
and epidemiological/clinical characteristics of patients were reported.



#### Main Findings

-   Many elevated cytokines with COVID-19 onset compared to healthy
    controls (IFNy, IL-1Ra, IL-2Ra, IL-6, IL-10, IL-18, HGF, MCP-3, MIG,
    M-CSF, G-CSF, MIG-1a, and IP-10).

-   IP-10, IL-1Ra, and MCP-3 (esp. together) were associated with
    disease severity and fatal outcome.

-   IP-10 was correlated to patient viral load (r=0.3006, p=0.0075).

-   IP-10, IL-1Ra, and MCP-3 were correlated to loss of lung function
    (PaO~2~/FaO~2~ (arterial/atmospheric O2) and Murray Score (lung
    injury) with MCP-3 being the most correlated (r=0.4104 p&lt;0.0001
    and r=0.5107 p&lt;0.0001 respectively).

-   Viral load (Lower Ct Value from qRT-PCR) was associated with
    upregulated IP-10 only (not IL-1Ra or MCP-3) and was mildly
    correlated with decreased lung function: PaO~2~/FaO~2~
    (arterial/atmospheric O2) and Murray Score (lung injury).

-   Lymphopenia (decreased CD4 and CD8 T cells) and increased neutrophil
    correlated w/ severe patients.

-   Complications were associated with COVID severity (ARDS, hepatic
    insufficiency, renal insufficiency).

#### Limitations

Collection time of clinical data and lab results
not reported directly (likely 4 days (2,6) after illness onset), making
it very difficult to determine if cytokines were predictive of patient
outcome or reflective of patient compensatory immune response (likely
the latter). Small N for cytokine analysis (N=2 fatal and N=5
severe/critical, and N=7 moderate or discharged). Viral treatment
strategy not clearly outlined.

#### Expanded Results

*NOTE*: Moderate COVID-19 was classified by fever, respiratory
manifestations, and radiological findings consistent with pneumonia
while severe patients had one or more of the following: 1) respiratory
distraction, resting O2 saturation, or 3) arterial PaO2/FiO2 *&lt;* 300
mmHg.

Cytokine Results (Human Cytokine Screening Panel, Bio-Rad):

-   **Significant elevation of cytokines observed in COVID patients
    compared to healthy controls: IFNy, IL-1Ra, IL-2Ra, IL-6, IL-10,
    IL-18, HGF, MCP-3, MIG, M-CSF, G-CSF, MIG-1a, and IP-10.**

-   Severity was correlated **with increase in measured IP-10, MCP-3,
    and IL-Ra** as measure by area under the curve analysis during
    sample timecourse (2-24 days after illness onset).

-   IL-1Ra incr. significant 0-7 days after onset, MCP-3 signif.
    upregulated throughout observation timecourse, and IP-10 increased
    and upregulated throughout (trending downwards over time).

-   **The three cytokines together (IP-10, IL-1Ra, and MCP-3 AUC) served
    as the best predictors of disease deterioration and fatal outcome.**

-   No significant differences between moderate/severe observed between
    groups in IL-2Ra, IL-6, IL-10, IL-18, CTACK, G-CSF, HGF, M-CSF,
    MIP-1a, MIG, and IFNy at any timepoints.

-   **Viral load (Lower Ct Value from qRT-PCR) was associated with
    upregulated IP-10 only (not IL-1Ra or MCP-3) and was highly
    correlated with decreased lung function: PaO~2~/FaO~2~
    (arterial/atmospheric O2) and Murray Score (lung injury).**

-   **Antibodies against these cytokines (esp. anti-IP-10) may serve as
    a potential treatment for amelioration of COVID-19 (and associated
    ARDS).**

Lab results:

-   **Decreased lymphocytes (%) in all patients – lymphopenia corr. w/
    severe patients**

    -   **Decreased CD4 and CD8 T cells** – no monocyte or
        eosino/basophil % measured

-   **Increased neutrophils (%)**

-   Increased BUN (mmol/L) – other kidney markers, liver markers, and
    LDH were not significantly different between groups and were not
    compared to healthy controls.

Clinical features (between moderate vs. severe patient groups):

-   **Complications were associated with severity (ARDS, hepatic
    insufficiency, renal insufficiency).**

-   Coexisting conditions between groups were not significantly
    different (chronic heart/lung/renal/liver disease, diabetes, or
    cancer) and patient time courses (onset to admission and onset to
    viral tx) also not significantly different – 4 days (2, 6) on
    average for admission and 4 (3,7) for antiviral.

-   Increased corticosteroids and mechanical/ invasive mechanical
    ventilation in severe patients.

-   Increased median age in severe group (Median (Range = 63.5 (42-74)
    vs. 51 (22-78)) and patients *&gt;* 60 yrs had higher ratio of
    severe patients as compared patients 16-59 yrs.

-   Higher incidence of fever is severe patients (91.2 vs. 68.4%),
    myalgia (57.7 vs. 48.1%), and chill (17.6% vs. 0%).

-   No differences in cough, headache, nausea/vomiting, or diarrhea.

#### Significance

Outline of pathological time course (implicating innate
immunity esp.) and identification key cytokines associated with disease
severity and prognosis (+ comorbidities). Anti-IP-10 as a possible
therapeutic intervention (ex: Eldelumab).

#### Credit

*Review by Natalie Vaninov as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Zhao Jr. et al. *medRxiv*. [@doi:10.1101/2020.03.02.20030189]

#### Keywords
- SARS-CoV-2 IgG
- seroconversion rate
- total Ab
- Ig
- IgM

#### Main Findings

This study examined antibody responses in
the blood of COVID-19 patients during the early SARS CoV2 outbreak in
China. Total 535 plasma samples were collected from 173 patients (51.4%
female) and were tested for seroconversion rate using ELISA. Authors
also compared the sensitivity of RNA and antibody tests over the course
of the disease . The key findings are:

-   Among 173 patients, the seroconversion rates for total antibody
    (Ab), IgM and IgG were 93.1% (161/173), 82.7% (143/173) and 64.7%
    (112/173), respectively.

-   The seroconversion sequentially appeared for Ab, IgM and then IgG,
    with a median time of 11, 12 and 14 days, respectively. Overall, the
    seroconversion of Ab was significantly quicker than that of IgM (p =
    0.012) and IgG (p &lt; 0.001). Comparisons of seroconversion rates
    between critical and non-critical patients did not reveal any
    significant differences.

-   RNA tests had higher sensitivity in early phase and within 7 days of
    disease onset than antibody assays (66.7% Vs 38.3% respectively).

-   The sensitivity of the Ab assays was higher 8 days after disease
    onset, reached 90% at day 13 and 100% at later time points (15-39
    days). In contrast, RNA was only detectable in 45.5% of samples at
    days 15-39.

-   In patients with undetectable RNA in nasal samples collected during
    day 1-3, day 4-7, day 8-14 and day 15-39 since disease onset, 28.6%
    (2/7), 53.6% (15/28), 98.2% (56/57) and 100% (30/30) had detectable
    total Ab titers respectively Combining RNA and antibody tests
    significantly raised the sensitivity for detecting COVID-19 patients
    in different stages of the disease (p &lt; 0.001).

-   There was a strong positive correlation between clinical severity
    and antibody titer 2-weeks after illness onset.

-   Dynamic profiling of viral RNA and antibodies in representative
    COVID-19 patients (n=9) since onset of disease revealed that
    antibodies may not be sufficient to clear the virus. It should be
    noted that increases in of antibody titers were not always
    accompanied by RNA clearance.

#### Limitations

Because different types of ELISA assays were used for
determining antibody concentrations at different time points after
disease onset, sequential seroconversion of total Ab, IgM and IgG may
not represent actual temporal differences but rather differences in the
affinities of the assays used. Also, due to the lack of blood samples
collected from patients in the later stage of illness, how long the
antibodies could last remain unknown. For investigative dynamics of
antibodies, more samples were required.

#### Significance

Total and IgG antibody titers could be used to understand
the epidemiology of SARS CoV-2 infection and to assist in determining
the level of humoral immune response in patients.

The findings provide strong clinical evidence for routine serological
and RNA testing in the diagnosis and clinical management of COVID-19
patients. The understanding of antibody responses and their half-life
during and after SARS CoV2 infection is important and warrants further
investigations.

#### Credit

*This review was undertaken by Zafar Mahmood and edited by K Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients

Chen et al. *medRxiv* [@doi:10.1101/2020.03.03.20030437]

#### Keywords

- COVID-19
- T cell
- B cell
- NK cell
- IL-6
- pro-calcitonin
- cytokine storm

#### Main Findings

The authors collected data on 25 COVID-19 patients (n=11 men, n=14
women) using standard laboratory tests and flow cytometry. All patients
were treated with antibiotics. Twenty-four of the 25 patients were also
treated with anti-viral Umefinovir and 14 of the patients were treated
with corticosteroids. 14 patients became negative for the virus after
8-14 days of treatment. The same treatment course was extended to 15-23
days for patients who were still positive for the virus at day 14.

The authors found a negative association between age and resolution of
infection. Patients with hypertension, diabetes, malignancy or chronic
liver disease were all unable to clear the virus at day 14, though not
statistically significant.

Elevated procalcitonin and a trend for increased IL-6 were also found in
peripheral blood prior to the treatment.

A trend for lower NK cell, T cell and B cell counts in patients was also
reported. B cell, CD4 and CD8 T cell counts were only increased upon
treatment in patients who cleared the virus. NK cell frequencies
remained unchanged after treatment in all the patients.

#### Limitations

73% of the patients who remained positive for SARS-CoV2 after the 1^st^
treatment, and 43% of all patients who cleared the virus were treated
with corticosteroids. Corticosteroids have strong effects on the immune
compartment in blood [@doi:10.1038/srep23002]. The authors should have accounted for
corticosteroid treatment when considering changes in T, NK and B cell
frequencies.

Assessing if IL-6 concentrations were back to baseline levels following
treatment would have provided insights into the COVID-19 cytokine storm
biology. Patients with higher baseline levels of IL-6 have been reported
to have lower CD8 and CD4 T cell frequencies [@doi:10.1101/2020.03.01.20029785]. Correlating IL-6 with
cell counts before and after treatment would thus have also been of
interest. The report of the laboratory measures in table 2 is incomplete
and should include the frequencies of patients with increased/decreased
levels for each parameter.

Correction is needed for the 1^st^ paragraph of the discussion as data
does not support NK cell restoration upon treatment in patients who
cleared the virus. NK cells remain unchanged after the 1^st^ treatment
course and only seem to increase in 2 out of 6 donors after the 2^nd^
treatment course in those patients.

#### Significance

Previous reports suggest an association between disease severity and
elevated IL-6 or pro-calcitonin concentrations in COVID-19
patients [@doi:10.1101/2020.02.29.20029520; @doi:10.1016/j.cca.2020.03.004]. IL-6 receptor blockade is also being administered to
patients enrolled in clinical trials (NCT04317092). This report thus
contributes to highlight elevated concentrations of these analytes in
COVID-19 patients. Mechanisms underlying the association between viral
clearance and restoration of the T cell and B cell frequencies suggests
viral-driven immune dysregulation, which needs to be investigated in
further studies.

#### Credit

*Review by Bérengère Salomé as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical findings in critically ill patients infected with SARS-CoV-2 in Guangdong Province, China: a multi-center, retrospective, observational study


Xu et al. *medRxiv*. [@doi:10.1101/2020.03.03.20030668]

#### Keywords

- clinical outcomes
- prognosis
- critically ill patients
- ICU
- lymphopenia
- LDH

#### Main Findings:

This work analyses laboratory and clinical data from 45 patients treated
in the in ICU in a single province in China. Overall, 44% of the
patients were intubated within 3 days of ICU admission with only 1
death.

Lymphopenia was noted in 91% of patient with an inverse correlation with
LDH.

Lymphocyte levels are negatively correlated with Sequential Organ
Failure Assessment (SOFA) score (clinical score, the higher the more
critical state), LDH levels are positively correlated to SOFA score.
Overall, older patients (&gt;60yo), with high SOFA score, high LDH
levels and low lymphocytes levels at ICU admission are at higher risk of
intubation.

Of note, convalescent plasma was administered to 6 patients but due to
limited sample size no conclusion can be made.

#### Limitations

While the study offers important insights into disease course and
clinical lab correlates of outcome, the cohort is relatively small and
is likely skewed towards a less-severe population compared to other ICU
reports given the outcomes observed. Analysis of laboratory values and
predictors of outcomes in larger cohorts will be important to make
triage and treatment decisions. As with many retrospective analyses,
pre-infection data is limited and thus it is not possible to understand
whether lymphopenia was secondary to underlying comorbidities or
infection.

Well-designed studies are necessary to evaluate the effect of
convalescent plasma administration.

#### Significance

This clinical data enables the identification of at-risk
patients and gives guidance for research for treatment options. Indeed,
further work is needed to better understand the causes of the
lymphopenia and its correlation with outcome.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Immune Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2)

[@doi:10.1101/2020.03.03.962332]

#### Keywords

- Vaccine
- in silico
- B cell epitopes
- T cell epitopes

#### Main Findings

Using in silico bioinformatic tools, this study identified putative
antigenic B-cell epitopes and HLA restricted T-cell epitopes from the
spike, envelope and membrane proteins of SARS-CoV-2, based on the genome
sequence available on the NCBI database. T cell epitopes were selected
based on predicted affinity for the more common HLA-I alleles in the
Chinese population. Subsequently, the authors designed vaccine peptides
by bridging selected B-cell epitopes and adjacent T-cell epitopes.
Vaccine peptides containing only T-cell epitopes were also generated.

From 61 predicted B-cell epitopes, only 19 were exposed on the surface
of the virion and had a high antigenicity score. A total of 499 T-cell
epitopes were predicted. Based on the 19 B-cell epitopes and their 121
adjacent T-cell epitopes, 17 candidate vaccine peptides were designed.
Additionally, another 102 vaccine peptides containing T-cell epitopes
only were generated. Based on the epitope counts and HLA score, 13 of
those were selected. Thus, a total of 30 peptide vaccine candidates were
designed.

#### Limitations

While this study provides candidates for the development of vaccines
against SARS-CoV-2, in vitro and in vivo trials are required to validate
the immunogenicity of the selected B and T cell epitopes. This could be
done using serum and cells from CoV-2-exposed individuals, and in
preclinical studies. The implication of this study for the current
epidemic are thus limited. Nevertheless, further research on this field
is greatly needed.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China

Cao et al. *medRxiv* [@doi:10.1101/2020.03.04.20030395]

#### Keywords

- Disease severity
- clinical features
- laboratory abnormalities

#### Main Findings

This single-center cohort study analyzes the clinical and
laboratory features of 198 patients with confirmed COVID-19 infection in
Shanghai, China and correlated these parameters with clinical disease
severity, including subsequent intensive care unit (ICU) admission. 19
cases (9.5%) required ICU admission after developing respiratory failure
or organ dysfunction. Age, male sex, underlying cardiovascular disease,
and high symptom severity (high fever, dyspnea) were all significantly
correlated with ICU admission. Additionally, ICU admission was more
common in patients who presented with lymphopenia and elevated
neutrophil counts, among other laboratory abnormalities. Flow cytometric
analysis revealed that patients admitted to the ICU had significantly
reduced circulating CD3+ T cell, CD4+ T cell, CD8+ T cell, and CD45+
leukocyte populations compared to the cohort of patients not requiring
ICU admission.

#### Limitations

The limitations of this study include the relatively
small sample size and lack of longitudinal testing. The authors also did
not assess whether respiratory comorbidity – such as asthma or chronic
obstructive lung disease – in addition to immunosuppression affected ICU
admission likelihood.

#### Significance

COVID-19 has already sickened thousands across the globe,
though the severity of these infections is markedly diverse, ranging
from mild symptoms to respiratory failure requiring maximal
intervention. Understanding what clinical, laboratory, and immunologic
factors predict the clinical course of COVID-19 infection permits
frontline providers to distribute limited medical resources more
effectively.

#### Credit

*Review by Andrew Charap as part of a project by students, postdocs and
faculty at the Immunology Institute of the Icahn School of Medicine at
Mount Sinai.*


### Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing

Zhang et al. *medRxiv*. [@doi:10.1101/2020.03.04.20030916]

#### Keywords

- Immunoassay
- serum IgM and IgG
- specific antibodies

#### Main Finding

This study showed that both anti-2019-nCov IgM and IgG were detected by
automated chemiluminescent immunoassay in the patients who had been
already confirmed as positive by nucleic acid detection, while single
positivity of IgM or IgG were detected in a very few cases in the other
population including 225 non-COVID-19 cases. In addition to the increase
of anti-2019-nCov IgM 7-12 days after morbidity, the increase of IgG was
detected in three patients with COVID-19 within a very short of time
(0-1 day).

#### Limitations

The limitation of this study is only
3 confirmed COVID-19 cases were included, so that the relationship
between anti-2019-nCov antibodies and disease progression might not be
clearly defined. Another limitation is that they did not show the course
of 2019-nCov specific antibodies in the cases with positive for COVID-19
but without clinical symptoms.

#### Significance

The detection of anti-2019-nCov antibodies can be an alternative method
to diagnose and treat COVID-19 more comprehensively by distinguish non
COVID-19 patients. It may be helpful to understand the course of
individual cases with COVID-19 to predict the prognosis if more cases
will be evaluated.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

[@doi:10.1101/2020.03.04.20031120]

#### Keywords

- Kidney/Renal Failure
- Macrophage Infiltration
- Complement Activation

#### Main Finding

Analyzing the eGFR (effective glomerular flow rate) of 85 Covid-19
patients and characterizing tissue damage and viral presence in
post-mortem kidney samples from 6 Covid-19 patients, the authors
conclude that significant damage occurs to the kidney, following
Covid-19 infection. This is in contrast to the SARS infection from the
2003 outbreak. They determine this damage to be more prevalent in
patients older than 60 years old, as determined by analysis of eGFR. H&E
and IHC analysis in 6 Covid-19 patients revealed that damage was in the
tubules, not the glomeruli of the kidneys and suggested that macrophage
accumulation and C5b-9 deposition are key to this process. 

#### Limitations

Severe limitations include that the H&E and IHC samples were performed
on post-mortem samples of unknown age, thus we cannot assess how/if age
correlates with kidney damage, upon Covid-19 infection. Additionally,
eGFR was the only *in-vivo* measurement. Blood urea nitrogen and
proteinuria are amongst other measurements that could have been obtained
from patient records. An immune panel of the blood was not performed to
assess immune system activation. Additionally, patients are only from
one hospital. 

#### Significance

This report makes clear that kidney damage is prevalent
in Covid-19 patients and should be accounted for. 

#### Credit

*Review by Dan Fu Ruan, Evan Cody and Venu Pothula as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine at Mount Sinai.*


### COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients

Song et al. *medRxiv*. [@doi:10.1101/2020.03.05.20031906]

#### Keywords

- retrospective
- electronic health records
- blood counts
- diagnostic
- prognostic
- modeling

#### Main Findings

The aim of this study was to identify diagnostic or prognostic criteria
which could identify patients with COVID-19 and predict patients who
would go on to develop severe respiratory disease. The authors use EMR
data from individuals taking a COVID-19 test at Zhejiang hospital, China
in late January/Early February. A large number of clinical parameters
were different between individuals with COVID-19 and also between
‘severe’ and ‘non-severe’ infections and the authors combine these into
a multivariate linear model to derive a weighted score, presumably
intended for clinical use.

#### Limitations

Unfortunately, the paper is lacking a lot of crucial information, making
it impossible to determine the importance or relevance of the findings.
Most importantly, the timings of the clinical measurements are not
described relative to the disease course, so it is unclear if the
differences between ‘severe’ and ‘non-severe’ infections are occurring
before progression to severe disease (which would make them useful
prognostic markers), or after (which would not).

#### Significance

This paper is one of many retrospective studies coming from hospitals in
China studying individuals with COVID-19. Because of the sparse
description of the study design, this paper offers little new
information. However, studies like this could be very valuable and we
would strongly encourage the authors to revise this manuscript to
include more information about the timeline of clinical measurements in
relation to disease onset and more details of patient outcomes.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### LY6E impairs coronavirus fusion and confers immune control of viral disease

Pfaender et al. *bioRxiv*. [@doi:10.1101/2020.03.05.979260]

#### Keywords

- interferon-stimulated genes
- antiviral interferons
- human coronaviruses (CoV)
- murine hepatitis virus (MHV)

#### Main Findings

Screening a cDNA library of &gt;350 human interferon-stimulated genes
for antiviral activity against endemic human coronavirus HCoV-229E
(associated with the common cold), Pfaender S & Mar K *et al.* identify
lymphocyte antigen 6 complex, locus E (Ly6E) as an inhibitor of cellular
infection of Huh7 cells, a human hepatoma cell line susceptible to
HCoV-229E and other coronaviruses. In a series of consecutive *in vitro*
experiments including both stable Ly6E overexpression and
CRISPR-Cas9-mediated knockout the authors further demonstrate that Ly6E
reduces cellular infection by various other coronaviruses including
human SARS-CoV and SARS-CoV-2 as well as murine CoV mouse hepatitis
virus (MHV). Their experiments suggest that this effect is dependent on
Ly6E inhibition of CoV strain-specific spike protein-mediated membrane
fusion required for viral cell entry.

To address the function of Ly6E *in vivo*, hematopoietic stem
cell-specific Ly6E knock-out mice were generated by breeding Ly6E^fl/fl^
mice (referred to as functional wild-type mice) with transgenic
*Vav-iCre* mice (offspring referred to as Ly6E HSC ko mice); wild-type
and Ly6E HSC ko mice of both sexes were infected intraperitoneally with
varying doses of the natural murine coronavirus MHV, generally causing a
wide range of diseases in mice including hepatitis, enteritis and
encephalomyelitis. Briefly, compared to wild-type controls, mice lacking
hematopoietic cell-expressed Ly6E were found to present with a more
severe disease phenotype as based on serum ALT levels (prognostic of
liver damage), liver histopathology, and viral titers in the spleen.
Moreover, bulk RNAseq analysis of infected liver and spleen tissues
indicated changes in gene expression pathways related to tissue damage
and antiviral immune responses as well as a reduction of genes
associated with type I IFN response and inflammation. Finally, the
authors report substantial differences in the numbers of hepatic and
splenic APC subsets between wild-type and knockout mice following MHV
infection and show that Ly6E-deficient B cells and to a lesser extent
also DCs are particularly susceptible to MHV infection *in vitro*.

#### Limitations

Experiments and data in this study are presented in an overall logical
and coherent fashion; however, some observations and the conclusions
drawn are problematic and should be further addressed & discussed by the
authors. Methodological & formal limitations include relatively low
replicate numbers as well as missing technical replicates for some *in
vitro* experiments (*cf*. Fig. legend 1; Fig. legend 2e); the omission
of “outliers” in Fig. legend 2 without an apparent rationale as to why
this approach was chosen; the lack of detection of actual Ly6E protein
levels in Ly6E HSC ko or wild-type mice; and most importantly, missing
information on RNAseq data collection & analysis in the method section
and throughout the paper. A more relevant concern though is that the
interpretation of the experimental data presented and the language used
tend to overrate and at times overgeneralize findings: for example,
while the authors demonstrate statistically significant, Ly6E-mediated
reduction of coronavirus titers in stable cells lines *in vitro*, it
remains unclear whether a viral titer reduction by one log decade would
be of actual biological relevance in face of high viral titers *in
vivo*. After high-dose intraperitoneal MHV infection *in vivo*, early
viral titers in Ly6E HSC knockout vs. wt mice only showed an elevation
in the spleen (\~1.5 log decades) but not liver of the ko mice (other
tissue not evaluated), and while ko mice presented with only modestly
increased liver pathology, both male and female ko mice exhibited
significantly higher mortality. Thus, the manuscript tile statement that
“Ly6E … confers immune control of viral disease” is supported by only
limited *in vivo* data, and gain-of-function experiments (eg. Ly6E
overexpression) were not performed. Of additional note here, tissue
tropism and virulence differ greatly among various MHV strains and
isolates whereas dose, route of infection, age, genetic background and
sex of the mice used may additionally affect disease outcome and
phenotype (*cf*. Taguchi F & Hirai-Yuki A,
<https://doi.org/10.3389/fmicb.2012.00068>; Kanolkhar A et al,
[https://jvi.asm.org/content/
83/18/9258](https://jvi.asm.org/content/%2083/18/9258)). Observations
attributed to hematopoietic stem cell-specific Ly6E deletion could
therefore be influenced by the different genetic backgrounds of floxed
and cre mice used, and although it appears that littermates wt and ko
littermates were used in the experiments, the potentially decisive
impact of strain differences should at least have been discussed. Along
these lines, it should also be taken into account that the majority of
human coronaviruses cause respiratory symptoms, which follow a different
clinical course engaging other primary cellular mediators than the
hepatotropic murine MHV disease studied here. It therefore remains
highly speculative how the findings reported in this study will
translate to human disease and it would therefore be important to test
other routes of MHV infection and doses that have been described to
produce a more comparable phenotype to human coronavirus disease (*cf.*
Kanolkhar A et al, [https://jvi.asm.org/content/
83/18/9258](https://jvi.asm.org/content/%2083/18/9258)). Another
important shortcoming of this study is the lack of any information on
functional deficits or changes in Ly6E-deficient immune cells and how
this might relate to the phenotype observed. Overall, the *in vitro*
experiments are more convincing than the *in vivo* studies which appear
somewhat limited.

#### Significance

Despite some shortcomings, the experiments performed in this study
suggest a novel and somewhat unexpected role of Ly6E in the protection
against coronaviruses across species. These findings are of relevance
and should be further explored in ongoing research on potential
coronavirus therapies. Yet an important caveat pertains to the authors’
suggestion that “therapeutic mimicking of Ly6E action” may constitute a
first line of defense against novel coronaviruses since their own prior
work demonstrated that Ly6E can enhance rather than curtail infection
with influenza A and other viruses.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Liu et al. *medRxiv*. [@doi:10.1101/2020.03.06.20031856]

#### Keywords
- diagnosis
- serological assay
- ELISA
- RT-PCR

#### Main Findings

While RT-PCR is being used currently to routinely diagnose infection
with SARS-CoV-2, there are significant limitations to the use of a
nucleic acid test that lead to a high false-negative rate. This
article describes ELISAs that can measure IgM and IgG antibodies
against the N protein of SARS-CoV-2 to test samples from 238
patients (153 positive by RT-PCR and 85 negative by RT-PCR) at
different times after symptom onset. The positivity rate of the IgM
and/or IgG ELISAs was greater than that of the RT-PCR (81.5%
compared to 64.3%) with similar positive rates in the confirmed and
suspected cases (83% and 78.8%, respectively), suggesting that many
of the suspected but RT-PCR-negative cases were also infected. The
authors also found that the ELISAs have higher positive rates later
after symptom onset while RT-PCR is more effective as a diagnostic
test early during the infection.

#### Limitations

I cannot identify any limitations to this study.

#### Significance

The authors make a strong case for using a combination of ELISA and
RT-PCR for diagnosis of infection with SARS-CoV-2, especially
considering the dynamics of positivity rates of RT-PCR and ELISA.
Fewer false-negative diagnoses would improve infection control and
patient management.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2

[@doi:10.1101/2020.03.06.980037]

#### Keywords

- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- Spike protein
- Cross- reactive antibodies

#### Main Findings

Whole genome sequencing-based comparisons of the 2003
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the 2019
SARS-CoV-2 revealed conserved receptor binding domain (RBD) and host
cell receptor, angiotensin-converting enzyme 2 (ACE2). In line with
this, the authors tested cross-reactivity of murine monoclonal
antibodies (mAbs) previously generated against the SARS-CoV spike (S)
glycoprotein involved in viral entry. One of the screened mAb, 1A9, was
able to bind and cross-neutralize multiple strains of SARS-CoV, as well
as, detect the S protein in SARS-CoV-2-infected cells. mAb 1A9 was
generated using an immunogenic fragment in the S2 subunit of SARS-CoV
and binds through a novel epitope within the S2 subunit at amino acids
1111-1130. It is important to note that CD8+ T lymphocyte epitopes
overlap with these residues, suggesting that S2 subunit could be
involved in inducing both, humoral and cell-mediated immunity.

#### Limitations

The authors used previously generated mouse mAbs
against the S protein in SARS-CoV expressed in mammalian cell line.
Future experimental validation using COVID-19 patient samples is needed
to validate these findings. In addition, the results of these studies
are predominantly based on in vitro experiments and so, evaluating the
effects of the mAb 1A9 in an animal model infected with this virus will
help us better understand the host immune responses in COVID-19 and
potential therapeutic vaccines.

#### Significance

This study identified mAbs that recognize the new
coronavirus, SARS-Cov-2. These cross-reactive mAbs will help in
developing diagnostic assays for COVID-19.

#### Credit

*This review was undertaken by Tamar Plitt and Katherine Lindblad as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Mortality of COVID-19 is Associated with Cellular Immune Function Compared to Immune Function in Chinese Han Population

Zeng et al. *medRxiv*. [@doi:10.1101/2020.03.08.20031229]

#### Keywords
- WBC
- peripheral blood
- CD4
- CD8 T cells

#### Main Findings

Retrospective study of the clinical characteristics of 752
patients infected with COVID-19 at Chinese PLA General Hospital, Peking
Union Medical College Hospital, and affiliated hospitals at Shanghai
University of medicine & Health Sciences. This study is the first one
that compares PB from healthy controls from the same regions in Shanghai
and Beijing, and infected COVID-19 patients to standardize a reference
range of WBCs of people at high risk.

#### Limitations

Lower levels of leukocyte counts -B cells, CD4 and CD8 T
cells- correlated with mortality (WBCs are significantly lower in severe
or critical UCI patients vs mild ones). Based on 14,117 normal controls
in Chinese Han population (ranging in age from 18-86) it is recommended
that reference ranges of people at high risk of COVID-19 infection are
CD3+ lymphocytes below 900 cells/mm3, CD4+ lymphocytes below 500
cells/mm3, and CD8+ lymphocytes below 300 cells/mm3. Importantly, this
study also reported that the levels of D-dimer, C-reactive protein and
IL-6 were elevated in COVID-19 pts., indicating clot formation, severe
inflammation and cytokine storm.

#### Significance

This study sets a threshold to identify patients at risk
by analyzing their levels of leukocytes, which is an easy and fast
approach to stratify individuals that require hospitalization. Although
the study is limited (only counts of WBC are analyzed and not its
profile) the data is solid and statistically robust to correlate levels
of lymphopenia with mortality.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Retrospective Analysis of Clinical Features in 101 Death Cases with COVID-19

Chen et al. *medRxiv*. [@doi:10.1101/2020.03.09.20033068]

#### Keywords

- death biomarkers
- cardiac damage
- Troponin
- Blood type
- respiratory failure
- hypertension

#### Main Findings

This is a retrospective study involving 101 death cases with COVID-19 in
Wuhan Jinyintan Hospital. The aim was to describe clinical,
epidemiological and laboratory features of fatal cases in order to
identify the possible primary mortality causes related to COVID-19.

Among 101 death cases, 56.44% were confirmed by RT-PCR and 43.6% by
clinical diagnostics. Males dominated the number of deaths and the
average age was 65.46 years. All patients died of respiratory failure
and multiple organs failure, except one (acute coronary syndrome). The
predominant comorbidities were hypertension (42.57%) and diabetes
(22.77%). 25.74% of the patients presented more than two underlying
diseases. 82% of patients presented myocardial enzymes abnormalities at
admission and further increase in myocardial damage indicators with
disease progression: patients with elevated Troponin I progressed faster
to death. Alterations in coagulation were also detected. Indicators of
liver and kidney damage increased 48 hours before death. The authors
studied the deceased patients’ blood type and presented the following
results: type A (44.44%), type B (29.29%), type AB (8.08%) and type O
(18.19%), which is inconsistent with the distribution in Han population
in Wuhan.

Clinical analysis showed that the most common symptom was fever (91.9%),
followed by cough and dyspnea. The medium time from onset of symptoms to
acute respiratory distress syndrome (ARDS) development was 12 days.
Unlike SARS, only 2 patients with COVID-19 had diarrhea. 98% presented
abnormal lung imaging at admission and most had double-lung
abnormalities. Related to the laboratorial findings some inflammatory
indicators gradually increased during the disease progression, such as
IL-6 secretion in the circulation, procalcitonin (PCT) and C-reactive
protein (CRP), while platelets numbers decreased. The authors also
reported an initial lymphopenia that was followed by an increase in the
lymphocytes numbers. Neutrophil count increased with disease
progression.

The patients received different treatments such as antiviral drugs
(60.40%), glucocorticoids, thymosin and immunoglobulins. All patients
received antibiotic treatment and some received antifungal drugs. All
patients received oxygen therapy (invasive or non-invasive ones).

#### Limitations

This study involves just fatal patients, lacking comparisons with other
groups of patients e.g. patients that recovered from COVID-19. The
authors didn’t discuss the different approaches used for treatments and
how these may affect the several parameters measured. The possible
relationship between the increase of inflammatory indicators and
morbidities of COVID-19 are not discussed.

#### Significance

This study has the largest cohort of fatal cases reported so far. The
authors show that COVID-19 causes fatal respiratory distress syndrome
and multiple organ failure. This study highlights prevalent myocardial
damage and indicates that cardiac function of COVID-19 patients should
be carefully monitored. The data suggest that Troponin I should be
further investigated as an early indicator of patients with high risk of
accelerated health deterioration. Secondary bacterial and fungal
infections were frequent in critically ill patients and these need to be
carefully monitored in severe COVID-19 patients. Differences in blood
type distribution were observed, suggesting that type A is detrimental
while type O is protective – but further studies are needed to confirm
these findings and elucidate if blood type influences infection or
disease severity. Several inflammatory indicators (neutrophils, PCT, CRP
and IL-6, D-dimer) increased according to disease severity and should be
assessed as biomarkers and to better understand the biology of
progression to severe disease.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Relationship between the ABO Blood Group and the COVID-19 Susceptibility

Zhao et al. *medRxiv*. [@doi:10.1101/2020.03.11.20031096]

#### Keywords

- ABO blood group
- COVID-19 susceptibility

#### Main Findings

These authors compared the ABO blood group of 2,173 patients with
RT-PCR-confirmed COVID-19 from hospitals in Wuhan and Shenzhen with the
ABO blood group distribution in unaffected people in the same cities
from previous studies (2015 and 2010 for Wuhan and Shenzhen,
respectively). They found that people with blood group A are
statistically over-represented in the number of those infected and who
succumb to death while those with blood group O are statistically
underrepresented with no influence of age or sex.

#### Limitations

This study compares patients with COVID-19 to the general population
but relies on data published 5 and 10 years ago for the control. The
mechanisms that the authors propose may underlie the differences they
observed require further study.

#### Significance

Risk stratification based on blood group may be beneficial for
patients and also healthcare workers in infection control. Additionally,
investigating the mechanism behind these findings could lead to better
developing prophylactic and therapeutic targets for COVID-19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Matsuyama et al. *bioRxiv* [@doi:10.1101/2020.03.11.987016]

#### Keywords

- Corticosteroids
- ciclesonide
- mometasone
- NSP15
- MERS-CoV

#### Main Findings

This study reconsiders the use of inhaled corticosteroids in the
treatment of pneumonia by coronavirus. Corticosteroids were associated
with increased mortality for SARS in 2003 and for MERS in 2013, probably
due to that fact that systemic corticosteroids suppress the innate
immune system, resulting in increased viral replication. However, some
steroid compounds might block coronavirus replication. The authors
screened steroids from a chemical library and assessed the viral growth
suppression and drug cytotoxicity. Ciclesonide demonstrated low
cytotoxicity and potent suppression of MERS-CoV viral growth. The
commonly used systemic steroids cortisone, prednisolone and
dexamethasone did not suppress viral growth, nor did the commonly used
inhaled steroid fluticasone. To identify the drug target of virus
replication, the authors conducted 11 consecutive MERS-CoV passages in
the presence of ciclesonide or mometasone, and they could generate a
mutant virus that developed resistance to ciclesonide, but not to
mometasone. Afterwards, they performed next-generation sequencing and
identified an amino acid substitution in nonstructural protein 15
(NSP15) as the predicted mechanism for viral resistance to ciclesonide.
The authors were able to successfully generate a recombinant virus
carrying that amino acid substitution, which overcome the antiviral
effect of ciclesonide, suggesting that ciclosenide interacts with NSP15.
The mutant virus was inhibited by mometasone, suggesting that the
antiviral target of mometasone is different from that of ciclesonide.
Lastly, the effects of ciclesonide and mometason on suppressing the
replication of SARS-CoV-2 were evaluated. Both compounds were found to
suppress viral replication with a similar efficacy to lopinavir.

#### Limitations

Most of the experiments, including the identification of the mutation in
NSP15 were conducted with MERS-CoV. This is not the closest related
virus to SARS-CoV-2, as that would be SARS-CoV. Thus, to repeat the
initial experiments with SARS-CoV, or preferably SARS-CoV-2, is
essential. The manuscript should address this and, therefore, it will
require considerable editing for organization and clarity. Also, in
terms of cell immunogenic epitopes, while SARS-CoV-2 spike protein
contains several predicted B and T cell immunogenic epitopes that are
shared with other coronaviruses, some studies have shown critical
differences between MERS-CoV, SARS-CoV and SARS-CoV-2. A main criticism
is that the authors only used VeroE6/TMPRSS2 cells to gauge the direct
cytotoxic effects of viral replication. To evaluate this in other cell
lines, including human airway epithelial cells, is crucial, as the
infectivity of coronavirus strains greatly varies in different cell
lines,

#### Significance

Nevertheless, these findings encourage evaluating ciclesonide and
mometasone as better options for patients with COVID-19 in need of
inhaled steroids, especially as an alternative to other corticosteroids
that have been shown to increase viral replication in vitro. This should
be evaluated in future clinical studies.

#### Credit

*This review was undertaken by Alvaro Moreira, MD as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A human monoclonal antibody blocking SARS-CoV-2 infection **

Wang et al. *bioRxiv*. [@doi:10.1101/2020.03.11.987958]

#### Keywords

- Monoclonal antibodies
- SARS-CoV2
- cross-neutralization
- potential treatment
- spike receptor

#### Main Findings

The authors reported a human monoclonal
antibody that neutralizes SARS-CoV-2 and SARS-Cov which belong to same
family of corona viruses. For identifying mAbs, supernatants of a
collection of 51 hybridomas raised against the spike protein of SARS-CoV
(SARS-S) were screened by ELISA for cross-reactivity against the spike
protein of SARS-CoN2 (SARS2-S). Hybridomas were derived from immunized
transgenic H2L2 mice (chimeric for fully human VH-VL and rat constant
region). Four SARS-S hybridomas displayed cross-reactivity with SARS2-S,
one of which (47D11) exhibited cross-neutralizing activity for SARS-S
and SARS2-S pseudotyped VSV infection. A recombinant, fully human IgG1
isotype antibody was generated and used for further characterization.

The humanized 47D11 antibody inhibited infection of VeroE6 cells with
SARS-CoV and SARS-CoV-2 with IC50 values of 0.19 and 0.57 μg/ml
respectively. 47D11 mAb bound a conserved epitope on the spike receptor
binding domain (RBD) explaining its ability to cross-neutralize SARS-CoV
and SARS-CoV-2. 47D11 was shown to target the S1B RBD of SARS-S and
SARS2-S with similar affinities. Interestingly, binding of 47D11 to
SARS-S1B and SARS2-S1B did not interfere with S1B binding to ACE2
receptor-expressing cells assayed by flow cytometry.

#### Limitations

These results show that the human 47D11 antibody
neutralizes SARS-CoV and SARS-Cov2 infectivity via an as yet unknown
mechanism that is different from receptor binding interference.
Alternative mechanisms were proposed but these as yet remain to be
tested in the context of SARS-CoV2. From a therapeutic standpoint and in
the absence of in vivo data, it is unclear whether the 47D11 ab can
alter the course of infection in an infected host through virus
clearance or protect an uninfected host that is exposed to the virus.
There is a precedent for the latter possibility as it relates to
SARS-CoV that was cited by the authors and could turn out to be true for
SARS-CoV2.

#### Significance

This study enabled the identification of novel neutralizing
antibody against COV-that could potentially be used as first line of
treatment in the near future to reduce the viral load and adverse
effects in infected patients. In addition, neutralizing antibodies such
as 47D11 represent promising reagents for developing
antigen-antibody-based detection test kits and assays.

#### Credit

*This review was edited by K. Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

Zhang et al. *medRxiv* [@doi:10.1101/2020.03.12.20035048]

#### Keywords

- Biomarkers
- cytokines
- IgG
- immune cells

#### Main Findings

In a cohort of 222 patients, anti-SARS-CoV-2 IgM and IgG levels were
analyzed during acute and convalescent phases (up to day 35) and
correlated to the diseases’ severity. The same was done with
neutrophil-to-lymphocyte ratio. High IgG levels and high
neutrophil-to-lymphocyte ratio in convalescence were both independently
associated to the severity of the disease. The simultaneous occurrence
of both of these laboratory findings correlated even stronger to the
diseases’ severity.

Severe cases with high neutrophil-to-lymphocyte ratios had clearly
higher levels of IL-6. The authors propose that a robust IgG response
leads to immune-mediated tissue damage, thus explaining the worse
outcome in patients with overexuberant antibody response.

#### Limitations

A main criticism is that the criteria for stratifying patients in severe
vs. non-severe are not described. The only reference related to this is
the difference between the percentage of patients who needed mechanical
ventilation, which was greater in patients with both high IgG levels and
high neutrophil-to-lymphocyte ratio. No patient with both low IgG levels
and low neutrophil-to-lymphocyte ratio was treated with mechanical
ventilation.

The proposed correlation of severity with IL-2 and IL-10 levels is not
very strong.

Furthermore, although mostly ignored in the paper’s discussion, one of
the most interesting findings is that an early increase in
anti-SARS-CoV-2 IgM levels also seems to correlate with severe disease.
However, as only median values are shown for antibody kinetics curves,
the extent of variation in acute phase cannot be assessed.

#### Significance

Anti-SARS-CoV-2 IgG levels and with neutrophil-to-lymphocyte ratio
predict severity of COVID-19 independently of each other. An additive
predictive value of both variables is noticeable. Importantly, an
early-on increase in anti-SARS-CoV-2 IgM levels also seem to predict
outcome.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Reinfection could not occur in SARS-2 CoV-2 infected rhesus macaques

Bao et al. *bioRxiv* [@doi:10.1101/2020.03.13.990226]

#### Keywords

- SARS-CoV-2
- viral load
- reinfection
- relapse
- non-human primate model

#### Main Findings

This study addresses the issue or acquired immunity after a primary
COVID-19 infection in rhesus monkeys. Four Chinese rhesus macaques were
intratracheally infected with SARS-CoV-2 and two out of the four were
re-infected at 28 days post initial infection (dpi) with the same viral
dose after confirming the recovery by the absence of clinical symptoms,
radiological abnormalities and viral detection (2 negative RT-PCR
tests). While the initial infection led the viral loads in nasal and
pharyngeal swabs that reach approximately 6.5 log~10~ RNA copies/ml at 3
dpi in all four monkeys, viral loads in the swabs tested negative after
reinfection in the two reinfected monkeys. In addition, the necropsies
from a monkey (M1) at 7 days after primary infection, and another monkey
(M3) at 5 days post reinfection, revealed the histopathological damages
and viral replication in the examined tissues from M1, while no viral
replication as well as no histological damages were detected in the
tissues from M3. Furthermore, sera from three monkeys at 21 and 28 dpi
exhibited neutralizing activity against SARS-CoV-2 in vitro, suggesting
the production of protective neutralizing antibodies in these monkeys.
Overall, this study indicates that primary infection with SARS-CoV-2 may
protect from subsequent exposure to the same virus.

#### Limitations

In human, virus has been detected by nasopharyngeal swabs until 9 to 15
days after the onset of symptoms. In the infected monkeys in this study,
virus were detected from day 1 after the infection, declining to
undetectable level by day 15 post infection. It may suggest that there
is a faster viral clearance mechanism in monkeys, therefore the
conclusions of reinfection protection for humans need to be carefully
considered. In addition, only two monkeys were re-infected in this study
and the clinical signs of these monkeys were not similar: M3 did not
show weight loss and M4 showed relatively higher fever on the day of
infection and the day of re-challenge.

#### Significance

This study showed clear viral clearance and no indications of relapse or
viremia after a secondary infection with SARS-CoV-2 in a Chinese rhesus
macaque model. These results support the idea that patients with full
recovery (two negative RT-PCR results) may also be protected from
secondary SARS-CoV-2 infection. Recovered patients may be able to
reintegrate to normal public life and provide protective serum perhaps
even if having had a mild infection. The results are also encouraging
for successful vaccine development against SARS-CoV-2.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV

[@doi:10.1101/2020.03.13.991570]

#### Keywords

- neutralizing antibody
- cross-reactivity

#### Main Findings

Given the sequence similarity of the surface spike glycoprotein (S) of
SARS-CoV-2 and SAR-CoV, Yuan et al. (2020) propose that neutralizing
antibodies isolated from convalescent SARS-CoV patients may offer
insight into cross-reactive antibodies targeting SARS-CoV-2. In
particular, they find that the receptor-binding domain (RBD) of
SARS-CoV-2 S protein shares 86% sequence similarity with the RBD of
SARS-CoV S protein that binds to the CR3022 neutralizing antibody.
CR3022 also displays increased affinity for the “up” conformation of the
SARS-CoV-2 S protein compared to the “down” conformation as it does for
the SARS-CoV S protein. Therefore, the authors propose that this
cross-reactive antibody may confer some degree of protection *in vivo*
even if it fails to neutralize *in vitro*.

#### Limitations
Although the authors offer a logical rationale for
identifying cross-reactive neutralizing antibodies derived from
SARS-CoV, their study using only CR3022 failed to demonstrate whether
this approach will be successful. After all, CR3022 failed to neutralize
*in vitro* despite the binding affinity to a similar epitope on
SARS-CoV-2. They would benefit from testing more candidates and using an
*in vivo* model to demonstrate their claim that protection may be
possible in the absence neutralization if combinations are used *in
vivo.*

#### Significance

The ability to make use of previously characterized
neutralizing antibodies for conserved epitopes can expedite drug design
and treatment options.

#### Credit

*This review was undertaken by Dan Fu Ruan, Evan Cody and Venu Pothula as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR

Dong et al. *medRxiv* [@doi:10.1101/2020.03.14.20036129]

#### Keywords

- Diagnosis
- digital PCR

#### Main Findings

The authors present a digital PCR (dPCR) diagnostic test for
SARS-CoV-2 infection. In 103 individuals that were confirmed in a
follow-up to be infected, the standard qPCR test had a positivity
rate of 28.2% while the dPCR test detected 87.4% of the infections
by detecting an additional 61 positive cases. The authors also
tested samples from close contacts (early in infection stage) and
convalescing individuals (late in infection stage) and were able to
detect SARS-CoV-2 nucleic acid in many more samples using dPCR
compared to qPCR.

#### Limitations

I did not detect limitations.

#### Significance

The authors make a strong case for the need for a highly sensitive
and accurate confirmatory method for diagnosing COVID-19 during this
outbreak and present a potential addition to the diagnostic arsenal.
They propose a dPCR test that they present has a dramatically lower
false negative rate than the standard RT-qPCR tests and can be
especially beneficial in people with low viral load, whether they
are in the earlier or later stages of infection.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 invades host cells via a novel route: CD147-spike protein

Wang et al. *bioRxiv* [@doi:10.1101/2020.03.14.988345]

#### Keywords

- spike protein
- viral entry
- CD147
- SARS-CoV-2

#### Main Findings

The authors propose a novel mechanism of SARS-CoV-2 viral entry through
the interaction of the viral spike protein (SP) and the immunoglobulin
superfamily protein CD147 (also known as Basigin). Using an in-house
developed humanized antibody against CD147 (maplazumab), they show that
blocking CD147 decreases viral replication in Vero E6 cells. Using
surface plasmon resonance (SPR), ELISA, and Co-IP assays, they show that
the spike protein of SARS-CoV-2 directly interacts with CD147. Lastly,
they utilize immune-election microscopy to show spike protein and CD147
localize to viral inclusion bodies of Vero E6 cells.

#### Limitations

The authors claim that an anti-CD147 antibody (Meplazumab) inhibits
SARS-CoV-2 replication by testing cell growth and viral load in cells
infected with SARS-CoV-2, however there are key pieces of this
experiment that are missing. First, the authors fail to use a
non-specific antibody control. Second, the authors claim that viral
replication is inhibited, and that they test this by qPCR, however this
data is **not shown.** To further prove specificity, the authors should
introduce CD147 to non-susceptible cells and show that they become
permissive.

The authors claim that there is a direct interaction between CD147 and
SP through SPR, ELISA, and Co-IP, and this data seems generally
convincing. The electron microscopy provides further correlative
evidence that SARS-CoV-2 may interact with CD147 as they are both found
in the same viral inclusion body. A quantification of this data would
make the findings more robust.

Finally, the data in this paper lacks replicates, error bars, and
statistics to show that the data are reproducible and statistically
significant.

#### Significance

It has been shown in various studies that SARS-CoV-2 binds to the cell
surface protein ACE2 for cell entry, yet ACE2 is highly expressed in
heart, kidney, and intestinal cells, raising the concern that blocking
ACE2 would result in harmful side effects [@doi:10.1093/ndt/gfu302] CD147 on the other hand
is highly expressed in various tumor types, inflamed tissues, and
pathogen infected cells, suggesting that the inhibition of CD147 would
not result in major side effects [@doi:10.1016/j.yexmp.2018.05.001; @pmid:20551248] The research in this paper has
resulted in an ongoing clinical trail in China to test the safety and
efficacy of anti-CD147 Meplazumab to treat COVID-19. (ClinicalTrails.gov
identifier NCT04275245).

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Blood single cell immune profiling reveals that interferon-MAPK pathway mediated adaptive immune response for COVID-19

Huang et al. *medRxiv* [@doi:10.1101/2020.03.15.20033472]

#### Keywords

- COVID-19
- SARS-CoV-2
- PBMC
- single cell
- MAPK

#### Main Findings

The authors performed single-cell RNA sequencing (scRNAseq) of
peripheral blood mononuclear cells isolated from whole blood samples of
COVID-19 patients (n=10). Data was compared to scRNAseq of samples
collected from patients with influenza A (n=1), acute pharyngitis (n=1),
and cerebral infarction (n=1), as well as, three healthy controls.
COVID-19 patients were categorized into those with moderate (n=6),
severe (n=1), critical (n=1), and cured (n=2) disease. Analysis across
all COVID-19 disease levels revealed 56 different cellular subtypes,
among 17 immune cell types; comparisons between each category to the
normal controls revealed **increased proportions of CD1c^+^ dendritic
cells, CD8^+^ CTLs, and plasmacytoid dendritic cells and a decrease in
proportions of B cells and CD4^+^ T cells**.

**TCR sequencing revealed that greater clonality is associated with
milder COVID-19 disease**; BCR sequencing revealed that COVID-19
patients have circulating antibodies against known viral antigens,
including EBV, HIV, influenza A, and other RNA viruses. This may suggest
that the immune response to SARS-CoV-2 infection elicits production of
antibodies against known RNA viruses.

Excluding enriched pathways shared by COVID-19 patients and patients
with other conditions (influenza A, acute pharyngitis, and cerebral
infarction), the authors identified the **interferon-MAPK signaling
pathway as a major response to SARS-CoV-2 infection**. The authors
performed quantitative real-time reverse transcriptase polymerase chain
reaction (RT-PCR) for interferon-MAPK signaling genes: *IRF27, BST2,*
and *FOS*. These samples were collected from a separate cohort of
COVID-19 patients (critical, n=3; severe, n=3; moderate, n=19; mild,
n=3; and cured, n=10; and healthy controls, n=5). Notably, consistent
with the original scRNAseq data, *FOS* showed up-regulation in COVID-19
patients and down-regulation in cured patients. **The authors propose
that *FOS* may be a candidate marker gene for curative COVID-19
disease**.

#### Limitations

The sample size of this study is limited. To further delineate
differences in the immune profile of peripheral blood of COVID-19
patients, a greater sample size is needed, and longitudinal samples are
needed, as well. A better understanding of the immunological
interactions in cured patients, for example, would require a profile
before and after improvement.

Moreover, the conclusions drawn from this scRNAseq study point to
potential autoimmunity and immune deficiency to distinguish different
severities of COVID-19 disease. However, this requires an expanded
number of samples and a more robust organization of specific immune cell
subtypes that can be compared across different patients. Importantly,
this criterion is likely needed to ensure greater specificity in
identifying markers for COVID-19 infection and subsequent immune
response.

#### Significance

At the single-cell level, COVID-19 disease has been characterized in the
lung, but a greater understanding of systemic immunological responses is
furthered in this study. Type I interferon is an important signaling
molecule for the anti-viral response. The identification of the
interferon-MAPK signaling pathway and the differential expression of
MAPK regulators between patients of differing COVID-19 severity and
compared to cured patients may underscore the importance of either
immune deficiency or autoimmunity in COVID-19 disease.

#### Credit

*This review was undertaken by Matthew D. Park as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infection.

Lv et al. *bioRxiv* [@doi:10.1101/2020.03.15.993097]

#### Keywords

SARS-CoV-2, SARS-CoV, spike protein, RBD, cross-reactivity,
cross-neutralization, antibody, human patients, mouse

#### Main Findings

The authors explore the antigenic differences between SARS-CoV-2 and
SARS-CoV by analyzing plasma samples from SARS-CoV-2 (n = 15) and
SARS-CoV (n = 7) patients. Cross-reactivity in antibody binding to the
spike protein between SARS-CoV-2 and SARS-CoV was found to be common,
mostly targeting non-RBD regions in plasma from SARS-CoV-2 patients.
Only one SARS-CoV-2 plasma sample was able to cross-neutralize SARS-CoV,
with low neutralization activity. No cross-neutralization response was
detected in plasma from SARS-CoV patients.

To further investigate the cross-reactivity of antibody responses to
SARS-CoV-2 and SARS-CoV, the authors analyzed the antibody response of
plasma collected from mice infected or immunized with SARS-CoV-2 or
SARS-CoV (n = 5 or 6 per group). Plasma from mice immunized with
SARS-CoV-2 displayed cross-reactive responses to SARS-CoV S ectodomain
and, to a lesser extent, SARS-CoV RBD. Similarly, plasma from mice
immunized with SARS-CoV displayed cross-reactive responses to SARS-CoV-2
S ectodomain. Cross-neutralization activity was not detected in any of
the mouse plasma samples.

#### Limitations

The size of each patient cohort is insufficient to accurately determine
the frequency of cross-reactivity and cross-neutralization in the
current SARS-CoV-2 pandemic. Recruitment of additional patients from a
larger range of geographical regions and time points would also enable
exploration into the effect of the genetic diversity and evolution of
the SARS-CoV-2 virus on cross-reactivity. This work would also benefit
from the mapping of specific epitopes for each sample. Future studies
may determine whether the non-neutralizing antibody responses can confer
*in vitro* protection or lead to antibody-dependent disease enhancement.

#### Significance

The cross-reactive antibody responses to S protein in the majority of
SARS-CoV-2 patients is an important consideration for development of
serological assays and vaccine development during the current outbreak.
The limited extent of cross-neutralization demonstrated in this study
indicates that vaccinating to cross-reactive conserved epitopes may have
limited efficacy, presenting a key concern for the development of a more
universal coronavirus vaccine to address the global health risk of novel
coronavirus outbreaks.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

Duan et al. *medRxiv* [@doi:10.1101/2020.03.16.20036145]

#### Keywords

- COVID-19
- SARS-CoV-2
- convalescent plasma
- treatment outcome
- pilot
- therapy
- transfusion

#### Main Findings

This is the first report to date of convalescent plasma therapy as a
therapeutic against COVID-19 disease. This is a feasibility pilot study.
The authors report the administration and clinical benefit of 200 mL of
convalescent plasma (CP) (1:640 titer) derived from recently cured
donors (CP selected among 40 donors based on high neutralizing titer and
ABO compatibility) to 10 severe COVID-19 patients with confirmed
viremia. The primary endpoint was the safety of CP transfusion. The
secondary endpoint were clinical signs of improvement based on symptoms
and laboratory parameters.

The authors reported use of methylene blue photochemistry to inactivate
any potential residual virus in the plasma samples, without compromising
neutralizing antibodies, and no virus was detected before transfusion.

The authors report the following:

-   No adverse events were observed in all patients, except 1 patient
    who exhibited transient facial red spotting.

-   All patients showed significant improvement in or complete
    disappearance of clinical symptoms, including fever, cough,
    shortness of breath, and chest pain after 3 days of CP therapy.

-   Reduction of pulmonary lesions revealed by chest CT.

-   Elevation of lymphocyte counts in patients with lymphocytopenia.

-   Increase in SaO~2~ in all patients, indicative of recuperating lung
    function.

-   Resolution of SARS-CoV-2 viremia in 7 patients and increase in
    neutralizing antibody titers in 5 patients. Persistence of
    neutralizing antibody levels in 4 patients.

#### Limitations

It is important to note that most recipients had high neutralization
titers of antibodies before plasma transfusion and even without
transfusion it would be expected to see an increase in neutralizing
antibodies over time. In addition to the small sample set number (n=10),
there are additional limitations to this pilot study:

1.  All patients received concurrent therapy, in addition to the CP
    transfusion. Therefore, it is unclear whether a combinatorial or
    synergistic effect between these standards of care and CP
    transfusion contributed to the clearance of viremia and improvement
    of symptoms in these COVID-19 patients.

2.  The kinetics of viral clearance was not investigated, with respect
    to the administration of CP transfusion. So, the definitive impact
    of CP transfusion on immune dynamics and subsequent viral load is
    not well defined.

3.  Comparison with a small historical control group is not ideal.

#### Significance

For the first time, a pilot study provides promising results involving
the use of convalescent plasma from cured COVID-19 patients to treat
others with more severe disease. The authors report that the
administration of a single, high-dose of neutralizing antibodies is
safe. In addition, there were encouraging results with regards to the
reduction of viral load and improvement of clinical outcomes. It is,
therefore, necessary to expand this type of study with more
participants, in order to determine optimal dose and treatment kinetics.
It is important to note that CP has been studied to treat H1N1
influenza, SARS-CoV-1, and MERS-CoV, although it has not been proven to
be effective in treating these infections.

#### Credit

*Review by Matthew D. Park and revised by Alice O. Kamphorst and Maria A. Curotto de Lafaille as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial

[@doi:10.1101/2020.03.16.20037135]

#### Keywords

- hydroxychloroquine
- clearance
- viral load
- clinical trial

#### Main Findings

This study was a single-arm, open label clinical trial with
600 mg hydroxychloroquine (HCQ) in the treatment arm (n = 20). Patients
who refused participation or patients from another center not treated
with HCQ were included as negative controls (n = 16). Among the patients
in the treatment arm, 6 received concomitant azithromycin to prevent
superimposed bacterial infection. The primary endpoint was respiratory
viral loads on day 6 post enrollment, measured by nasopharyngeal swab
followed by real-time reverse transcription-PCR.

HCQ alone was able to significantly reduce viral loads by day 6 (n =
8/14, 57.1% complete clearance, p &lt; 0.001); azithromycin appears to
be synergistic with HCQ, as 6/6 patients receiving combined treatment
had complete viral clearance (p &lt; 0.001).

#### Limitations

Despite what is outlined above, this study has a number
of limitations that must be considered. First, there were originally n =
26 patients in the treatment arm, with 6 lost to follow up for the
following reasons: 3 transferred to ICU, 1 discharge, 1
self-discontinued treatment d/t side effects, and 1 patient expired.
Total length of clinical follow up was 14 days, but the data beyond day
6 post-inclusion are not shown.

Strikingly, in supplementary table 1, results of the real-time RT-PCR
are listed for the control and treatment arms from D0 – D6. However, the
data are not reported in a standard way, with a mix of broadly positive
or negative result delineation with Ct (cycle threshold) values, the
standard output of real time PCR. It is impossible to compare what is
defined as a positive value between the patients in the control and
treatment arms without a standardized threshold for a positive test.
Further, the starting viral loads reported at D0 in the groups receiving
HCQ or HCQ + azithromycin were significantly different (ct of 25.3 vs
26.8 respectively), which could explain in part the differences observed
in the response to treatment between 2 groups. Finally, patients in the
control arm from outside the primary medical center in this study
(Marseille) did not actually have samples tested by PCR daily. Instead,
positive test results from every other day were extrapolated to mean
positive results on the day before and after testing as well (Table 2,
footnote ^a^).

Taken together, the results of this study suggest that HCQ represents a
promising treatment avenue for COVID-19 patients. However, the limited
size of the trial, and the way in which the results were reported does
not allow for other medical centers to extrapolate a positive or
negative result in the treatment of their own patients with HCQ +/-
azithromycin. Further larger randomized clinical trials will be required
to ascertain the efficacy of HCQ +/- azithromycin in the treatment of
COVID-19.

#### Significance

Chloroquine is thought to inhibit viral infection,
including SARS-Cov-2, by increasing pH within endosomes and lysosomes,
altering the biochemical conditions required for viral fusion [@doi:10.1038/s41422-020-0282-0; @doi:10.1016/j.imlet.2013.07.004].
However, chloroquine also has immuno-modulatory effects that I think may
play a role. Chloroquine has been shown to increase CTLA-4 expression at
the cell surface by decreasing its degradation in the endo-lysosome
pathway; AP-1 traffics the cytoplasmic tail of CTLA-4 to lysosomes, but
in conditions of increased pH, the protein machinery required for
degradation is less functional [@doi:10.1126/science.aaa1663]. As such, more CTLA-4 remains in
endosomes and is trafficked back to the cell surface. It is possible
that this may also contribute to patient recovery via reduction of
cytokine storm, in addition to the direct anti-viral effects of HCQ.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Recapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids

[@doi:10.1101/2020.03.16.990317]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- liver
- organoids
- Cholangiocyte

#### Main Findings

-   Used human liver ductal organoids to determine ACE2+ cholangiocytes
    in healthy liver (2.92% of all cells) are infectable and support
    SARS-CoV-2 viral replication.

-   Plaque-purified SARS-CoV-2 viral infection disrupted organoid
    barrier and bile transporting functions of cholangiocytes through
    dysregulation of genes involved in tight junction formation (CLDN1)
    and bile acid transportation (ASBT and CFTR).

#### Limitations:

-   Unclear if liver damage observed in patients due to direct
    cholangiocyte infection or due to secondary immune/cytokine effects.
    This study argues for direct damage as it lacks immune contexture;
    but further studies needed with autopsy samples or organoid-immune
    cell co-culture to conclude strongly.

-   Would be important to measure cholangiocyte-intrinsic anti-viral
    response and alarmins secreted upon infection, and furthermore study
    tropism of various immune cells to conditioned media from organoids
    infected with SARS-CoV-2.

-   Does not address how cirrhotic liver or
    alcohol/smoking/obesity-associated liver organoids respond to
    SARS-CoV-2 infectivity and replication, worth pursuing to
    experimentally address clinical data indicating co-morbidities.

#### Significance


-   Useful model to rapidly study drug activity against SARS-CoV-2
    infection in liver, while monitoring baseline liver damage.

-   Liver abnormality observed in &gt;50% of CoVID-19 patients; the
    results from this study could explain the bile acid accumulation and
    consequent liver damage observed.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2

[@doi:10.1101/2020.03.16.994236]

#### Keywords

- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- Spike protein S
- ACE2

#### Main Findings

Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) infects cells through S spike glycoprotein binding
angiotensin-converting enzyme (ACE2) on host cells. S protein can bind
both membrane-bound ACE2 and soluble ACE2 (sACE2), which can serve as a
decoy that neutralizes infection. Recombinant sACE2 is now being tested
in clinical trials for COVID-19. To determine if a therapeutic sACE2
with higher affinity for S protein could be designed, authors generated
a library containing every amino acid substitution possible at the 117
sites spanning the binding interface with S protein. The ACE2 library
was expressed in human Expi293F cells and cells were incubated with
medium containing the receptor binding domain (RBD) of SARS-CoV-2 fused
to GFP. Cells with high or low affinity mutant ACE2 receptor compared to
affinity of wild type ACE2 for the RBD were FACS sorted and transcripts
from these sorted populations were deep sequenced. Deep mutagenesis
identified numerous mutations in ACE2 that enhance RBD binding. This
work serves to identify putative high affinity ACE2 therapeutics for the
treatment of CoV-2.

#### Limitations

The authors generated a large library of mutated
ACE2, expressed them in human Expi293F cells, and performed deep
mutagenesis to identify enhanced binders for the RBD of SARS-CoV-2 S
protein. While these data serve as a useful resource, the ability of the
high affinity ACE2 mutants identified to serve as therapeutics needs
further validation in terms of conformational stability when purified as
well as efficacy/safety both *in vitro* and *in vivo*. Additionally,
authors mentioned fusing the therapeutic ACE2 to Fc receptors to elicit
beneficial host immune responses, which would need further design and
validation.

#### Significance

This study identified structural ACE2 mutants that
have potential to serve as therapeutics in the treatment of SARS-CoV-2
upon further testing and validation.

#### Credit

*This review was undertaken by Katherine Lindblad and Tamar Plitt as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2

Hu et al. *medRxiv*. [@doi:10.1101/2020.03.12.20034231]

#### Keywords

- Heat inactivation
- immunochromatography
- diagnosis
- serum antibodies
- IgM
- IgG

#### Main Findings

Coronaviruses can be killed by heat inactivation, and this is an
important safety precaution in laboratory manipulation of clinical
samples. However, the effect of this step on downstream
SARS-CoV-2-specific serum antibody assays has not been examined. The
authors tested the effect of heat inactivation (56 deg C for 30 minutes)
versus no heat inactivation on a fluorescence immunochromatography
assay. Heat inactivation reduced all IgM measurements by an average of
54% and most IgG measurements (22/36 samples, average reduction of 50%),
consistent with the lower thermal stability of IgM than that of IgG.
Heat inactivation caused a subset of IgM but not IgG readings to fall
below a specified positivity threshold.

#### Limitations

Limitations included the use of only one type of assay for testing heat
inactivated vs non-inactivated sera, and the use of the same baseline
for heat inactivated and non-inactivated sera. The results indicate that
heat inactivation affects the quantification of SARS-CoV-2-antibody
response, specially IgM, but still allows to distinguish positive
specific IgG. Therefore, the effect of heat inactivation should be
studied when designing assays that quantitatively associate
immunoglobulin levels (especially IgM) to immune state.

#### Significance

The use of heat inactivation to neutralize pathogens in serum samples
collected from suspected COVID-19 patients reduces the sensitivity of a
fluorescent immunochromatographic assay to detect anti-SARS-CoV-2 IgM
and IgG.

#### Credit

*Review by Andrew M. Leader as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### COMPARATIVE PATHOGENESIS OF COVID-19, MERS AND SARS IN A NON-HUMAN PRIMATE MODEL

[@doi:10.1101/2020.03.17.995639]

#### Keywords

- SARS-CoV2
- cynomolgus macaque
- SARS-CoV

#### Main Findings

This work assesses SARS-CoV-2 infection in young adult and aged
cynomolgus macaques. 4 macaques per age group were infected with
low-passage clinical sample of SARS-CoV-2 by intranasal and
intratracheal administration. Viral presence was assessed in nose,
throat and rectum through RT-PCR and viral culture. SARS-CoV-2
replication was confirmed in the respiratory track (including nasal
samples), and it was also detected in ileum. Viral nucleocapsid
detection by IHC showed infection of type I and II pneumocytes and
epithelia. Virus was found to peak between 2 and 4 days after
administration and reached higher levels in aged vs. young animals. The
early peak is consistent with data in patients and contrasts to SARS-CoV
replication. SARS-CoV-2 reached levels below detection between 8 and 21
days after inoculation and macaques established antibody immunity
against the virus by day 14. There were histopathological alteration in
lung, but no overt clinical signs. At day 4 post inoculation of
SARS-CoV-2, two of four animals presented foci of pulmonary
consolidation, with limited areas of alveolar edema and pneumonia, as
well as immune cell infiltration. In sum, cynomolgus macaques are
permissive to SARS- CoV-2 and develop lung pathology (less severe than
SARC-CoV, but more severe than MERS-CoV).

#### Limitations

Even though cynomolgus macaques were permissive to SARS-CoV-2
replication, it is unclear if the viral load reaches levels comparable
to humans and there wasn’t overt clinical pathology.

#### Significance

The development of platforms in which to carry out relevant
experimentation on SARS-CoV-2 pathophysiology is of great urgency.
Cynomolgus macaques offer an environment in which viral replication can
happen, albeit in a limited way and without translating into clinically
relevant symptoms. Other groups are contributing to SARS-CoV2 literature
using this animal model [@doi:10.1101/2020.03.13.990226], potentially showing protection against
reinfection in cured macaques. Therefore, this platform could be used to
examine SARS-CoV2 pathophysiology while studies in other animal models
are also underway [@doi:10.1128/JVI.02012-06; @doi:10.1101/2020.02.07.939389].

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Investigating the Impact of Asymptomatic Carriers on COVID-19 Transmission

[@doi:10.1101/2020.03.18.20037994]

#### Keywords

- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- asymptomatic carriers
- mathematical model
- transmission

#### Main Findings

Multiple studies reported the same level of infectiousness
between symptomatic and asymptomatic carriers of SARS-CoV-2. Given that
asymptomatic and undocumented carriers escape public health surveillance
systems, a better mathematical model of transmission is needed to
determine a more accurate estimate of the basic reproductive number
(R~0~) of the virus to assess the contagiousness of virus. The authors
developed a SEYAR dynamical model for transmission of the new
coronavirus that takes into account asymptomatic and undocumented
carriers. The model was validated using data reported from thirteen
countries during the first three weeks of community transmission. While
current studies estimate R~0~ to be around 3, this model indicates that
the value could range between 5.5 to 25.4.

#### Limitations

The SEYAR model realistically depicts
transmission of the virus only during the initial stages of the disease.
More data is necessary to better fit the model with current trends. In
addition, multiple factors (e.g. behavioral patterns, surveillance
capabilities, environmental and socioeconomic factors) affect
transmission of the virus and so, these factors must be taken into
consideration when estimating the R~0~.

#### Significance

Public health authorities use the basic reproductive
number to determine the severity of disease. An accurate estimate of
R~0~ will inform intervention strategies. This model can be applied to
different locations to assess the potential impact of COVID-19.

#### Credit

*This review was undertaken by Tamar Plitt and Katherine Lindblad as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

Long et al. *medRxiv* [@doi:10.1101/2020.03.18.20038018]

#### Keywords

- Serum antibodies
- IgM
- IgG
- immunoassay
- diagnosis
- seroconversion

#### Main Findings

This study investigated the profile of the acute antibody response
against SARS-CoV-2 and provided proposals for serologic tests in
clinical practice. Magnetic Chemiluminescence Enzyme Immunoassay was
used to evaluate IgM and IgG seroconversion in 285 hospital admitted
patients who tested positive for SARS-CoV-2 by RT-PCR and in 52 COVID-19
suspected patients that tested negative by RT-PCR. A follow up study
with 63 patients was performed to investigate longitudinal effects. In
addition, IgG and IgM titers were evaluated in a cohort of close
contacts (164 persons) of an infected couple.

The median day of seroconversion for both IgG and IgM was 13 days after
symptom onset. Patients varied in the order of IgM/ IgG seroconversion
and there was no apparent correlation of order with age, severity, or
hospitalization time. This led the authors to conclude that for
diagnosis IgM and IgG should be detected simultaneously at the early
phase of infection.

IgG titers, but not IgM titers were higher in severe patients compared
to non-severe patients after controlling for days post-symptom onset.
Importantly, 12% of COVID-19 patients (RT-PCR confirmed) did not meet
the WHO serological diagnosis criterion of either seroconversion or
*&gt;* 4-fold increase in IgG titer in sequential samples. This suggests
the current serological criteria may be too stringent for COVID-19
diagnosis.

Of note, 4 patients from a group of 52 suspects (negative RT-PCR test)
had anti-SARS-Cov-2 IgM and IgG. Similarly, 4.3% (7/162) of "close
contacts" who had negative RT-PCR tests were positive for IgG and/or
IgM. This highlights the usefulness of a serological assay to identify
asymptomatic infections and/or infections that are missed by RT-PCR.

#### Limitations

This group’s report generally confirms the findings of others that have
evaluated the acute antibody response to SARS-Cov-2. However, these data
would benefit from inclusion of data on whether the participants had a
documented history of viral infection. Moreover, serum samples that were
collected prior to SARS-Cov-2 outbreak from patients with other viral
infections would serve as a useful negative control for their assay.
Methodological limitations include that only one serum sample per case
was tested as well as the heat inactivation of serum samples prior to
testing. It has previously been reported that heat inactivation
interferes with the level of antibodies to SARS-Cov-2 and their protocol
may have resulted in diminished quantification of IgM, specifically [@doi:10.1101/2020.03.12.20034231].

#### Significance

Understanding the features of the antibody responses against SARS-CoV is
useful in the development of a serological test for the diagnosis of
COVID-19. This paper addresses the need for additional screening methods
that can detect the presence of infection despite lower viral titers.
Detecting the production of antibodies, especially IgM, which are
produced rapidly after infection can be combined with PCR to enhance
detection sensitivity and accuracy and map the full spread of infection
in communities, Moreover, serologic assays would be useful to screen
health care workers in order to identify those with immunity to care for
patients with COVID19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 specific antibody responses in COVID-19 patients

[@doi:10.1101/2020.03.18.20038059]

#### Keywords
- immunoassay
- antibody specificity
- serology
- cross-reactivity
  
#### Main findings

Antibodies specific to SARS-CoV-2 S protein, the S1 subunit and the RBD (receptor-binding domain) were detected in all SARS-CoV-2 patient sera by 13 to 21 days post onset of disease.  Antibodies specific to SARS-CoV N protein (90% similarity to SARS-CoV-2) were able to neutralize SARS-CoV-2 by PRNT (plaque reduction neutralizing test).  SARS-CoV-2 serum cross-reacted with SARS-CoV S and S1 proteins, and to a lower extent with MERS-CoV S protein, but not with the MERS-CoV S1 protein, consistent with an analysis of genetic similarity.  No reactivity to SARS-CoV-2 antigens was observed in serum from patients with ubiquitous human CoV infections (common cold) or to non-CoV viral respiratory infections.  
 
#### Limitations

Authors describe development of a serological ELISA based assay for the detection of neutralizing antibodies towards regions of the spike and nucleocapsid domains of the SARS-CoV-2 virus.  Serum samples were obtained from PCR-confirmed COVID-19 patients.  Negative control samples include a cohort of patients with confirmed recent exposure to non-CoV infections (i.e. adenovirus, bocavirus, enterovirus, influenza, RSV, CMV, EBV) as well as a cohort of patients with confirmed infections with ubiquitous human CoV infections known to cause the common cold. The study also included serum from patients with previous MERS-CoV and SARS-CoV zoonotic infections. This impressive patient cohort allowed the authors to determine the sensitivity and specificity of the development of their in-house ELISA assay. Of note, seroconversion was observed as early as 13 days following COVID-19 onset but the authors were not clear how disease onset was determined.  
 
#### Significance

Validated serological tests are urgently needed to map the full spread of SARS-CoV-2 in the population and to determine the kinetics of the antibody response to SARS-CoV-2.  Furthermore, clinical trials are ongoing using plasma from patients who have recovered from SARS-CoV-2 as a therapeutic option.  An assay such as the one described in this study could be used to screen for strong antibody responses in recovered patients.  Furthermore, the assay could be used to screen health care workers for antibody responses to SARS-CoV-2 as personal protective equipment continues to dwindle.  The challenge going forward will be to standardize and scale-up the various in-house ELISA’s being developed in independent laboratories across the world.  
 
 




### A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19

Belhadi et al. [@doi:10.1101/2020.03.18.20038190]

#### Keywords

- Clinical trials
- COVID-19
- SARS CoV-2
- 2019-nCoV
- SARS Cov-2
- Hcov-19
- novel coronal virus
- new corona virus
- antiviral drugs

#### Main Findings

Summary of clinical trials registered as
of March7, 2020 from U.S, Chinese, Korean, Iranian and European
registries. Out of the 353 studies identified, 115 were selected for
data extraction. 80% of the trials were randomized with parallel
assignment and the median number of planned inclusions was 63 (IRQ,
36-120). Most frequent therapies in the trials included; 1) antiviral
drugs \[lopinavir/ritonavir (n-15); umifenovir (n=9); favipiravir (n=7);
redmesivir (n=5)\]; 2) anti-malaria drugs \[chloroquine (n-11);
hydroxychloroquine (n=7)}; immunosuppressant drugs \[methylprednisolone
(n=5)\]; and stem cell therapies (n=23). Medians of the total number of
planned inclusions per trial for these therapies were also included.
Stem cells and lopunavir/ritonavir were the most frequently evaluated
candidate therapies (23 and 15 trials respectively), whereas remdesivir
was only tested in 5 trials but these trials had the highest median
number of planned inclusions per trial (400, IQR 394-453). Most of the
agents used in the different trials were chosen based on preclinical
assessments of antiviral activity against SARS CoV and MERS Cov corona
viruses.

The primary outcomes of the studies were clinical (66%); virological
(23%); radiological (8%); or immunological (3%). The trials were
classified as those that included patients with severe disease only;
trials that included patients with moderate disease; and trials that
included patients with severe or moderate disease.

#### Limitations

The trials evaluated provided incomplete information:
23% of these were phase IV trials but the bulk of the trials (54%) did
not describe the phase of the study. Only 52% of the trials (n=60)
reported treatment dose and only 34% (n=39) reported the duration. A lot
of the trials included a small number of patients and the trials are
still ongoing, therefore no insight was provided on the outcome of the
trials.

#### Significance

Nonetheless, this review serves as framework for
identifying COVID-19 related trials, which can be expanded upon as new
trials begin at an accelerated rate as the disease spreads around the
world.

#### Credit

*This review was undertaken by K Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19

Leung et al. *medRxiv*. [@doi:10.1101/2020.03.18.20038455]

#### Keywords

- chronic obstructive pulmonary disease
- COPD
- smokingE-2
- risk factors

#### Main Findings

In bronchial epithelial samples from 3 different cohorts of
individuals, ACE-2 gene expression was found to be significantly
increased in both COPD patients and smokers relative to healthy
controls. Across all test subjects, ACE-2 gene expression was also
highly correlated with decreased forced expiratory volume in 1 second
(FEV1), which may explain the increased COVID-19 disease severity in
COPD patients. Former smokers were also found to show decreased ACE2
expression relative to current smokers and had no significant difference
when compared to non-smokers.

#### Limitations

While the upregulation of ACE-2 is an interesting
hypothesis for COVID-19 disease severity in COPD patients, this study
leaves many more unanswered questions than it addresses. Further studies
are required to show whether the specific cell type isolated in these
studies is relevant to the pathophysiology of COVID-19. Furthermore,
there is no attempt to show whether that increased ACE-2 expression
contributes to greater disease severity. Does the increased ACE-2
expression lead to greater infectivity with SARS-CoV-2? There is no
mechanistic explanation for why ACE-2 levels are increased in COPD
patients. The authors could also have considered the impact of
co-morbidities and interventions such as corticosteroids or
bronchodilators on ACE-2 expression. Finally, given the extensive
sequencing performed, the authors could have conducted significantly
more in-depth analyses into gene signature differences.

#### Significance

This study attempts to address an
important clinical finding that both smokers and COPD patients show
increased mortality from COVID-19. The novel finding that ACE-2
expression is induced in smokers and COPD patients suggests not only a
mechanism for the clinical observation, but also highlights the
potential benefit of smoking cessation in reducing the risk of severe
COVID-19 disease.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Dynamic profile of severe or critical COVID-19 cases

[@doi:10.1101/2020.03.18.20038513]

#### Keywords
- Coronavirus Disease 2019 (COVID-19)
- SARS-CoV-2
- progressive lymphopenia (PLD)
- T-lymphocytes
- clinical data
- co-infection
- influenza A

#### Main Findings

Authors evaluate clinical correlates of 10 patients (6 male
and 4 female) hospitalized for severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2). All patients required oxygen support and
received broad spectrum antibiotics and 6 patients received anti-viral
drugs. Additionally, 40% of patients were co-infected with influenza A.
All 10 patients developed lymphopenia, two of which developed
progressive lymphopenia (PLD) and died. Peripheral blood (PB)
lymphocytes were analyzed – low CD4 and CD8 counts were noted in most
patients, though CD4:CD8 ratio remained normal.

#### Limitations

The authors evaluated a small cohort of severe
SARS-CoV-2 cases and found an association between T cell lymphopenia and
adverse outcomes. However, this is an extremely small and diverse cohort
(40% of patients were co-infected with influenza A). These findings need
to be validated in a larger cohort. Additionally, the value of this data
would be greatly increased by adding individual data points for each
patient as well as by adding error bars to each of the figures.

#### Significance

This study provides a collection of clinical data and
tracks evolution of T lymphocyte in 10 patients hospitalized for
SARS-CoV-2, of which 4 patients were co-infected with influenza A.

#### Credit

*This review was undertaken by Katherine Lindblad and Tamar Plitt as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Association between Clinical, Laboratory and CT Characteristics and RT-PCR Results in the Follow-up of COVID-19 patients

Fu et al. *medRxiv*. [@doi:10.1101/2020.03.19.20038315]

#### Keywords

- COVID-19
- clinical
- lymphocyte
- CRP
- LDH
- HSST TNT
- PCR test
- readmission
- CT
- GGO
- disease progression

#### Study description

Data analyzed from 52 COVID-19 patients admitted
and then discharged with COVID-19. Clinical, laboratory, and
radiological data were longitudinally recorded with illness timecourse
(PCR + to PCR-) and 7 patients (13.5%) were readmitted with a follow up
positive test (PCR+) within two weeks of discharge.

#### Main Findings

-   At admission:

    -   The majority of patients had increased CRP at admission (63.5%).

    -   LDH, and HSST TNT were significantly increased at admission.

    -   Radiographic signs via chest CT showed increased involvement in
        lower lobes: right lower lobe (47 cases, 90.4%), left lower lobe
        (37 cases, 71.2%).

    -   GGO (90.4%), interlobular septal thickening (42.3%), vascular
        enlargement (42.3%), and reticulation (11.5%) were most commonly
        observed.

-   After negative PCR test (discharge):

    -   CRP levels decreased lymphocyte counts (\#/L) increased
        significantly (CD3+, CD3+/8+ and CD3+/4+) after negative PCR.

    -   Consolidation and mixed GGO observed in longitudinal CT imaging
        w different extents of inflammatory exudation in lungs, with
        overall tendency for improvement (except 2/7 patients that were
        readmitted after discharge with re-positive test) after negative
        PCR.

-   Seven patients repeated positive RT-PCR test and were readmitted to
    the hospital (9 to 17 day after initial discharge).

    -   Follow up CT necessary to monitor improvement during recovery
        and patients with lesion progression should be given more
        attention.

    -   Dynamic CT in addition to negative test essential in clinical
        diagnosis due to nasal swab PCR sampling bias (false-negatives).

    -   Increase in CRP occurred in 2 readmitted patients (and decr. in
        lymphocytes in one patient), but was not correlated with new
        lesions or disease progression vs. improvement (very low N).

    -   Patients readmitted attributed to false-negative PCR vs.
        re-exposure.

#### Limitations

Patients sampled in this study were generally
younger (65.4% &lt; 50 yrs) and less critically ill/all discharged.
Small number of recovered patients (N=18). Time of follow up was
relatively short.. Limited clinical information available about patients
with re-positive test (except CRP and lymph tracking).

#### Extended Results

*NOTE*: Patients sampled in this study were generally younger (65.4%
&lt; 50 yrs) and less critically ill/all discharged. After two
consecutive negative PCR tests, patients were discharged.

Clinical Results at Admission

-   Median interval disease onset to admission (5 days, IQR: 3-7)

-   Most common symptoms included fever, fatigue, dry cough, and
    expectoration.

-   Fifteen patients had reduced lymphocyte counts (28.8%).

-   No change in WBC or Neutrophil counts.

-   **The majority of patients had increased CRP at admission (63.5%).**

-   **LDH, and HSST TNT were significantly increased at admission.**

-   Fibrinogen was trending high though not significant.

-   No major changes in liver function observed.

-   **Radiographic signs via chest CT showed increased involvement in
    lower lobes: right lower lobe (47 cases, 90.4%), left lower lobe (37
    cases, 71.2%).**

-   **GGO (90.4%), interlobular septal thickening (42.3%), vascular
    enlargement (42.3%)**, and reticulation (11.5%) were most commonly
    observed.

Change in Clinical Results following Negative Test

-   **CRP levels decreased after negative PCR.**

-   **Lymphocyte counts (\#/L) increased significantly (CD3+, CD3+/8+
    and CD3+/4+).**

-   No significant change to CD4/8 ratio.

-   LDH, HSST TNT, and Fibronegin remained high throughout, though range
    observed decreased over time.

-   **Consolidation and mixed GGO observed in longitudinal CT imaging.**

-   **Patients showed different extents of inflammatory exudation in
    lungs, with overall tendency for improvement (except 2/7 patients
    that were readmitted after discharge with re-positive test).**

Patients Readmitted with PCR+ test

-   **Seven patients repeated positive RT-PCR test and were readmitted
    to the hospital (9 to 17 day after initial discharge).**

-   Improvement during readmission in 4 patients and observation of
    segmental progression CT in 2 patients (2/18 or 11.1% - re-positive
    9 and 10 days post-discharge).

-   Two patients showed new GGO, while others improved greatly.

-   **Follow up CT necessary to monitor improvement during recovery and
    patients with lesion progression should be given more attention.**

-   **Dynamic CT in addition to negative test essential in clinical
    diagnosis due to nasal swab PCR sampling bias (false-negatives).**

-   **Increase in CRP occurred in 2 readmitted patients (and decr. in
    lymphocytes in one patient), but was not correlated with new lesions
    or disease progression vs. improvement (very low N).**

#### Significance

Study tracked key clinical features associated with
disease progression, recovery, and determinants of clinical
diagnosis/management of COVID-19 patients.

#### Credit

*This review was undertaken by Natalie Vaninov as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple 2 endemic, epidemic and bat coronavirus

Sheahan et al. *bioRxiv*. [@doi:10.1101/2020.03.19.997890]

#### Keywords
- Treatment
- Antiviral
- Broad spectrum antiviral
- ribonucleoside analog β-D-N4 30 hydroxycytidine (NHC)
- Remdesivir

#### Main Findings

β-D-N4 30 –hydroxycytidine (NHC, EIDD-1931) is an
orally bioavailable ribonucleoside with antiviral activity against
various RNA viruses including Ebola, Influenza and CoV. NHC activity
introduce*d*~~s~~ mutations in the viral (but not cellular) RNA in a
dose dependent *manner* that directly correlated with a decrease in
viral titers. Authors show that NHC inhibited multiple genetically
distinct Bat-CoV viruses in human primary epithelial cells *without
affecting* *cell viability even at high concentrations (100* *µM)*.
Prophylactic oral administration of NHC in C57BL/6 mice reduce lung
titers of SARS-CoV and prevented weight loss and hemorrhage. Therapeutic
administration of NHC in C57BL/6 mice 12 hours post infected with
SARS-CoV reduced acute lung injury, viral titer, and lung hemorrhage.
The degree of clinical benefit was dependent on the time of treatment
initiation post infection. The authors also demonstrate that NHC reduces
MERS-CoV infection titers, pathogenesis, and viral RNA in prophylactic
and therapeutic settings.

#### Limitations

Most of the experiments were conducted using MERS-CoV, and
SARS-CoV and a few experiments were conducted using other strains of CoV
as opposed to SARS-CoV-2. The authors note the core residues that make
up the RNA interaction sites (which constitutes the NHC interaction
sites) are highly conserved among CoV and because of this conservation
their understanding is that NHC can inhibit a broad-spectrum of CoV
including SARS-CoV-2.

The increased viral mutation rates associated with NHC activity may have
adverse effects if mutations cause the virus to become drug resistant,
more infectious or speed-up immune evasion. *In addition, the temporal
diminishing effectiveness of NHC on clinical outcome when NHC was used
therapeutically is concerning. However, the longer window (7-10 days)
for clinical disease onset in human patients from the time of infection
compared to that of mice (24-48 hours), may associate with increased NHC
effectiveness in the clinic.*

#### Significance

Prophylactic or therapeutic oral administration of NHC
reduces lung titers and prevents acute lung failure in C57B\\6 mice
infected with CoV. Given its *broad-spectrum antiviral activity, NHC
could turn out to be a useful drug for treating current, emerging and
future corona virus outbreaks.*
 
#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

Sangeun Jeon et al. [@doi:10.1101/2020.03.20.999730]

#### Keywords

- COVID-19
- SARS CoV-2
- antiviral drugs
- niclosamide
- ciclesonide

#### Main Findings

A panel of \~3,000 FDA- and IND-approved
antiviral drugs were previously screened for inhibitory efficacy against
SARS CoV, a coronavirus related to the novel coronavirus SARS CoV-2
(79.5%) homology. 35 of these drugs along with another 15 (suggested by
infectious disease specialists) were tested in vitro for their ability
to inhibit SARS CoV-2 infectivity of Vero cells while preserving cell
viability. The infected cells were scored by immunofluorescence analysis
using an antibody against the N protein of SARS CoV-2. Chloroquine,
lopinavir and remdesivir were used as reference drugs.

Twenty four out of 50 drugs exhibited antiviral activity with IC50
values ranging from 0.1-10µM. Among these, two stood ou: 1) the-anti
helminthic drug niclosamide which exhibited potent antiviral activity
against SARS CoV-2 (IC50=0.28 µM). The broad-spectrum antiviral effect
of niclosamide against SARS and MERS-CoV have been previously documented
and recent evidence suggests that in may inhibit autophagy and reduce
MERS C0V replication. 2) Ciclesonide, a corticosteroid used to treat
asthma and allergic rhinitis, also exhibited antiviral efficacy but with
a lower IC50 (4.33µM) compared to niclosamide. The antiviral effects of
ciclesonide were directed against NSP15, a viral riboendonuclease which
is the molecular target of this drug.

#### Limitations

The drugs were tested against SARS CoV-2 infectivity in
vitro only, therefore preclinical studies in animals and clinical trials
in patients will be need for validation of these drugs as therapeutic
agents for COVID-19. In addition, niclosamide exhibits low adsorption
pharmatokinetically which could be alleviated with further development
of drug formulation to increase effective delivery of this drug to
target tissues. Nonetheless, niclosamide and ciclesonide represent
promising therapeutic agents against SARS CoV-2 given that other
compounds tested in the same study including favipiravir (currently used
in clinical trials) and atazanavir (predicted as the most potent
antiviral drug by AI-inference modeling) did not exhibit antiviral
activity in the current study.

#### Credit

*This review was undertaken by K Alexandropoulos as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2

Munster et al. *bioRxiv*. [@doi:10.1101/2020.03.21.001628]

#### Keywords

animal model, pulmonary infiltrates, dynamic
of antibody response, cytokine

#### Main Findings

Inoculation of 8 Resus macaques with SARS-Cov-2 , which
all showed clinical signs of infection (respiratory pattern, reduced
appetite, weight loss, elevated body temperature) resulting in moderate,
transient disease. Four animals were euthanized at 3dpi, the 4 others at
21 dpi. Study of viral loads in different organs showed that nose swab
and throat swabs were the most sensitive, with bronchio-alveolar lavage.
Interstitial pneumonia was visible in radiographies and at the
histological scale too. Clinically, the macaques had similar symptoms as
described in human patients with moderate disease.

Viral shedding was consistently detected in nose swabs and throat swabs
immediately after infection but less consistent thereafter which could
reflect virus administration route (intranasal, oral). Bronchoalveolar
lavages performed as a measure of virus replication in the lower
respiratory tract on animals maintained for 21 days, contained high
viral loads in 1 and 3dpi. The majority of the animals exhibited
pulmonary edema and mild to moderate interstitial pneumonia on terminal
bronchioles. In addition to the lung, viral RNA could also be detected
throughout the respiratory track where viral replication mainly
occurred.

Immunologic responses included leukocytosis, neutrophilia, monocytosis
and lymphopenia in the majority of the animals at 1dpi. Lymphocytes and
monocytes re-normalized at 2dpi. Neutrophils declined after 3dpi and
through 10dpi after which they started to recover. After infection,
serum analysis revealed significant increases in **IL1ra, IL6, IL10,
IL15, MCP-1, MIP-1b, but quick normalization** (3dpi). **Antibody
response started around 7dpi, and the antibody titers stayed elevated
until 21dpi** (day of animal euthanasia).

#### Limitations

The macaques were inoculated via a combination
of intratracheal, intranasal, ocular and oral routes, which might not
reproduce how humans get infected. Maybe this can lead to different
dynamics in the host immune response. Also, the authors noted that the
seroconversion was not directly followed by a decline in viral loads, as
observed in covid19 patients.

#### Significance

This work confirms that rhesus
macaques can be a good model to study Covid-19, as it has been shown by
other groups [@doi:10.1101/2020.03.13.990226; @doi:10.1101/2020.03.13.990036; @doi:10.1101/2020.03.17.995639]. While these experiments recapitulate
moderate COVID-19 in humans, the mode of inoculation via a combination
of intratracheal, intranasal, ocular and oral routes, might not
reproduce how humans get infected and may lead to different dynamics in
the host immune response. For example, the authors noted that the
seroconversion was not directly followed by a decline in viral loads, as
observed in COVID-19 patients. Therefore, it will be interesting to
follow their antibody titers longer and further assess the
possibility/effect of reinfection in these macaques. It is essential to
be able to understand the dynamic of the disease and associated immune
responses, and to work on vaccine development and antiviral drug
testing.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19

[@doi:10.1101/2020.03.21.20040261]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- lung
- comorbidities
- histone
- epigenetics

#### Main Findings

-   Transcriptomic analysis using systems-level meta-analysis and
    network analysis of existing literature to determine ACE2 regulation
    in patients who have frequent COVID-19 comorbidities \[eg-
    cardiovascular diseases, familial pulmonary hypertension, cancer\].

-   Enrichment analyses indicated pathways associated with inflammation,
    metabolism, macrophage autophagy, and ER stress.

-   ACE2 higher in adenocarcinoma compared to adjacent normal lung; ACE2
    higher in COPD patients compared to normal.

-   Co-expression analysis identified genes important to viral entry
    such as RAB1A, ADAM10, HMGBs, and TLR3 to be associated with ACE2 in
    diseased lungs.

-   ACE2 expression could be potentially regulated by enzymes that
    modify histones, including HAT1, HDAC2, and KDM5B.

#### Limitations:

-   Not actual CoVID-19 patients with co-morbidities, so interpretations
    in this study need to be confirmed by analyzing upcoming
    transcriptomics from CoVID-19 patients having co-morbidity metadata.

-   As mentioned by authors, study does not look at diabetes and
    autoimmunity as risk factors in CoVID-19 patients due to lack of
    data; would be useful to extend such analyses to those datasets when
    available.

-   Co-expression analysis is perfunctory and needs
    validation-experiments especially in CoVID-19 lung samples to mean
    anything.

-   Epigenomic analyses are intriguing but incomplete, as existence of
    histone marks does not necessarily mean occupancy. Would be
    pertinent to check cell-line data (CCLE) or actual CoVID-19 patient
    samples to confirm ACE2 epigenetic control.

#### Significance

-   Study implies vulnerable populations have ACE2 upregulation that
    could promote CoVID-19 severity. Shows important data-mining
    strategy to find gene-networks associated with ACE2 upregulation in
    co-morbid patients.

-   Several of the genes co-upregulated with ACE2 in diseased lung might
    play an important role in CoVID-19 and can be preliminary targets
    for therapeutics

-   If in silico findings hold true, epigenetic control of ACE2
    expression could be a new target for CoVID-19 therapy with
    strategies such as KDM5 demethylases.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial

Bian et al. *medRxiv*. [@doi:10.1101/2020.03.21.20040691]

#### Keywords

- Meplazumab
- CD147
- humanized antibody
- clinical trial

#### Main Findings

This work is based on previous work by the same group
that demonstrated that SARS-CoV-2can also enter host cells via CD147
(also called Basigin, part of the immunoglobulin superfamily, is
expressed by many cell types) consistent with their previous work with
SARS-CoV-1. ^1^ A prospective clinical trial was conducted with 17
patients receiving Meplazumab, a humanized anti-CD147 antibody, in
addition to all other treatments. 11 patients were included as a control
group (non-randomized).

They observed a faster overall improvement rate in the Meplazumab group
(e.g. at day 14 47% vs 17% improvement rate) compared to the control
patients. Also, virological clearance was more rapid with median of 3
days in the Meplazumab group vs 13 days in control group. In laboratory
values, a faster normalization of lymphocyte counts in the Meplazumab
group was observed, but no clear difference was observed for CRP levels.

#### Limitations

While the results from the study are encouraging, this
study was non-randomized, open-label and on a small number of patients,
all from the same hospital. It offers evidence to perform a larger scale
study. Selection bias as well as differences between treatment groups
(e.g. age 51yo vs 64yo) may have contributed to results. The authors
mention that there was no toxic effect to Meplazumab injection but more
patient and longer-term studies are necessary to assess this.

#### Significance

These results seem promising as for now there are
limited treatments for Covid-19 patients, but a larger cohort of patient
is needed. CD147 has already been described to facilitate HIV [@doi:10.1073/pnas.111583198],
measles virus [@doi:10.1128/JVI.02168-09], and malaria [@doi:10.1038/nature10606] entry into host cells. This group was
the first to describe the CD147-spike route of SARS-Cov-2 entry in host
cells [@doi:10.1101/2020.03.14.988345] p147. Indeed, they had previously shown in 2005 that SARS-Cov
could enter host cells via this transmembrane protein [@doi:10.1086/427811]. Further
biological understanding of how SARS-CoV-2 can enter host cells and how
this integrates with ACE2R route of entry is needed. Also, the specific
cellular targets of the anti-CD147 antibody need to be assessed, as this
protein can be expressed by many cell types and has been shown to
involved in leukocytes aggregation [@doi:10.1371/journal.pone.0215557]. Lastly, Meplazumab is not a
commercially-available drug and requires significant health resources to
generate and administer which might prevent rapid development and use.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Potent human neutralizing antibodies elicited 1 by SARS-CoV-2 infection

Ju et al. *bioRxiv*. [@doi:10.1101/2020.03.21.990770]

#### Keywords

- monoclonal antibodies
- neutralization
- antibody cross-reactivity
- Receptor Binding Domain

#### Main Findings

In this study the authors report the affinity, cross reactivity (with
SARS-CoV and MERS-CoV virus) and viral neutralization capacity of 206
monoclonal antibodies engineered from isolated IgG memory B cells of
patients suffering from SARS-CoV-2 infection in Wuhan, China. All
patients but one recovered from disease. Interestingly, the patient that
did not recover had less SARS-CoV-2 specific B cells circulating
compared to other patients.

Plasma from all patients reacted to trimeric Spike proteins from
SARS-CoV-2, SARS-CoV and MERS-CoV but no HIV BG505 trimer. Furthermore,
plasma from patients recognized the receptor binding domain (RBD) from
SARS-CoV-2 but had little to no cross-reactivity against the RBD of
related viruses SARS-CoV and MERS-CoV, suggesting significant
differences between the RBDs of the different viruses. Negligible levels
of cross-neutralization using pseudoviruses bearing Spike proteins of
SARS-CoV-2, SARS-CoV or MERS-CoV, were observed, corroborating the ELISA
cross-reactivity assays on the RBDs.

SARS-CoV-2 RBD specific B cells constituted 0.005-0.065% of the total B
cell population and 0.023-0.329% of the memory subpopulation. SARS-CoV
specific IgG memory B cells were single cell sorted to sequence the
antibody genes that were subsequently expressed as recombinant IgG1
antibodies. From this library, 206 antibodies with different binding
capacities were obtained. No discernible patterns of VH usage were found
in the 206 antibodies suggesting immunologically distinct responses to
the infection. Nevertheless, most high-binding antibodies were derived
by clonal expansion. Further analyses in one of the patient derived
clones, showed that the antibodies from three different timepoints did
not group together in phylogenetic analysis, suggesting selection during
early infection.

Using surface plasmon resonance (SPR) 13 antibodies were found to have
10^-8^ tp 10^-9^ dissociation constants (Kd). Of the 13 antibodies, two
showed 98-99% blocking of SARS-CoV-2 RBD-ACE2 receptor binding in
competition assays. Thus, low Kd values alone did not predict ACE2
competing capacities. Consistent with competition assays the two
antibodies that show high ACE2 blocking (P2C-2F6 and P2C-1F11) were the
most capable of neutralizing pseudoviruses bearing SARS-CoV-2 spike
protein (IC~50~ of 0.06 and 0.03 µg/mL, respectively). Finally, using
SPR the neutralizing antibodies were found to recognize both overlapping
and distinct epitopes of the RBD of SARS-CoV-2.

#### Limitations

1.  Relatively low number of patients

    a.  No significant conclusion can be drawn about the possible
        > correlation between humoral response and disease severity

2.  *In vitro* Cytopathic Effect Assay (CPE) for neutralization activity

    a.  Huh7 cells were used in neutralization assays with
        > pseudoviruses, and they may not entirely mimic what happens in
        > the upper respiratory tract

    b.  CPE assay is not quantitative

3.  Duplicated panel in Figure 4C reported (has been fixed in version 2)

#### Significance

This paper offers an explanation as to why
previously isolated antibodies against SARS-CoV do not effectively block
SARS-CoV-2. Also, it offers important insight into the development of
humoral responses at various time points during the first weeks of the
disease in small but clinically diverse group of patients. Furthermore,
it provides valuable information and well characterized antibody
candidates for the development of a recombinant antibody treatment for
SARS-CoV-2. Nevertheless, it also shows that plasmapheresis might have
variability in its effectiveness, depending on the donor’s antibody
repertoire at the time of donation.

#### Credit

*Review by Jovani Catalan-Dibene as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site.

Davidson et al. [@doi:10.1101/2020.03.22.002204]

#### Keywords

- Transcription
- RNA-seq
- proteomics
- mass spec
- furin cleavage site
- mutation
- pathogenicity

#### Main Findings

The authors performed long read RNA sequencing using an Oxford Nanopore
MinION as well as tandem mass spec (MS) on Vero cells (a cell line
derived from kidney cells of the African green monkey that is deficient
in interferon) infected with SARS-CoV-2.

The authors found that passage of the virus in Vero cells gave rise to a
spontaneous 9 amino acid deletion (679-NSPRRARSV-687 to I) in the spike
(S) protein. The deleted sequence overlaps a predicted furin cleavage
site at the S1 / S2 domain boundary that is present in SARS-CoV-2 but
not SARS-CoV or the closely related bat coronavirus RaTG13, which are
cleaved at S1 / S2 by other proteases [@doi:10.1126/science.abb2507]. Furin cleavage sites at
similar positions in other viruses have been linked to increased
pathogenicity and greater cell tropism [@doi:10.1128/JVI.00797-10]. Loss of this site in
SARS-CoV-2 has also already been shown to increase viral entry into Vero
but not BHK cells (which are also interferon deficient) [@doi:10.1016/j.cell.2020.02.058]. The
authors therefore make an important contribution in demonstrating that
passage in Vero cells may lead to spontaneous loss of a key
pathogenicity-conferring element in SARS-CoV-2.

#### Limitations

As the authors note, a similar study posted earlier by Kim et al., which
also passaged SARS-CoV-2 in Vero cells, did not identify any loss in the
S protein furin cleavage site [@doi:10.1101/2020.03.12.988865]. It therefore remains to be
determined how likely it is that this mutation spontaneously arises. A
quantitative investigation using multiple experimental replicas to
understand the spontaneous viral mutation rate at this site and
elsewhere would be informative. Also, the mechanistic basis for the
higher viral fitness conferred by loss of the furin cleavage site in
Vero cells – but, evidently, not in vivo in humans, as this site is
maintained in all currently sequenced circulating isolates - remains to
be understood.

Due to the high base-call error rate of MinION sequencing, the authors’
bioinformatic pipeline required aligning transcripts to a reference to
correct sequencing artifacts. This presumably made it difficult or
impossible to identify other kinds of mutations, such as single
nucleotide substitutions, which may occur even more frequently than the
deletions identified in this work. Pairing long read sequencing with
higher-accuracy short-read sequencing may be one approach to overcome
this issue.

#### Significance

As the authors suggest, animal studies using live virus challenge may
need to periodically verify the genomic integrity of the virus, or
potentially risk unknowingly using a likely less-pathogenic variant of
the virus.

More broadly, the results emphasize the complexity and plasticity of the
SARS-CoV-2 viral transcriptome and proteome. For example, the authors
found multiple versions of transcripts encoding the nucleocapsid (N)
protein, each with different small internal deletions, some of which
were verified for translation by MS. A number of peptides arising from
translation of unexpected rearrangements of transcripts were also
detected. Additionally, the authors identified phosphorylation of a
number of viral proteins (N, M, ORF 3a, nsp3, nsp9, nsp12 and S). For
any cases where these have functional consequences, targeting the
kinases responsible could be an avenue for drug development.
Understanding the functional consequences of the mutations, transcript
variations, and post translational modifications identified in this
study will be important future work.

#### Credit

*This review was undertaken by Tim O’Donnell, Maria Kuksin as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug- Repurposing

Gordon et al. *bioRxiv* [@doi:10.1101/2020.03.22.002386]

#### Keywords

- protein-protein interactions
- mass spectrometry
- drug targets

#### Main Findings

Gordon et al cloned, tagged and expressed 26 of the 29
SARS-CoV-2 proteins individually in HEK293T cells and used mass
spectrometry to identify protein-protein interactions. They identified
332 viral-host protein-protein interactions. Furthermore, they used
these interactions to identify 66 existing drugs known to target host
proteins or host pathways (eg SARS-CoV-2 N and Orf8 proteins interact
with proteins regulated by the mTOR pathway, so mTOR inhibitors
Silmitasertib and Rapamycin are possible drug candidates).

#### Limitations

The main limitation of the study stems from
the reductionist model: overexpression of plasmids encoding individual
viral proteins in HEK293T cells. This precludes any interactions between
the viral proteins, or the combined effects of multiple proteins on the
host, as they are expressed individually. Moreover, HEK293T cells come
from primary embryonic kidney and therefore might not reflect how
SARS-CoV-2 interacts with its primary target, the lung. However, the
authors found that the proteins found to interact with viral proteins in
their experiments are enriched in lung tissue compared to HEK293Ts.

#### Significance

The authors provide a “SARS-CoV-2 interaction map,”
which may provide potential hypotheses as to how the virus interacts
with the host. Further, they identified existing drugs that could
disrupt these host-viral interactions and curb SARS-CoV-2 infection.
Although these interactions have not been validated, this paper acts as
a valuable resource.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients

Chen et al. *medRxiv*.
[@doi:10.1101/2020.03.22.20034041]

#### Keywords
- Clinical study
- HCV protease inhibitor
- Danoprevir
- Ritonavir
- Covid19 treatment

#### Main Findings

The authors treated 11 Covid-19 patients with Danoprevir, a
commercialized HCV protease inhibitor [@doi:10.1128/AAC.00699-08]^(p4)^, boosted by ritonavir [@doi:10.14218/JCTH.2019.00033], a
CYP3A4 inhibitor (which enhances the plasma concentration and
bioavailabilty of Danoprevir). Two patients had never received
anti-viral therapy before (=naïve), whereas nine patients were on
Lopinavir/Ritonavir treatment before switching to Danoprevir/Ritonavir
(=experienced). The age ranged from 18 to 66yo.

Naïve patients that received Danoprevir/Ritonavir treatment had a
decreased hospitalization time. Patients treated with
Lopinavir/Ritonavir did not have a negative PCR test, while after
switching to Danoprevir/Ritonavir treatment, the first negative PCR test
occurred at a median of two days.

#### Limitations

The results of the study are very hard to interpret as there is no
control group not receiving Danoprevir/Ritonavir treatment. This was
especially true in naïve patients who seemed to have more mild symptoms
before the start of the study and were younger (18 and 44yo) compared to
the experienced patients (18 to 66yo). The possibility that the patients
would have recovered without Danoprevir/Ritonavir treatment cannot be
excluded.

#### Significance

The authors of the study treated patients with Danoprevir, with the
rational to that this is an approved and well tolerated drug for HCV
patients [@doi:10.14218/JCTH.2019.00033], and that it could also target the protease from SARS-CoV-2
(essential for viral replication and transcription). Indeed, homology
modelling data indicated that HCV protease inhibitors have the highest
binding affinity to Sars-Cov2 protease among other approved drugs [@doi:10.1101/2020.02.05.936013].

While this study shows that the combination of Danoprevir and Ritonavir
might be beneficial for Covid-19 patients, additional clinical trials
with more patients and with better methodology (randomization and
control group) are needed to make further conclusions.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

[@doi:10.1101/2020.03.22.20040758]

#### Keywords

- hydroxychloroquine

#### Study Description

This is a randomized clinical trial of hydroxychloroquine (HCQ) efficacy
in the treatment of COVID-19. From February 4 – February 28, 2020 142
COVID-19 positive patients were admitted to Renmin Hospital of Wuhan
University. 62 patients met inclusion criteria and were enrolled in a
double blind, randomized control trial, with 31 patients in each arm.

Inclusion criteria:

1.  Age ≥ 18 years

2.  Positive diagnosis COVID-19 by detection of SARS-CoV-2 by RT-PCR

3.  Diagnosis of pneumonia on chest CT

4.  Mild respiratory illness, defined by SaO~2~/SPO~2~ ratio &gt; 93% or
    PaO~2~/FIO~2~ ratio &gt; 300 mmHg in hospital room conditions (Note:
    relevant clinical references described below.)

    a.  Hypoxia is defined as an SpO2 of 85-94%; severe hypoxia &lt;
        85%.

    b.  The PaO~2~/FIO~2~ (ratio of arterial oxygen tension to fraction
        of inspired oxygen) is used to classify the severity of acute
        respiratory distress syndrome (ARDS). Mild ARDS has a
        PaO~2~/FIO~2~ of 200-300 mmHg, moderate is 100-200, and severe
        &lt; 100.

5.  Willing to receive a random assignment to any designated treatment
    group; not participating in another study at the same time

Exclusion criteria:

1.  Severe or critical respiratory illness (not explicitly defined,
    presumed to be respiratory function worse than outlined in inclusion
    criteria); or participation in trial does not meet patient’s maximum
    benefit or safe follow up criteria

2.  Retinopathy or other retinal diseases

3.  Conduction block or other arrhythmias

4.  Severe liver disease, defined by Child-Pugh score ≥ C or AST &gt;
    twice the upper limit

5.  Pregnant or breastfeeding

6.  Severe renal failure, defined by eGFR ≤ 30 mL/min/1.73m^2^, or on
    dialysis

7.  Potential transfer to another hospital within 72h of enrollment

8.  Received any trial treatment for COVID-19 within 30 days before the
    current study

All patients received the standard of care: oxygen therapy, antiviral
agents, antibacterial agents, and immunoglobulin, with or without
corticosteroids. Patients in the HCQ treatment group received additional
oral HCQ 400 mg/day, given as 200 mg 2x/day. HCQ was administered from
days 1-5 of the trial. The primary endpoint was 5 days post enrollment
or a severe adverse reaction to HCQ. The primary outcome evaluated was
time to clinical recovery (TTCR), defined as return to normal body
temperature and cough cessation for &gt; 72h. Chest CT were imaged on
days 0 and 6 of the trial for both groups; body temperature and patient
reports of cough were collected 3x/day from day 0 – 6. The mean age and
sex distribution between the HCQ and control arms were comparable.

#### Main Findings

There were 2 patients showing mild secondary effects of HCQ treatment.
More importantly, while 4 patients in the control group progressed to
severe disease, none progressed in the treatment group.

TTCR was significantly decreased in the HCQ treatment arm; recovery from
fever was shortened by one day (3.2 days control vs. 2.2 days HCQ, p =
0.0008); time to cessation of cough was similarly reduced (3.1 days
control vs. 2.0 days HCQ, p = 0.0016).

Overall, it appears that HCQ treatment of patients with mild COVID-19
has a modest effect on clinical recovery (symptom relief on average 1
day earlier) but may be more potent in reducing the progression from
mild to severe disease.

#### Limitations

This study is limited in its inclusion of only patients with mild
disease, and exclusion of those on any treatment other than the standard
of care. It would also have been important to include the laboratory
values of positive RT-PCR detection of SARS-CoV-2 to compare the
baseline and evolution of the patients’ viral load.

#### Limitations

Despite its limitations, the study design has good rigor as a double
blind RCT and consistent symptom checks on each day of the trail. Now
that the FDA has approved HCQ for treatment of COVID-19 in the USA, this
study supports the efficacy of HCQ use early in treatment of patients
showing mild symptoms, to improve time to clinical recovery, and
possibly reduce disease progression. However, most of the current
applications of HCQ have been in patients with severe disease and for
compassionate use, which are out of the scope of the findings presented
in this trial. Several additional clinical trials to examine
[hydroxychloroquine](https://twitter.com/hashtag/hydroxychloroquine?src=hashtag_click)
are now undergoing; their results will be critical to further validate
these findings.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset

Lou et al. *medRxiv*. [@doi:10.1101/2020.03.23.20041707]

#### Keywords

- Seroconversion rate
- Total Antibody
- Ab
- IgG and IgM
- antibody

#### Main Findings

Currently, the diagnosis of SARS-CoV-2 infection
entirely depends on the detection of viral RNA using polymerase chain
reaction (PCR) assays. False negative results are common, particularly
when the samples are collected from upper respiratory. Serological
detection may be useful as an additional testing strategy. In this study
the authors reported that a typical acute antibody response was induced
during the SARS-CoV-2 infection, which was discuss earlier^1^. The
seroconversion rate for Ab, IgM and IgG in COVID-19 patients was 98.8%
(79/80), 93.8% (75/80) and 93.8% (75/80), respectively. The first
detectible serology marker was total antibody followed by IgM and IgG,
with a median seroconversion time of 15, 18 and 20 days-post exposure
(d.p.e) or 9, 10- and 12-days post-onset (d.p.o). Seroconversion was
first detected at day 7d.p.e in 98.9% of the patients. Interestingly
they found that viral load declined as antibody levels increased. This
was in contrast to a previous study [@doi:10.1101/2020.03.02.20030189], showing that increased antibody
titers did not always correlate with RNA clearance (low number of
patient sample).

#### Limitations

Current knowledge of the antibody response to SAR-CoV-2
infection and its mechanism is not yet well elucidated. Similar to the
RNA test, the absence of antibody titers in the early stage of illness
could not exclude the possibility of infection. A diagnostic test, which
is the aim of the authors, would not be useful at the early time points
of infection but it could be used to screen asymptomatic patients or
patients with mild disease at later times after exposure.

#### Significance

Understanding the antibody responses against SARS-CoV2 is
useful in the development of a serological test for the diagnosis of
COVID-19. This manuscript discussed acute antibody responses which can
be deducted in plasma for diagnostic as well as prognostic purposes.
Thus, patient-derived plasma with known antibody titers may be used
therapeutically for treating COVID-19 patients with severe illness.
[[]{#OLE_LINK4 .anchor}]{#OLE_LINK3 .anchor}

#### Credit

*This review was undertaken and edited by Konstantina A as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Blanco-Melo et al. *bioRxiv*. [@doi:10.1101/2020.03.24.004655]

#### Keywords

- host cellular response
- host-pathogen interaction
- type I interferon
- type III interferon
- inflammation
- RNA-seq
- comparative analysis

#### Main Findings

Given the high mortality rate of SARS-CoV-2 relative to
other respiratory viruses such seasonal IAV and RSV, there may be
underlying host-pathogen interactions specific to SARS-CoV-2 that
predispose to a worse clinical outcome. Using *in vivo*, *ex vivo*, and
*in vitro* systems, the authors profiled host cell transcriptional
responses to SARS-CoV-2 and to other common respiratory viruses
(seasonal IAV and RSV). SARS-CoV-2 infection *in vitro* led to an
induction of type I interferon response signaling and the upregulation
of cytokine/chemokines transcripts. In comparison with IAV and RSV
infection, SARS-CoV-2 *in vitro* appears to uniquely induce less type I
and type III interferon expression and higher levels of two cytokines
previously implicated in respiratory inflammation. Lastly, *in vivo*
data from ferrets showed a reduced induction of cytokines and chemokines
by SARS-CoV-2 infection relative to IAV infection.

#### Limitations

While these results are promising, there are several
key weaknesses of this paper. 1) As the authors point out, there is an
undetectable level of SARS-CoV-2 putative receptor (ACE2) and protease
(TMPRSS2) expression in the lung epithelial cell line used for the *in
vitro* studies. This raises the important question of whether viral
replication actually occurs in any of the models used, which may explain
the lack of interferon production observed *in vitro* in SARS-CoV-2
treated cells. Further studies characterizing viral titers across
timepoints are needed. 2) Furthermore, these studies only characterize
the host response at a single dose and timepoint per virus, and it is
unclear why these doses/timepoints were chosen. This leaves open the
possibility that the observed differences between viruses could be due
to differences in dose, timing, host response, or a combination of all
of these. 3) It is unclear whether ferrets are productively infected,
which cell types are infected, and the extent/timing of the clinical
course of infection. Moreover, the *in vitro* and *in vivo* data do not
strongly correlate and the reasons for this are unclear.

#### Significance

This paper describes potentially unique
transcriptional signatures of host cells exposed to SARS-CoV-2. If
validated, these findings may help explain clinical outcomes and could
be targeted in future therapeutic interventions.

#### Potential Conflicts of Interest Disclosure

The reviewers are also researchers at the Icahn School
of Medicine at Mount Sinai.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### A New Predictor of Disease Severity in Patients with COVID-19 in Wuhan, China

Zhou et al. *bioRxiv*. [@doi:10.1101/2020.03.24.20042119]

#### Keywords

- disease severity
- clinical data
- Neutrophils/lymphocytes ratio
- CRP
- D-dimer

#### Main Findings

377 hospitalized patients were divided into two groups: severe and
non-severe pneumonia. The laboratory results of their first day of
admission were retrospectively analyzed to identify predictors of
disease severity.

After adjusting for confounding factors from chronic comorbidities (such
as high blood pressure, type 2 diabetes, coronary heart disease, and
chronic obstructive pulmonary disease), the independent risk factors
identified for severe pneumonia were **age**, the **ratio of
neutrophil/lymphocytes counts**, **CRP** and **D-dimer** levels.

To further increase the specificity and sensibility of these markers,
they showed that their multiplication **\[(Neutrophil/lymphocyte count)
\* CRP \* D-dimer\]** was a better predictor of disease severity, with
higher sensitivity (95.7%) and specificity (63.3%), with a cutoff value
of 2.68.

#### Limitations

This study included 377 hospitalized patients. Among them, 45.6%
patients tested positive for SARS-Cov-2 nucleic acid test results, and
others were included in the study based on clinically diagnosis even if
the molecular diagnosis was negative. Thus, additional studies are
needed to verify this on a larger number of covid-19 certified patients
and the cutoff value might be adjusted. Also, all the patients that did
not have the clinical characteristics of severe pneumonia were included
in the non-severe pneumonia group, but usually patients are also divided
into moderate and mild disease.

Also, studying different subset of lymphocytes could lead to a more
specific predictor. Another study showed that the neutrophils to CD8+ T
cells ratio was a strong predictor of disease severity [@doi:10.1101/2020.02.16.20023671]. Another more
precise study showed that the percentage of helper T cells and
regulatory T cells decrease but the percentage of naïve helper T cells
increases in severe cases [@doi:10.1093/cid/ciaa248]. Taking these subpopulations into account
might make the predictor more powerful.

Other studies also noted an inverse correlation between disease severity
and LDH [@doi:10.1101/2020.03.03.20030668] or IL6 [@doi:10.1101/2020.03.08.20031229] levels, but the authors here do not discuss LDH nor
IL6 levels, although this could help to strengthen the predictor.

The study is based on the results obtained on the first day of
admission, studying the dynamic of the changes in patients might also be
interesting to better predict disease severity.

#### Significance

This study confirms that the neutrophil to lymphocyte ratio can be a
predictor of disease severity as shown by many others [@doi:10.1093/cid/ciaa248; @doi:10.1001/jama.2020.1585; @doi:10.1101/2020.02.10.20021584]. The
novelty here is that they show that a combination with other markers can
enhance the specificity and sensibility of the predictor, although the
study could be improved by taking into account sub-populations of
lymphocytes and more biological factors from patients such as LDH and
IL6.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study

Shuke Nie et al. *medRxiv*. [@doi:10.1101/2020.03.24.20042283]

#### Keywords

- metabolism
- fasting blood glucose
- serum total protein
- albumin
- blood lipid
- HDL-C
- APOA1
- lymphocytopenia
- IL-6
- CRP
- severity prediction of COVID19

#### Main Findings

Retrospective Study on 97 COVID-19 hospitalized patients
(25 severe and 72 non-severe) analyzing clinical and laboratory
parameter to predict transition from mild to severe disease based on
more accessible indicators (such as fasting blood glucose, serum protein
or blood lipid) than inflammatory indicators. In accordance with other
studies, age and hypertension were risk factors for disease severity,
and lymphopenia and increased IL-6 was observed in severe patients. The
authors show that fasting blood glucose (FBG) was altered and patients
with severe disease were often hyperglycemic. Data presented support
that hypoproteinaemia, hypoalbuminemia, and reduction in
high-densitylipoprotein (HDL-C) and ApoA1 were associated with disease
severity.

#### Limitations

In this study non-severe patients were divided in two groups based on
average course of the disease: mild group1 (14 days, n=28) and mild
group 2 (30 days, n=44). However mild patients with a longer disease
course did not show an intermediate phenotype (between mild patients
with shorter disease course and severe patients), hence it is unclear
whether this was a useful and how it impacted the analysis. Furthermore,
the non-exclusion of co-morbidity factors in the analysis may bias the
results (e.g. diabetic patients and glucose tests) It is not clear at
what point in time the laboratory parameters are sampled. In table 3, it
would have been interesting to explore a multivariate multiple
regression. The correlation lacks of positive control to assess the
specificity of the correlation to the disease vs. correlation in any
inflammatory case. The dynamic study assessing the predictability of the
laboratory parameter is limited to 2 patients. Hence there are several
associations with disease severity, but larger studies are necessary to
test the independent predictive value of these potential biomarkers.

#### Significance

As hospital are getting overwhelmed a set of
easily accessible laboratory indicators (such as serum total protein)
would potentially provide a triage methodology between potentially
severe cases and mild ones. This paper also opens the question regarding
metabolic deregulation and COVID-19 severity.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Viral Kinetics and Antibody Responses in Patients with COVID-19

[@doi:10.1101/2020.03.24.20042382]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- IgG
- IgM
- clinical
- kinetics
- antibodies

#### Main Findings

-   Prospective cohort of 67 patients, clinical specimens taken and
    follow-up conducted.

-   Viral shedding, serum IgM, IgG antibody against NP evaluated and
    correlated to disease severity and clinical outcome

-   Viral RNA levels peaked at 1 week from febrile/cough symptom onset
    in sputum, nasal swabs, and stool samples. Shedding ranged from
    12-19 days (median ranges) and was longer in severe patients.

-   IgM and IgG titers stratified patients into three archetypes as
    ‘strong vs weak vs non-responders’. Strong responders (with higher
    IgM/IgG titers) were significantly higher in severe patients.

#### Limitations

Specific for immune monitoring.

-   Not clear if stool RNA captured from live infection in
    intestine/liver or from swallowed sputum. Transmission electron
    microscopy (TEM) carried out on sputum samples as proof of concept,
    but not stools. TEM unreasonable for actual clinical diagnosis.

-   Several patients had co-morbidities (such as pulmonary and liver
    disease) that were not accounted for when tracking antibody
    responses. Viral kinetics and IgM/IgG titers in subsets of patients
    with underlying conditions/undergoing certain medication would be
    informative.

#### Significance

-   Three archetypes of antibody response to SARS-CoV-2 with different
    disease progression and kinetics is useful to stratify patients, and
    for future serological tests.

-   Strong spike-IgG levels often correlate with lymphopenia and
    CoVID-19 disease severity [@doi:10.1101/2020.03.20.20039495], similar to macaque
    studies in SARS [@doi:10.1172/jci.insight.123158]. It would be critical to see if anti-NP or
    anti-Spike IgG antibodies for SARS-CoV-2 also elicit similar
    detrimental effects before clinical use.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome

[@doi:10.1101/2020.03.24.20042655]

#### Keywords

- Monocytes
- FSC-high
- PBMC
- ACE2
- inflammatory cytokines

#### Main Findings

This study is based on flow cytometry immunophenotyping of
PBMCs from 28 patients diagnosed positive for SARS-Cov2 (COVID19). The
authors identify a population of abnormally large (FSC-hi) monocytes,
present in COVID19 patients, but absent in PBMCs of healthy volunteers
(n=16) or patients with different infections (AIDS, malaria, TB). This
FSC-hi monocytic population contains classical, intermediate and
non-classical (monocytes (based on CD14 and CD16 expression) that
produce inflammatory cytokines (IL-6, TNF and IL-10). The authors
suggest an association of FSC-hi monocytes with poor outcome and
correlate a high percentage of FSC-low monocytes, or higher ratio of
FSC-low/hi monocytes, with faster hospital discharge.

#### Limitations

While identification of the monocytic population based
on FSC is rather robust, the characterization of these cells remains
weak. A comprehensive comparison of FSC-hi monocytes with FSC-low
monocytes from patients and healthy controls would be of high value. It
is unclear if percentages in blood are among CD45+ cells. Furthermore,
it would have been important to include absolute numbers of different
monocytic populations (in table 1 there are not enough samples and it is
unclear what the authors show).

The authors show expression of the ACE2 receptor on the surface of the
monocytes, and highlight these cells as potential targets of SARS-Cov2.
However, appropriate controls are needed. CD16 has high affinity to
rabbit IgG and it is unclear whether the authors considered unspecific
binding of rabbit anti-ACE2 to Fc receptors. Gene expression of ACE-2 on
monocytes needs to be assessed. Furthermore, it would be important to
confirm infection of monocytes by presence of viral proteins or viral
particles by microscopy.

Considering the predictive role of FSC-hi monocytes on the development
of the disease and its severity, some data expected at this level are
neither present nor addressed. Although the cohort is small, it does
include 3 ICU patients. What about their ratio of FSC-low vs FSC-hi
monocytes in comparison to other patients? Was this apparent early in
the disease course? Does this population of FSC-hi monocytes differ
between ICU patients and others in terms of frequency, phenotype or
cytokine secretion?

In general, figures need to revised to make the data clear. For example,
in Fig. 5, according to the legend it seems that patients with FSC-high
monocytes are discharged faster from the hospital. However according to
description in the text, patients were grouped in high or low levels of
FSC-low monocytes.

#### Significance

Despite the limitations of this study, the discovery of
a FSC-high monocyte population in COVID-19 patients is of great
interest. With similar implication, a the recent study by Zhou et al. [@doi:10.1101/2020.02.12.945576]
identified a connection between an inflammatory CD14+CD16+ monocyte
population and pulmonary immunopathology leading to deleterious clinical
manifestations and even acute mortality after SARS-CoV-2 infections.
Although the presence of these monocytes in the lungs has yet to be
demonstrated, such results support the importance of monocytes in the
critical inflammation observed in some COVID19 patients.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

Miller et al. *medRxiv*. [@doi:10.1101/2020.03.24.20042937]

#### Keywords

- BCG vaccine
- epidemiology
- vaccination policy

#### Main Findings

The authors compared middle and high income countries that never had a
universal BCG vaccination policy (Italy, Lebanon, Nederland, Belgium)
and countries with a current policy (low income countries were excluded
from the analysis as their number of cases and deaths might be
underreported for the moment). **Countries that never implement BCG
vaccination have a higher mortality rate than countries which have a BCG
vaccination policy** (16.38 deaths per million people vs 0.78). Next,
**the authors show that an earlier start of vaccination correlates with
a lower number of deaths per million inhabitants**. They interpret this
as the vaccine protecting a larger fraction of elderly people, which are
usually more affected by COVID-19. Moreover, higher number of COVID-19
**cases** were presented in countries that never implemented a universal
BCG vaccination policy.

#### Limitations

While this study aims to test an intriguing hypothesis unfortunately,
the data is not sufficient at this time to accurately make any
determinations. Several caveats must be noted including: not all
countries are in the same stage of the pandemic, the number of
cases/deaths is still changing very rapidly in a lot of countries and
thus the association may only reflect exposure to the virus. This
analysis would need to be re-evaluated when all the countries are passed
the pandemic and more accurate numbers are available. Additionally, very
few middle and high-income countries ever implemented universal BCG
vaccination, which can be a source of bias (5 countries, vs 55 that have
a BCG vaccine policy). Effective screening and social isolation policies
also varied considerable across the countries tested and may reflect
another important confounder. The authors could consider analyzing the
Case Fatality Rate (CFR, % of patients with COVID-19 that die), to more
correct for exposure although testing availability will still bias this
result. Variability in mortality within countries or cities with
variable vaccination and similar exposure could also be appropriate
although confounders will still be present.

#### Significance

BCG vaccine is a live attenuated strain derived from *Mycobacterium
bovis* and used for a vaccine for tuberculosis (TB). This vaccine has
been proven to be efficient in preventing childhood meningitis TB, but
doesn’t prevent adult TB as efficiently. For this reason, several
countries are now only recommending this vaccine for at-risk population
only.

**This study shows that there is a correlation between BCG vaccination
policy and reduced mortality for Covid-19**. Indeed, BCG vaccine has
been shown to protect against several viruses and enhance innate
immunity [@doi:10.1016/j.cmi.2019.04.020], which could explain why it could protect against SARS-CoV-2
infection, but the exact mechanism is still unknown. **Moreover, the
efficiency of adult/older people vaccination and protection against
Covid-19 still needs to be assessed.** Regarding this, Australian
researchers are starting a clinical trial of BCG vaccine for healthcare
workers [@url:https://www.mcri.edu.au/BRACE], to assess if it can protect them against Covid-19.

#### Credit

*This review was undertaken as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium

[@doi:10.1101/2020.03.25.009084]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- anosmia
- olfaction
- scRNAseq


#### Main Findings

-   Study analyzed bulk and scRNAseq data of olfactory cell types from
    publicly-available mouse, nonhuman primate and human datasets.

-   show that *ACE2* and *TMPRSS2* (genes involved in SARS-CoV-2 entry)
    are expressed in olfactory epithelial (OE) cells, basal stem cells
    and respiratory epithelium (RE), but not sensory neurons.

-   Comparison of human RE and OE datasets (Deprez et al. 2019; Durante
    et al. 2020) revealed that *ACE2* and *TMPRSS2* expression in OE
    sustentacular cells was similar to expression in the remainder of
    the non-nasal respiratory tract.

#### Limitations

-   Transcript data alone from healthy respiratory/olfactory cells is
    not sufficient to confirm infectivity of nasal passage, or to
    indicate damage to epithelia.

-   No mechanism defined for anosmia; it is not clear if epithelial
    injury leads to reduced sensitivity or increased inflammation and
    altered immune contexture drives neural/epithelial dysfunction. Will
    be critical to test this in CoVID-19 patient samples or mouse
    models.

#### Significance

-   Study provides possible rationale for anosmia observed in several
    CoVID-19 patients.

-   Raises possibility that nasal respiratory goblet, ciliated cells,
    and olfactory epithelia may serve as a viral reservoir after initial
    SARS-CoV-2 infection.

-   Human olfactory sensory neurons express several other molecules
    important to CoV (not CoV-19) entry such as *FURIN, ST6GAL1,
    ST3GAL4*; this suggests wider mechanism of neuronal infectivity in
    other coronaviruses.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and
faculty at the Immunology Institute of the Icahn School of Medicine,
Mount Sinai.*


### Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2

[@doi:10.1101/2020.03.28.013672]

#### Keywords

- CoVID-19
- 2019-nCoV
- SARS-CoV-2
- respiration
- cigarette
- ACE2
- lung

#### Main Findings

-   Study uses scRNAseq, bulk seq data and air-liquid interface culture
    experiments to show that cigarette smoke causes a dose-dependent
    upregulation of ACE2 in mouse and human lungs (transplantation,
    tumor resection, or IPF datasets).

-   ACE2 was not up-regulated in patients with asthma or
    lung-sarcoidosis or in mouse models of cystic fibrosis or carcinogen
    exposure.

-   Cathepsin B (alternate protease involved in viral entry) is
    increased in smoke-exposed mouse or human lungs.

-   Smoke triggers a protective expansion of mucus-secreting MUC5AC+
    goblet and SCGB1A1+ club cells; ACE2 presence in these cells is
    increased upon smoke exposure.

#### Limitations:

-   Long-term smokers usually have several co-morbidities including
    immune dysfunction, which can affect interpretation of CoV-2
    susceptibility in these datasets. Ideally, analyses can control for
    major co-morbidities across smokers and non-smokers (immune
    suppression, cardiovascular disease and atherosclerosis).

-   Hyperplasia of ACE2+ goblet cells upon smoking needs to be separated
    from ACE2 upregulation in existing goblet cells.

-   ACE2 expression increase alone does not confirm increased viral
    entry into goblet cells; future studies with air-liquid interface
    cultures testing CoV-2 infectivity in *ex vivo* epithelial cells
    from human epithelial lines, ex vivo samples or hACE2 mice will be
    very informative.

#### Significance

-   This study may partially explain why smokers are more likely to
    develop severe SARS-CoV-2 infections. Also, the reversibility of
    ACE2 expression upon smoking cessation suggests that quitting
    smoking could lessen CoV-2 susceptibility.

-   Absence of ACE2 upregulation in other lung inflammation pathologies
    implies CoV-2 susceptibility might be smoking-specific, and not
    fibrosis-specific.

-   Another preprint showed ACE2 expression increases in lung of
    patients with CoV-2 co-morbidities such as hypertension [@doi:10.1101/2020.03.21.20040261]; these studies
    collectively paint a better picture of CoV-2 susceptibility before
    actual experiments can be carried out.

#### Credit

*Review by Samarth Hegde as part of a project by students, postdocs and faculty at the Immunology Institute of the Icahn School of Medicine, Mount Sinai.*


### The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis

Liu et al. *medRxiv*.
[@doi:10.1101/2020.03.28.20045765]

#### Keywords

- IgM/IgG antibody test
- nucleic acid test
- SARS-CoV-2 detection

#### Main Findings

The study compares IgM and IgG antibody testing to RT-PCR detection of
SARS-CoV-2 infection. 133 patients diagnosed with SARS-CoV-2 in Renmin
Hospital (Wuhan University, China) were analyzed. The positive ratio was
78.95% (105/133) in IgM antibody test (SARS-CoV-2 antibody detection kit
from YHLO Biotech) and 68.42% (91/133) in RT-PCR (SARS-CoV-2 ORF1ab/N
qPCR detection kit). There were no differences in the sensitivity of
SARS-CO-V2 diagnosis in patients grouped according to disease severity.
For example, IgG responses were detected in 93.18% of moderate cases,
100% of severe cases and 97.3% of critical cases. In sum, positive
ratios were higher in antibody testing compared to RT-PCR detection,
demonstrating a higher detection sensitivity of IgM-IgG testing for
patients hospitalized with COVID-19 symptoms.

#### Limitations

This analysis only included one-time point of 133 hospitalized patients,
and the time from symptom onset was not described. There was no
discussion about specificity of the tests and no healthy controls were
included. It would be important to perform similar studies with more
patients, including younger age groups and patients with mild symptoms
as well as asymptomatic individuals. It is critical to determine how
early after infection/symptom onset antibodies can be detected and the
duration of this immune response.

#### Significance

The IgM-IgG combined testing is important to improve clinical
sensitivity and diagnose COVID-19 patients. The combined antibody test
shows higher sensitivity than individual IgM and IgG tests or nucleic
acid-based methods, at least in patients hospitalized with symptoms.

#### Credit

*Review by Erica Dalla as part of a project by students, postdocs and
faculty at the Immunology Institute of the Icahn School of Medicine,
Mount Sinai.*


### Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis

Li et al. *bioRxiv*.
[@doi:10.1101/2020.03.31.019216]

#### Keywords
- PBMC
- virulence factors
– interaction network
– nsp9
- nsp10
– NKRF

#### Main findings

The authors identified **intra-viral protein-protein interactions**
(PPI) with two different approaches: genome wide yeast-two hybrid (Y2H)
and co-immunoprecipitation (co-IP). A total of 58 distinct PPI were
characterized. A screen of **viral-host PPI** was also established by
overexpressing all the SARS-CoV-2 genes with a Flag epitope into HEK293
cells and purifying each protein complex. Interacting host proteins were
then identified by liquid chromatography and tandem mass spectrometry.
251 cellular proteins were identified, such as subunits of ATPase, 40S
ribosomal proteins, T complex proteins and proteasome related proteins,
for a total of 631 viral-host PPI. Several interactions suggesting
protein-mediated modulation of the immune response were identified,
highlighting the multiple ways SARS-CoV-2 might reprogram infected
cells.

Subsequently, the authors compared global proteome profiles of PBMCs
from healthy donors (n=6) with PBMC from COVID-19 patients with mild
(n=22) or severe (n=13) symptoms. 220 proteins were found to be
differentially expressed between *healthy donors and mild COVID-19
patients*, and a pathway analysis showed **a general activation of the
innate immune response.** 553 proteins were differentially expressed
between the PBMC of *mild and severe COVID-19 patients*, most of them
(95%) being downregulated in severe patients*.* Functional pathway
analysis indicated a defect of T cell activation and function in severe
COVID-19. There was also evidence suggesting reduced antibody secretion
by B cells. Together, these results suggest a **functional decline of
adaptive immunity**. A FACS analysis of PBMC from severe patients
indicated higher levels of IL6 and IL8 but not IL17 compared to mild
patients.

Finally, the authors focused on NKRF, an endogenous repressor of IL8/IL6
synthesis that was previously identified as interacting with SARS-Cov-2
nsp9,10,12,13 and 15. Individually expressed nsp9 and nsp10 (but not
nsp12, nsp13, nsp15) induced both IL6 and IL8 in lung epithelial A459
cells, indicating that nsp9 and nsp10 may be directly involved in the
induction of these pro-inflammatory cytokines. The authors finally argue
that nsp9 and nsp10 represent potential drug targets to prevent
over-production of IL6 and IL8 in infected cells, and reducing the
over-activation of neutrophils.

### Limitations

First, the authors seem to have forgotten to include the extended data
in the manuscript, and their proteomic data does not seem to be publicly
available for the moment, which limits greatly our analysis of their
results.

While this work provides important data on host and viral PPI, only 19
interactions were identified by Y2H system but 52 with co-IP. The
authors do not comment about what could lead to such differences between
the two techniques and they don’t specify whether they detected the same
interactions using the two techniques.

Moreover, the PBMC protein quantification was performed comparing bulk
PBMC. Consequently, protein differences likely reflect differences in
cell populations rather than cell-intrinsic differences in protein
expression. While this analysis is still interesting, a similar
experiment performed on pre-sorted specific cell populations would allow
measuring proteome dynamics at a higher resolution.

Finally, the authors did not discussed their results in regards to
another SARS-CoV-2 interactome of host-viral PPI that had been published
previously^1^. This study reported 332 host-virus PPI, but no
interaction of viral proteins with NKRF was found. Some interactions
were found in both studies (eg. N and G3BP1, Orf6 and RAE1). However,
the time point used to lyse the cells were different (40h previously vs
72h here), which could explain some of the differences.

#### Relevance

The identification of many interactions between intra-viral and
host-virus PPI provides an overview of host protein and pathways that
are modulated by SARS-CoV-2, which can lead to the identification of
potential targets for drug development.

In the model proposed by the authors, nsp9 and nsp10 from SARS-Cov-2
induce an over-expression of IL6 and IL8 by lung epithelial cells, which
recruits neutrophils and could lead to an excess in lung infiltration.
Nsp9 has been shown to be essential for viral replication for
SARS-Cov-1^2^, and shares a 97% homology with nsp9 from SARS-Cov-2^3^.
Further, nsp9 crystal structure was recently solved^3^, which can help
to develop drug inhibitors if this protein is further confirmed as being
important for the virulence of SARS-Cov-2.

1\. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-Human
Protein-Protein Interaction Map Reveals Drug Targets and Potential
Drug-Repurposing. *bioRxiv*. March 2020:2020.03.22.002386.
doi:10.1101/2020.03.22.002386

2\. Miknis ZJ, Donaldson EF, Umland TC, Rimmer RA, Baric RS, Schultz LW.
Severe acute respiratory syndrome coronavirus nsp9 dimerization is
essential for efficient viral growth. *J Virol*. 2009;83(7):3007-3018.
doi:10.1128/JVI.01505-08

3\. Littler DR, Gully BS, Colson RN, Rossjohn J. *Crystal Structure of
the SARS-CoV-2 Non-Structural Protein 9, Nsp9*. Molecular Biology; 2020.
doi:10.1101/2020.03.28.013920


